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ABSTRACT OF THE DISSERTATION 
MicroRNAs in ALS: Defining Cell-Type Specific Expression, Developing Methods to 
Modulate MicroRNAs in vivo, and Identifying Novel Therapeutic Targets 
by 
Erica Danielle Koval 
Doctor of Philosophy in Biology & Biomedical Sciences 
Neurosciences 
Washington University in St. Louis, 2014 
Professor Timothy M Miller, M.D., Ph.D., Chairperson 
 
Amyotrophic lateral sclerosis (ALS) is an adult-onset, fatal neuromuscular disease with no 
adequate therapies. MicroRNAs (miRNAs) are dysregulated in a variety of disease states, 
suggesting that this newly discovered class of gene expression repressors may be viable 
therapeutic targets. A microarray of miRNA changes in ALS model SOD1G93A rodents identified 
12 miRNAs as significantly changed. Six miRNAs tested in human ALS tissues were confirmed 
increased. Specifically, miR-155 was increased 5-fold in mice and 2-fold in human spinal cords. 
Generation of mice that express a GFP-tagged miRNA processing protein behind cell-type 
specific promoters allowed for the identification of miRNA expression patterns in various neural 
cell types. From this information, we focused on the role of miR-155 on glial cells and 
particularly on neuroinflammatory pathways in ALS. miR-155, miR-146a, and miR-142-5p were 
upregulated beginning in a mid-disease stage and were highly correlated with one another and 
with various neuroinflammatory mediators. To test miRNA inhibition in the central nervous 
system as a potential novel therapeutic, we developed oligonucleotide-based miRNA inhibitors 
x 
(anti-miRs) that could inhibit miRNAs throughout the central nervous system and in the 
periphery. Anti-miR-155 caused global derepression of targets in peritoneal macrophages and, 
following intraventricular delivery, demonstrated widespread functional distribution in the brain 
and spinal cord. After treating SOD1G93A mice with anti-miR-155, we significantly extended 
survival by 10 days and disease duration by 15 days (38%) while a scrambled control anti-miR 
did not significantly improve survival or disease duration. Therefore, antisense oligonucleotides 
may be used to successfully inhibit miRNAs throughout the brain and spinal cord, and miR-155 
is a promising new therapeutic target for human ALS. 
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CHAPTER 1 
 
 
Introduction and perspective 
 
2 
1.1) ALS: epidemiology and pathology 
Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig’s disease) is a 
progressive, fatal, neurodegenerative disorder characterized by the selective death of motor 
neurons in the brain and spinal cord. The annual incidence of ALS is 1.5-2.5 per 100,000 
individuals with a typical age-of-onset between 40 and 70 years (Chio et al., 2013). Typically, 
patients experience progressive muscle weakness, spasticity, and atrophy, followed by death 
within two to four years of disease onset due to respiratory failure. Only 7% of patients live 5 
years past diagnosis (del Aguila et al., 2003). Despite ALS being first characterized in 1869 by 
Jean-Martin Charcot (Kumar et al., 2011), Riluzole remains the only FDA approved treatment 
and only prolongs survival by two to three months (Miller et al., 2012).  
While the majority of ALS cases are singleton cases with no known genetic cause or 
family history, 5-10% are familial (Pasinelli and Brown, 2006). In 2011, two groups discovered 
a hexanucleotide repeat expansion in C9orf72 that is responsible for up to 30-40% of familial 
ALS in the United States (Laaksovirta et al., 2010; van Es et al., 2009) and up to an additional 
7% of patients without known family history of ALS (Majounie et al., 2012). Many research 
groups are actively pursuing the pathological mechanism of this hexanucleotide repeat. Theories 
include a loss of function (Ciura et al., 2013), a gain of function due to sequestration of RNA 
binding proteins (Donnelly et al., 2013), or buildup of toxic protein aggregates (Zu et al., 2013). 
However, no C9orf72 mouse model has yet been generated that has an ALS phenotype, thus 
relegating translational research in C9orf72 linked-ALS to cell culture systems for the time 
being.  
In contrast, a previously identified mutation in the copper-zinc superoxide dismutase 1 
gene (SOD1) (Rosen, 1993) has led to the generation of a widely used ALS-rodent model 
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(Gurney et al., 1994). Up to 20% of familial cases of ALS have been linked to a mutation in 
SOD1 (Al-Chalabi and Hardiman, 2013), and over 131 distinct ALS-associated SOD1 mutations 
have been characterized (Andersen, 2006), including the SOD1G93A mutation. SOD1 is a 
ubiquitously expressed protein that reduces free radicals to oxygen and hydrogen peroxide. 
Because SOD1 knockout mice do not display overt ALS-like symptoms similar to that seen in 
the SOD1G93A mouse model (Reaume et al., 1996), most groups consider SOD1 mutations to 
likely confer a gain of function toxicity. SOD1G93A mice undergo normal development but at ~3 
months of age, depending on the mouse strain, they begin to lose weight and develop atrophy in 
hind limb muscles. This phenotype progresses rapidly with paralysis and death typically 
occurring between 4 and 6 months of age. So while SOD1 mutations only account for 
approximately 2% of total ALS cases, mouse models based on SOD1 mutation have provided a 
useful in vivo system for studying ALS pathology and therapeutic targets. While other ALS-
mouse models have been created using known ALS-causing mutations including 12 other SOD1 
variants, TAR DNA-binding protein-43 (TDP-43), and fused in sarcoma (FUS) (Qiu et al., 
2014), the SOD1G93A mouse model is by far the most widely used (Moser et al., 2013). Key 
benefits of the SOD1G93A mouse line over other ALS models include its more predictable timing 
of disease onset and progression (Leitner, 2009), its recapitulation of patient phenotypes, and its 
genetic relevancy to a relatively large percentage of familial ALS patients.  
In the studies presented here, our primary mouse model was the SOD1G93A model. 
However, the TDP-43 mouse model was also used as confirmation of our therapeutic targets. 
TDP-43 was identified biochemically as a component of cellular aggregates associated with 
ALS and Frontotemporal Dementia (Neumann et al., 2006). Subsequently, in 2008, a causative 
mutation in TDP-43 was identified; TDP-43 mutations are thought to account for ~5% of 
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familial ALS (Gitcho et al., 2008; Kabashi et al., 2008). A transgenic mouse line was then 
developed that expresses this human mutation, TDP-43A315T (Wegorzewska et al., 2009). TDP-
43A315T mice develop progressive weakness and difficulty walking associated with loss of motor 
neurons and have ubiquitinated inclusions in motor neurons and layer V cortical neurons 
(Wegorzewska et al., 2009; Wils et al., 2010). Spinal cords and brains from these mice show 
neuron loss, as well as astrocyte and microglial activation (Wegorzewska et al., 2009). The 
utility of this line has since been questioned because of an obstructive bowel phenotype that 
eclipses a phenotype that would result from classical motor neuron loss in the brain and spinal 
cord (Hatzipetros et al., 2013). Therefore, our use of this line is as a second confirmation of 
interesting targets and not as a primary source in identifying therapeutic targets. By using two 
genetic models for validation, top therapeutic targets were more rigorously chosen for future 
large-scale therapeutic experiments that have a greater chance of success for translating to ALS 
patients broadly.  
Growing controversy exists on the usefulness of the ALS-rodent model as more clinical 
trials fail to translate rodent targets to patients (Benatar, 2007; Perrin, 2014). This may be due to 
attempts at applying experiments based on a single genetic mutation, often SOD1G93A, to patients 
of whom over 98% do not harbor this mutation. Also, many therapeutic targets found in the 
rodent are not well validated in ALS patients before completing a clinical trial based on that 
target. Importantly, most therapeutic experiments in ALS-model mice that report a positive effect 
serve to delay onset (on average by 12 days) but do not robustly extend disease duration (on 
average 3 days) (Benatar, 2007). As ALS patients typically enter the clinic after symptom onset, 
the most relevant therapeutic targets will likely be those that slow disease progression. We aimed 
to strengthen our ability to identify therapeutic targets with translational potential in two ways 
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against these justified concerns. First, we used the TDP-43A315T mouse line as a second validator 
of our top targets before deciding to continue with more ambitious intervention experiments. 
Second, we used human autopsy tissue from both familial and sporadic ALS patients to validate 
our targets of interest in Chapter 2. We also robustly followed onset and survival measures in our 
mice to accurately determine if we were delaying symptom onset or extending disease duration. 
Despite the numerous emerging genetic causes for ALS including SOD1, C9orf72, TDP-
43, ataxin 2 (ATXN2), valosin-containing protein (VCP), and others (Al-Chalabi and Hardiman, 
2013), several pathological pathways remain consistent across patients. For example, 
endoplasmic reticulum (ER) stress is a result of the accumulation of misfolded proteins that 
results in an unfolded-protein response (UPR). While initially a protective pathway, sustained 
activation of the UPR can lead to apoptosis (Ferraiuolo et al., 2011) and is thought to be one of 
several toxic pathways that contribute to neuronal death in ALS (Ilieva et al., 2009). Next, 
several studies have observed excess glutamate and signs of excitotoxicity in both patients and in 
the ALS-mouse model. The ability of Riluzole to reduce presynaptic glutamate release is 
considered one potential mechanism in which Riluzole leads to a survival benefit in patients 
(Cheah et al., 2010). Some of the other well studied pathogenic pathways in ALS include 
mitochondrial dysfunction, (Damiano et al., 2006), synaptic vesicle defects (Ilieva et al. 2009), 
impaired axonal transport (De Vos et al., 2007), and neuroinflammation.  
 
1.2) Neuroinflammation in ALS 
ALS is a non-cell autonomous disease  
 ALS is a non-cell autonomous disease in which astrocytes, microglia, oligodendrocytes, 
and neurons all play critical rolls in disease progression (Ferraiuolo et al., 2011; Ilieva et al., 
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2009). The impact of non-neuronal cells on ALS was made clear through experiments that 
performed genetic ablation of the ALS-causing SOD1 mutation in distinct cell types. For this, 
Boillee et al created mice that harbored the SOD1G37R mutation flanked by LoxP sequences 
(Boillee et al., 2006). Upon removal of SOD1G37R expression exclusively in motor and dorsal 
root ganglion neuron progenitors using the Islet-1 transcription factor promoter to drive Cre 
recombinase expression, mice lived on average 64 days longer as compared to mice that 
maintained ubiquitous SOD1G37R expression. Given that ALS symptoms are the result of a 
selective loss of motor neurons in the brain and spinal cord, it is not surprising that removal of 
the ALS-causing gene in neurons is significant. More interesting, removal of SOD1G37R 
expression in glial cells also extended survival. Using a CD11b Cre recombinase driver, 
SOD1G37R was specifically ablated from myeloid cells including monocytes, macrophages, and 
microglia resulting in a survival benefit of 99 days (Boillee et al., 2006). Also, selectively 
removing SOD1G37R from astrocytes using the GFAP Cre recombinase driver resulted in a 
survival extension of 60 days (Yamanaka et al., 2008), and selective removal in oligodendrocytes 
using the PDGFαR Cre recombinase driver extended survival by 130 days (Kang et al., 2013). 
These studies show that motor neuron survival is greatly influenced by surrounding glial cells 
and that ALS is a non-cell autonomous disease. Non-neuronal cells are important mediators of 
disease pathogenesis and may themselves be valid therapeutic targets. However, their specific 
supportive or maladaptive roles remained unclear with these genetic ablation experiments. 
Recently, experiments that aim to elucidate the complex and critical roles glial cells in ALS have 
gained greater attention. I will highlight the roles of the innate and adaptive immune response in 
ALS by detailing multiple critical cell types involved in neuroinflammation, their trafficking, 
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signaling, and activation, and the mixed success achieved with immunomodulatory therapies in 
ALS-model mice.  
 
Innate immune system in ALS 
 Neuroinflammation is characterized by the integrated response of multiple cell types in 
the central nervous system to injury, insult, or disease.  Commonly in neurodegenerative 
disorders, neuroinflammation involves in part the activation and proliferation of resident 
microglia and the infiltration of peripheral immune cells including macrophages and 
lymphocytes. Macrophages are white blood cells derived from monocytes, and microglia are the 
resident macrophages in the brain and spinal cord. Originally thought to be derived from bone 
marrow precursor cells, fate mapping (Ginhoux et al., 2010) and gene expression experiments 
(Butovsky et al., 2012; Chiu et al., 2013) have since confirmed microglia to be a unique type of 
mononuclear phagocyte that derives from the yolk sac (Alliot et al., 1999). Microglia populate 
the brain and spinal cord early in embryogenesis, are long-lived, and self-renew (Ajami et al., 
2007; Mildner et al., 2007). Both microglia and peripheral macrophages require the transcription 
factor PU.1 for maturation (McKercher et al., 1996) but have recently been further distinguished 
in their expression of Ly6C (splenic monocytes) and CD39 (resident microglia) (Butovsky et al., 
2012; Yamasaki et al., 2014).  
 Under basal conditions, the inappropriately named “resting microglia” serve active 
surveillance and supportive roles to the brain and spinal cord. Under resting, physiological 
conditions, microglia are important in synapse maintenance (Wake et al., 2009) and cell survival 
in part by providing trophic support (Nakajima et al., 2001). Furthermore, two-photon imaging 
of mice expressing a GFP-tagged chemokine receptor, CX3CR1, serving to label lymphocytes 
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and myeloid cells, showed that as a class, microglia are motile cells that use their dynamically 
extended processes to survey the complete parenchyma once every few hours (Nimmerjahn et 
al., 2005). In response to a variety of CNS insults, microglia withdraw these surveying processes 
and activate in order to act at the first line of defense (Tambuyzer et al., 2009). While microglia 
activation has been well studied in a myriad of diseases and conditions, I will focus here on the 
responses of microglia most relevant to ALS research.  
 Mirroring research on the response of microglia to a bacterial toxin, lipopolysaccharide 
(LPS), Dr. Appel’s group has published several papers thoroughly characterizing the dynamic 
polarization of microglia from ALS-model mice throughout disease progression (Beers et al., 
2008; Beers et al., 2011; Liao et al., 2012). They observed that early in disease, microglia enter 
an M2 alternatively activated state in which they serve neuroprotective roles. M2 microglia 
secrete anti-inflammatory cytokines (IL-4, IL-10), neurotrophic factors (IGF-1, GDNF), and 
recruit T-helper type 2 (Th2) cells and T regulatory cells (Tregs) from the periphery to further 
strengthen this protective response (Lewis et al., 2012). However, later in disease, they found 
that microglia change their polarized activated state from M2 to the classical activated M1 state. 
M1 microglia are thought to serve neurotoxic functions. M1 microglia secrete pro-inflammatory 
cytokines (IL-6, IL-1β, TNFα), pro-apoptotic signals (reactive oxygen species (ROS), glutamate) 
(Zhao et al., 2004), and secrete chemokines (CXCL9, CXCL10) to recruit T-helper type 1 cells 
(Th1) and cytotoxic CD8 cells from the periphery to further augment the neurotoxic response 
(reviewed: (Evans et al., 2013; Lewis et al., 2012; Prinz and Priller, 2014). These three microglia 
responses are sometimes referred to as “the good” (M2), “the bad” (M1), and “the resting” (non-
activated) (Henkel et al., 2009).  
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 However, others believe that the concept of polarization to be inaccurate. By performing 
deep RNA sequencing, microglia from ALS-model mice were shown to have the potential to be 
concurrently both cytotoxic and protective by expressing a mixture of “M2” and “M1” genes 
including IGF-1, Progranulin, DAP12 and MMP-12, Optineurin, and Nox2 respectively (Chiu et 
al., 2013). Therefore, the concept of microglia polarization to M1 and M2 derived from LPS 
experiments may not be accurate to describe the complex nature of microglial responses during 
ALS. It remains unknown whether ‘good’ or ‘bad’ microglia exist as potential ALS therapeutic 
targets and if blunting or modulatory therapies will be beneficial for patients with ALS. 
 The chemokine response in the brain and spinal cord upon ALS disease progression can 
serve to recruit peripheral lymphocytes and monocytes. With the identification of microglia and 
monocyte specific markers (CD39 and Ly6C respectively), Dr. Weiner’s research group found 
that contrary to previously published studies, native microglia do not proliferate in ALS. Instead 
of “microgliosis”, CCL2 expressed by microglia recruits Ly6Chi monocytes via the CCR2 
receptor. Through fate-mapping and gene expression experiments, the authors concluded that 
native microglia were selectively lost in the late-stage ALS-model mouse spinal cords while 
there was a robust neural recruitment and proliferation of Ly6C+ monocytes. A limitation in 
these experiments is the inability to account for potential changes in gene expression during 
disease and therefore an inability to definitively claim cell origin based solely on Ly6C and 
CD39. Furthermore, the fate-mapping experiment involved bone-marrow ablation by irradiation 
in an ALS-model mouse, reconstituted with donor bone marrow cells that express GFP. By 
observing an increase in GFP signal in the brain during disease progression, it is impossible to 
know if monocyte infiltration occurs naturally in ALS or if this observation is instead an artifact 
due to a break down in the blood brain barrier, common with irradiation (Ajami et al., 2007; 
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Diserbo et al., 2002). In 2013, Chiu et al. found no increase in Ly6C/monocyte signal in ALS 
model mouse spinal cords as measured with flow cytometry and qPCR (Chiu et al., 2013). These 
disparate data may be due to current limitations in techniques, and there is an active interest in 
resolving these differences (Chiu et al., 2013). The distinction of microglia and macrophage 
involvement is beyond the scope of this dissertation, but in light of these data and this 
controversy, these specific inflammatory markers, CD39 and Ly6C, were included in our panel 
of neuroinflammatory transcripts when assessing microglia in the ALS model.   
 As sophisticated experiments further distinguished microglia, macrophages, and 
monocytes, the best Cre recombinase driver for studying myeloid cell function has come under 
renewed debate. Previously to study microglia, researchers often relied on the integrin M 
(CD11b), integrin-αx (CD11c) (Town et al., 2008) and lysozyme M (LysM, or Lyz2) promoters. 
However, in 2013, a new mouse was generated that expresses Cre recombinase behind the 
chemokine receptor CX3CR1 (fractalkine) driver (Goldmann et al., 2013; Yona et al., 2013). In 
comparing three microglial Cre drivers, Goldmann et al. found that the CD11c driven Cre 
recombinase only resulted in 7% expression in CD11b+CD45lo FACS gated microglia. The 
LysM driver performed much better with a 46% expression of Cre recombinase in Iba-1+ spinal 
cord microglia, but the novel CX3CR1 Cre driver showed the best recombination levels with 
expression in 99% of the CD11b+CD45lo FACS gated microglia (Goldmann et al., 2013). LysM-
Cre expression by FACS was not determined. Of note, by taking advantage of the low expression 
of CX3CR1 in peritoneal macrophages, the high turnover rate of intestinal macrophages and 
blood monocytes from stem cell precursors, and the self-renewal properties of microglia, the 
authors were able to use an inducible tamaxofen system to drive nuclear translocation and 
activation of CX3CR1-Cre-ER to create microglia specific Cre expression (reviewed in (Wolf et 
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al., 2013)). In the cell-specific experiments detailed in Chapter 3, our goal is to distinguish 
neuron, astrocyte, and myeloid/microglia microRNA expression levels; however, distinguishing 
macrophages and microglia is beyond the scope of these studies. Furthermore, the generation of 
double-transgenic mouse lines for these experiments began in early 2013 precluding our use of 
the novel CX3CR1- Cre driver. Nonetheless, we were pleased with the strong signal of Cre 
recombinase in our Lyz2 driver mice (Chapter 3) and are aware of the caveat that we are 
potentially only labeling half of the brain and spinal cord microglia.  
 Astrocytes are an abundant type of glial cell that have been well studied in ALS 
(Maragakis and Rothstein, 2006) and serve some immunologic functions similar to that 
discussed for microglia under physiological and pathological conditions. That is, under resting 
conditions, astrocytes provide trophic support, but upon activation, astrocytes can enhance 
inflammation with the secretion of neurotoxic factors and even inflammatory cytokines (Kim et 
al., 2011; Philips and Robberecht, 2011). Typically, astrocytes play important roles in 
maintaining extracellular neurotransmitter concentrations, supplying nutrition and metabolic 
support to neurons, regulating the brain blood barrier, and more (Philips and Robberecht, 2011; 
Rossi et al., 2011). Upon activation, termed astrogliosis, astrocytes increase expression of 
intermediate filament proteins, including GFAP and vimentin, and may secrete reactive oxygen 
species. Furthermore, astrocytes may become dysfunctional themselves leading to an inability to 
effectively regulate glutamate, resulting in neuronal death due to hypertoxicity. The importance 
of astrocytes in ALS disease pathogenesis was made clear with astrocyte-neuron co-culture 
experiments with which several groups found that SOD1G93A expressing astrocytes, from mice 
and patients, were sufficient to cause neuronal death (Haidet-Phillips et al., 2011; Nagai et al., 
2007). Given the importance of this cell type to neuronal survival, one goal of this dissertation is 
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to further our knowledge of miRNA expression in astrocytes (Chapter 3) while also surveying 
the correlation of astrogliosis in response to miRNA modulatory therapies (Chapter 5). 
 
Adaptive immune system in ALS 
 T cell activation and infiltration into spinal cord tissue is a pathological hallmark of ALS, 
both in patients (Engelhardt et al., 1993) and in the SOD1 ALS mouse model (Chiu et al., 2008) 
and is well correlated with microglia activation (Beers et al., 2008). T cells are a type of 
lymphocyte that play critical roles in adaptive immunity. Relevant to ALS, T cells can mature to 
become cytotoxic T cells (CD8), T helper cells (TH; CD4+), or T regulatory cells (Treg; 
CD4+CD25+FoxP3+). CD8+ T cells are capable of driving apoptosis in neurons through the 
release of cytotoxic molecules including perforin and granzyme and the expression of Fas ligand 
(Lewis et al., 2012; Melzer et al., 2009). CD4+ TH cells serve to modulate the activation and 
function of other immune cells including other T cells and myeloid cells through the release of 
cytokines. T helper type 1 cells (TH1) secrete pro-inflammatory molecules including IFNγ, TNF-
α and IL-1β that can drive M1 microglia polarization, whereas T helper type 2 cells (TH1) secrete 
anti-inflammatory molecules including IL-4, IL-5, and IL-10 capable of driving M2 microglia 
polarization (Mosmann and Sad, 1996; Beers et al., 2011; Lewis et al., 2012). Furthermore, 
FoxP3+ Tregs can modulate the adaptive and innate immune response and have been shown to 
have potent immunosuppressive function in ALS-model mice (Beers et al., 2011).  
 Early in disease (10 weeks of age), TH2 and Treg cells were observed in ALS-mouse 
spinal cord tissue and were correlated with M2 microglia. Later in disease, at approximately 20 
weeks of age, CD8+ T cells were also observed (Chiu et al., 2008). Through genetic ablation of 
the T cell antigen receptor β chain (TCRβ) in SOD1G93A mice, T cell maturation was prevented 
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and CD4+ and CD8+ T cells were markedly absent in spinal cord tissue. In these mice, disease 
progression was accelerated, with mice dying 11 days earlier on average (Chiu et al., 2008) 
showing T cells to be important and beneficial in slowing ALS disease progression.  
 Also, natural killer cells (NK) are a distinct class of cytotoxic lymphocytes and have been 
observed to also be present in late disease ALS-model mouse spinal cord tissue (Chiu et al., 
2008) and in patient blood (Rentzos et al., 2012); however, this class of cells has not received 
much attention in ALS studies to date. Finally, B cells, an important class of antigen presenting 
cells, are not thought to be important mediators of ALS pathogenesis. By crossing SOD1G93A 
mice with immunoglobulin heavy chain, Igµ, knockout mice, B cell deficient ALS-model mice 
were generated, and these mice had no alterations in behavioral or survival measures as 
compared to SOD1G93A mice with unimpaired B cell function (Naor et al., 2009).  In light of 
these studies, the immunologic transcripts measured in in Chapter 5 following our ALS-mouse 
model intervention treatments focus on innate immunity and cell-mediated immunity over the 
humoral component, and include measurements for the number and activation states of 
astrocytes, myeloid cells, and T cells in spinal cord tissue. 
 
Insights from immunomodulatory experiments in ALS-model mice  
 Neuroinflammation has been well characterized in ALS, both in patients and in the 
mouse model. Increased numbers of microglia can be observed in affected tissues including the 
ventral horns of the spinal cord, corticospinal tracts, brainstem motor nuclei, and the motor 
cortex (Weydt and Moller, 2005). A number of recent experiments using the ALS-mouse model 
suggest that while overall blunting of the immune system is potentially detrimental, selectively 
modulating and even increasing components of the neuroimmune response in ALS may be 
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beneficial. However, one of the largest remaining questions in studying neuroinflammation in 
ALS is whether microglia and lymphocytes are neuroprotective, neurotoxic, or both and whether 
modulating their activation states could be a valid therapy. While Alzheimer’s disease (AD) and 
ALS are distinct neurodegenerative diseases, they have several shared pathological mechanisms 
including a gain of toxic protein aggregates and marked increases in neuroinflammatory markers, 
allowing AD experiments to be potentially useful in furthering our understanding of ALS 
pathogenesis. Presented here are a series of experiments in both the ALS-model mice and in AD 
model mice that inform the role of the immune system in neurodegenerative disease 
pathogenesis. 
 First, upon removing the spleen, an organ that houses a large percentage of lymphocytes 
and monocytes, SOD1G93A mice died 8 days sooner showing that the immune system has a clear 
beneficial role in ALS disease progression (Butovsky et al., 2012). These data are supported with 
the discovery that preventing myeloid-cell proliferation, by introducing ganciclovir in CD11b 
thymidine kinase expressing mice, in AD model mice resulted in increased accumulation of toxic 
β-amyloid (Simard et al., 2006), again showing a positive role for monocytes in 
neurodegenerative diseases.  
 It was theorized that increasing the protective M2 response and blunting the detrimental 
M1 response would protect against neuronal death and increase survival in the mouse. Based on  
this hypothesis, minocycline, a drug that can selectively inhibit M1 microglia (Makeyev and 
Maniatis, 2008), was found to be extend survival of SOD1G93A mice (Zhu et al., 2002); however, 
administration of minocycline to ALS patients was detrimental (Gordon et al., 2007). While still 
unknown why the results of these mouse and human experiments differ, some theorize that the 
failed clinical trial was due to the drastically increased dosage (400 mg/day) in the Phase 3 
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clinical trial (Leigh et al., 2008). Immunomodulatory studies in Alzheimer’s disease provide an 
alternative hypothesis for why blunting microglia responses may be detrimental. Upon treating 
(APPSwe)/PS1 AD model mice with the cytokine colony-stimulating factor (M-CSF), mice 
displayed a lower β-amyloid plaque burden along with improved performances in learning and 
memory tasks. Correlated with these biochemical and behavioral benefits were increased 
numbers of activated microglia and the increased expression of proinflammatory cytokines in the 
mouse cortex (Boissonneault et al., 2009). These data support a beneficial role of pro-
inflammatory microglia, likely through increased phagocytosis and clearance of toxic proteins 
and cells. Overall, it remains unclear the best way to therapeutically modulate monocytes and 
microglia in ALS, but it is evident that these immune cells are important drivers of 
neurodegenerative disease. 
 In addition to therapeutic strategies to target myeloid cells, several studies have found 
beneficial roles for adaptive immune cells in ALS, largely led by Dr. Appel’s research group. 
The role of T cells in ALS was tested by genetic ablation of recombination-activating gene 2 
(RAG2), a protein necessary for the genetic recombination required to develop mature 
lymphocytes. In these ALS-model mice that lacked functional T and B cells, disease duration 
was significantly increased by 19 days. Furthermore, SOD1G93A CD4 knockout mice that lack TH 
and Treg cells died on average 16 days sooner than littermate controls (Beers et al., 2008), 
suggesting a positive role of lymphocytes in ALS. Adoptive transfer of Tregs into ALS model 
mice also enhanced survival, showing that Tregs are potentially the relevant T cell subset that 
confer a survival benefit in ALS (Beers et al., 2011). Overall, given the relatively new efforts to 
study immunomodulatory therapies in ALS, there remain more questions than answers. While 
convincing data have been generated showing neuroinflammation to be important to disease 
16 
progression in ALS-model mice, the very nature of the immune response remains unknown. 
Blunting the involvement of myeloid cells and lymphocytes appears detrimental, but varying 
success has been achieved through selective immunomodulatory therapies, through targeting 
either canonical anti- and pro-inflammatory compartments. However, it has also been recently 
suggested that these distinctions are in of themselves inaccurate (Chiu et al., 2013). Given the 
fluid nature of research on neuroinflammation related to ALS, care was taken to be unbiased in 
the gene targets measured as this dissertation progressed to study potential modulations in the 
number, activation, and signaling of immune cells in ALS. Therefore, a diverse panel was 
created to measure astrocyte, myeloid, and lymphocyte number and activation states as well as 
various signaling molecules canonically associated with pro- and anti-inflammatory effects. 
 
1.3) MicroRNAs: biogenesis, expression, and applications to disease 
In targeting pathogenic pathways in ALS, including neuroinflammation, microRNAs may 
prove to be a powerful tool. Since their discovery in 1993 (Lee et al., 1993), microRNAs 
(miRNAs) have emerged as key regulators in numerous physiological and pathological 
processes. miRNAs are highly conserved single-stranded, non-coding RNA molecules 19-25 
nucleotides in length. miRNA sequences are located throughout the genome – in coding and 
noncoding genes; in introns and in exons (Rodriguez et al., 2004). Following transcription by 
RNA polymerase II, primary-miRNA (pri-miRNA) transcripts form hairpin structures that are 
then cleaved by Drosha and Dicer, RNase III enzymes. This results in a ~70 nucleotide fragment 
known as the precursor-miRNA (pre-miRNA) (Krol et al., 2010). The pre-miRNA is then 
exported to the cytoplasm by Exportin-5 before being further cleaved by Dicer. The result is a 
19-25 double stranded RNA that unwinds to form what typically becomes a passenger/degraded 
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strand and a guide strand (Winter et al., 2009), although sometimes both strands of the miRNA 
are biologically active. The minor species is typically annotated with a “*” as in miR-24-2*.   
Typically, miRNAs direct translational repression by binding to the 3’UTR of mRNAs 
after first being incorporated into an Argonaute containing RNA-induced silencing complexes 
(RISC). While four distinct mammalian Argonaute proteins exist (Ago1-4), research into miRNA 
function is typically restricted to Ago2 as it is the only Argonaute protein that has retained 
catalytic, endoribonuclease activity (Meister et al., 2004). The second to eighth nucleotide of the 
miRNA, called the seed region, is considered to be the most important for target recognition and 
is often emphasized in target prediction algorithms (Bartel, 2009). Depending on the level of 
miRNA-mRNA complementarity, RISCs will inhibit and/or degrade the target mRNA 
(Chekulaeva and Filipowicz, 2009). Currently, there are several substantiated theories on the 
method of microRNA mediated translational repression. For example, with partial 
complementarity, the RISC can serve to destabilize the target mRNA through deadenylation or 
decapping. Alternatively, the target mRNA may simply be inhibited through sequestration, often 
in processing bodies (P-bodies). Finally, with near perfect complementarity, the miRNA/RISC 
can cause endonucleolytic cleavage of the target mRNA (Morozova et al., 2012). miRNAs are 
highly associated with the RISC in vivo, with only 1-3% of miRNAs existing unbound to Ago2 
(Tang et al., 2008). This high affinity has allowed researchers to successfully isolate miRNAs ex 
vivo using immunoprecipitation against Ago2 (Chi et al., 2009).  
Because only partial complementarity is required for miRNA-mRNA interactions, a 
single miRNA can potentially regulate hundreds of mRNA transcripts (Selbach et al., 2008). 
miRNA-mRNA targets are identified through bioinformatics algorithms and/or experimental 
validation. First, several target prediction programs have been designed with most surveying the 
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3’UTR of mRNAs for an exact miRNA seed region compliment while also calculating 
thermodynamic stability and evolutionary conservation (Min and Yoon, 2010). The predicted 
success of this approach is relatively high at 50-85% accuracy for conserved miRNAs (Chen and 
Rajewsky, 2006), but there remains a high number of false hits and missed targets through using 
a bioinformatics approach alone. Therefore, to confirm predicted mRNA targets for a particular 
miRNA, experimental validation is necessary through either genetic or molecular assays. The 
most common approach is an in vitro assay in which cells are transfected with a luciferase 
reporter that contains the 3’UTR of the predicted mRNA target. By either transfecting the 
miRNA, inhibiting the miRNA, or mutating the direct predicted binding site, the predicted 
mRNA target for a given miRNA can be confirmed. If a valid 3’UTR target, increasing the 
amount of that miRNA will inhibit luciferase expression, and in contrast, inhibiting the miRNA 
will derepress/increase luminescence. Likewise, mutating the predicted binding site within the 
3’UTR will similarly derepress luciferase signal (van Rooij et al., 2012).  
Alternatively, Argonaute high-throughput sequencing of RNAs isolated by crosslinking 
immunoprecipitation (HITS-CLIP) is a recent method developed to validate mRNA targets for 
miRNAs globally. With this technique, the close proximity of the three molecules (Ago2, 
miRNA, and mRNA) allows the generation of ternary structures that can then be sequenced to 
generate two data sets: Ago-miRNA and Ago-mRNA binding sites. Bioinformatics analysis can 
then be applied to determine interactions between miRNA and target mRNA (Chi et al., 2009). 
In our studies, to determine novel miRNA binding targets, we also used a mixture of target 
prediction algorithms and luciferase assays. The number of verified miRNAs continues to 
increase, with the latest version of miRBase annotating 2578 distinct miRNA sequences in Homo 
sapiens, (miRBase.org, v20.0). With the large number of predicted binding targets for a given 
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miRNA, miRNAs, as a class, are potential regulators of over 50% of all human genes (Friedman 
et al., 2009).  
 One of the first steps to studying the role of a particular miRNA is to learn its expression 
patterns in distinct cell populations. The current popular methods for determining miRNA cell 
type specific expression are fluorescence activated cell sorting (FACS), laser capture 
microdisections (LCMs), and in situ histology; however, each of these methods has significant 
limitations. FACS and LCM introduce cellular stress that can alter gene expression, are low 
yield, and may only isolate miRNAs located at the cell body, potentially at a loss of miRNAs 
present in the synapses (Lugli et al., 2005) and the dendrites (Tai and Schuman, 2006). Histology 
with in situ hybridization using miRNA probes may be used to detect abundant miRNAs but are 
difficult, expensive, and only serve to assay a single miRNA at a time.  
 Recently, He et al. developed a method for determining miRNA specific expression in 
distinct GABAergic and gluamatergic cell populations from whole brain and spinal cord tissue, 
called miRAP (miRNA tagging and affinity purification). By expressing cell specific Cre 
recombinase and ubiquitous floxed stop GFP-myc tagged Ago2, mice were generated that only 
expressed GFP-myc-Ago2 in the neural cell type of interest. Using flash-frozen whole tissue 
from these miRAP mice, an immunoprecipitation against the GFP or myc tag allowed miRNAs 
to be isolated from only the specific cell type of interest. This novel method has several 
advantages including its physiological relevance, its sensitivity, and its ability to generate high-
throughput data sets (He et al., 2013). Given the importance of both neuronal and non-neuronal 
cell populations in ALS, we adapted this method to generate datasets of miRNA expression in 
neurons, motor neurons, astrocytes, and myeloid cells in the brain and spinal cord (Chapter 3).  
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 While most research on the role of miRNAs is focused on cancer (Reid et al., 2011; 
Volinia et al., 2006; Yanaihara et al., 2006), significant discoveries have also been made linking 
miRNAs to neurodegenerative disease. First, it was discovered that patients who had high levels 
of beta-secretase (BACE1, the enzyme responsible for the generation of pathogenic amyloid-β 
peptides) also had lower levels of miR-29a/b. The authors then performed in vitro experiments 
confirming the predicted direct interaction of miR-29 and BACE1 (Hebert et al., 2008). In 
Parkinson’s disease, Pitx3 is a transcription factor required for dopaminergic neuronal survival. 
It was found that miR-133b and Pitx3 form a negative feedback loop, and that the midbrain of 
Parkinson’s disease model mice have reduced levels of miR-133b (Kim et al., 2007). In ALS, 
miR-206 was found to be increased in the skeletal muscles of ALS model mice. Upon knocking 
out miR-206, mice died more quickly, determined to be from a lack of neuromuscular synapse 
reorganization normally driven by miR-206. Therefore, increased levels of miR-206 is thought to 
be a beneficial driver in ALS, although the authors did not pursue a rescue experiment to test if 
increasing miR-206 levels more would create a survival benefit (Williams et al., 2009). These 
studies all serve as examples of the importance of miRNAs in neurodegenerative disease 
pathways and outcomes.  
 Because a single miRNA can have hundreds of mRNA targets through partial 
complementarity, there may be some concern that modulating miRNAs would not be a good 
therapeutic approach. However, one study of miRNA in disease is now progressing beyond the 
animal model. Following the discovery that miR-122, a liver specific miRNA, drives the 
replication of the hepatitis C virus (HCV) (Jopling et al., 2005), Santaris Pharma developed an 
antisense oligonucleotide inhibitor against miR-122, called Miriversen. Following successful 
chimpanzee studies (Lanford et al., 2010), the authors have continued to complete a successful 
21 
Phase I (Janssen et al., 2011) and Phase IIa trial (NCT01200420) (Janssen et al., 2013). Hepatitis 
C patients that received Miriversen reported no significantly greater number of adverse events 
over placebo, and their viral titer counts were robustly and significantly reduced, even at the 
lowest dosage level tested, 3mg/kg. Reduced HCV RNA was observed over 3 months beyond the 
last injection. This clinical trial shows that despite the vast number of potential mRNA targets for 
each miRNA, miRNAs remain both powerful and realistic therapeutic targets.  
 
1.4) Antisense oligonucleotides 
 Several methods exist to manipulate the function of miRNAs in vivo including 
enhancement via miRNA mimics and repression via sponges/decoys and antisense 
oligonucleotides (ASOs). When testing the role of downregulated miRNAs in disease, 
commercially available synthetic miRNA mimics can be a useful tool for reintroducing the 
miRNA – allowing the effect of the miRNA of interest on direct gene targets and/or changes in 
physiological and pathological pathways to be determined. miRNA mimics can be introduced at 
various stages of the miRNA processing pathway including the precursor hairpin (van Rooij et 
al., 2012), the double-stranded mature miRNA duplex (LifeTechnologies, 2012), or the fully 
processed single stranded miRNA (Trang et al., 2011). Given the novelty of this method, it is not 
yet known which form of the miRNA mimic has the best cellular uptake, specificity, and 
potency. If the goal instead is to reduce upregulated miRNAs back to baseline, several 
technologies exist for synthetically inhibiting the function of a target miRNA. Recently 
developed miRNA sponges are mRNAs that contain multiple miRNA binding sites (often 4-10), 
acting as dominant negative inhibitors (Ebert and Sharp, 2010). Since their development in 2007 
(Ebert et al., 2007), miRNA sponges are showing promise in their potency and adaptability, 
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including an ability to target complete miRNA families that contain homologous seed regions. 
However, sponges are sometimes limited in their ability to sufficiently inhibit abundant 
microRNAs and are not as prepared for safe delivery in patients as ASO technology (Ebert and 
Sharp, 2010).  
 As seen with Miriversen, antisense oligonucleotides (ASOs) against miRNAs are able to 
inhibit the function of the target miRNA in vivo. ASOs are short, synthetic, single-stranded DNA 
molecules that hybridize to a target RNA through Watson-Crick base pairing. The ASO then 
serves to either sequester the RNA species or degrade it through recruitment of endogenous 
RNaseH (Crooke, 2004). The mode of action will depend upon the backbone and sugar 
modifications of the ASO. Numerous modifications have arisen from attempts to enhance 
potency, extend half-life, increase specificity, and decrease toxicity. The most widely used of 
these backbone modifications is the phosphorothioate modification (PS), which involves 
substituting the non-bridging oxygen at the phosphodiester linkage with sulfur. The most widely 
used modifications at the 2’ sugar are the 2’O-methyl and the 2’-O-methoxyethyl substitutions. 
Several ASOs with these backbones have entered clinical trials in the treatment of cancer (Dean 
and Bennett, 2003). In contrast with sponges, ASO technology is considered more promising as a 
potential therapeutic method in light of recent, successful clinical trials covering a wide range of 
diseases (reviewed: (Kole et al., 2012)). 
ASO-mediated miRNA inhibition has been successful in the periphery but has not been 
readily applied to the CNS. ASOs are highly charged molecules that resist crossing the blood-
brain barrier (BBB). In fact, peripheral dosing would have to be approximately 100-fold higher 
than a direct CNS delivery to equal the same level of tissue concentration (Banks et al., 2001). 
However, direct CNS delivery has recently become a proven method to deliver ASOs to patients 
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for targeting mRNAs. After discovering that a 20-mer anti-SOD1 ASO delivered to the lateral 
ventricles resulted in a 10 day survival extension in the ALS-rat model, preclinical primate 
experiments were conducted, showing distribution of the ASO throughout the brain and spinal 
cord (Smith et al., 2006). In 2013, a clinical trial testing the safety of an intrathecal delivery of 
this same anti-SOD1 ASO found no significantly increased occurrence of adverse events. The 
most common adverse reactions were related to the lumbar puncture and included back pain and 
nausea (Miller et al., 2013). Given these promising studies that safely inhibit mRNAs in the 
central nervous system both in patients and in mouse models, we aimed to adapt this technology 
to study microRNA inhibition in vivo in order to determine the mechanism and the importance of 
dysregulated miRNAs in ALS. 
 
1.5) Summary and goals of the dissertation: 
ALS is a devastating neurodegenerative disease with no adequate therapies but with an 
ample number of potential cellular pathways to target. One well studied pathological feature of 
ALS is that of neuroinflammation. Many studies have recently shown that the immune response 
is not overall a negative driver of disease progression in ALS and other neurodegenerative 
disorders. Instead, selective immune modulating techniques have afforded promising survival 
benefits whereas global blunting the inflammatory pathways have been shown to be detrimental. 
miRNAs are an exciting new avenue of research. These small translation inhibitors have the 
potential to target hundreds of targets including entire gene batteries (Makeyev and Maniatis, 
2008) including potentially pathogenic pathways involved in ALS. As one approach to modulate 
miRNA levels in vivo, recent studies have shown that antisense oligonucleotides can be 
administered both safely and effectively.  
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 To address the need for novel approaches to ALS therapeutics, we researched changes in 
miRNA expression levels in spinal cord tissue. For this, we first used the well-studied SOD1G93A 
ALS-model mouse line to identify dysregulated miRNAs. In order to enhance the translational 
potential of our findings, we screened miRNA targets in two ALS mouse models, the ALS rat 
model, and in ALS patient autopsy spinal cord tissues. Understanding the important role of non-
neuronal cells in ALS disease progression, we next developed physiologically relevant methods 
to determine cellular location of miRNAs in a high-throughput fashion. Specifically, we found 
that our top miRNA of interest, miR-155, was robustly enriched in microglia. No study had 
previously inhibited miRNAs throughout the brain and spinal cord in a mouse model of 
neurodegeneration, so we carefully screened multiple ASO chemical modifications and delivery 
methods to develop a way to broadly and potently inhibit a miRNA in the CNS.  
 After finding that anti-miR-155 treatment successfully extended survival in an ALS-
mouse model without affecting onset of disease, we performed a panel screen of 
neuroinflammatory transcripts in the treated spinal cord and spleen tissue. Previous research has 
clearly shown the robust activation of the innate and adaptive immune system in ALS patients 
and in the ALS mouse model, and several studies have shown the potential of 
immunomodulatory therapies in treating ALS. However, several recent controversies have 
emerged concerning the specific nature of neuroinflammation in ALS including the role of 
microglia versus macrophages and the beneficial versus detrimental nature of the immune system 
in ALS. By performing an unbiased panel screen, we generated correlative data linking the 
survival benefit of anti-miR-155 treatment in the ALS-mouse model to increased levels of 
specific transcripts for cellular and molecular neuroinflammatory genes. This work serves 
several important functions. It identifies several interesting miRNA targets for studying 
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neurodegenerative diseases. It develops important methods for identifying miRNA cellular 
expression and for inhibiting miRNA function in vivo. Finally, this thesis work identifies an 
exciting new therapeutic target for ALS while also informing a potential role of 
neuroinflammation in ALS. The experiments and methods discussed here will likely have 
important ramifications broadly in both microRNA and ALS research.  Overall, this dissertation 
aimed to discover novel therapeutic targets for ALS, enhance understanding of pathological 
pathways in ALS, and develop methods to study miRNAs in vivo.     
26 
Ajami, B., Bennett, J.L., Krieger, C., Tetzlaff, W., Rossi, F.M., 2007. Local self-renewal can 
sustain CNS microglia maintenance and function throughout adult life. Nature 
Neuroscience. 10, 1538-43. 
Al-Chalabi, A., Hardiman, O, 2013. The epidemiology of ALS: a conspiracy of genes, 
environment and time. Nat Rev Neurol. 9, 617-28. 
Alliot, F., Godin, I., Pessac, B., 1999. Microglia derive from progenitors, originating from the 
yolk sac, and which proliferate in the brain. Brain Res Dev Brain Res. 117, 145-52. 
Andersen, P.M., 2006. Amyotrophic lateral sclerosis associated with mutations in the CuZn 
superoxide dismutase gene. Curr Neurol Neurosci Rep. 6, 37-46. 
Bartel, D.P., 2009. MicroRNAs: target recognition and regulatory functions. Cell. 136, 215-33. 
Beers, D.R., Henkel, J.S., Zhao, W., Wang, J., Appel, S.H., 2008. CD4+ T cells support glial 
neuroprotection, slow disease progression, and modify glial morphology in an animal 
model of inherited ALS. Proc Natl Acad Sci U S A. 105, 15558-63. 
Beers, D.R., Henkel, J.S., Zhao, W., Wang, J., Huang, A., Wen, S., Liao, B., Appel, S.H., 2011. 
Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice 
and correlate with disease progression in patients with amyotrophic lateral sclerosis. 
Brain. 134, 1293-314. 
Benatar, M., 2007. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. 
Neurobiol Dis. 26, 1-13. 
Boillee, S., Yamanaka, K., Lobsiger, C.S., Copeland, N.G., Jenkins, N.A., Kassiotis, G., Kollias, 
G., Cleveland, D.W., 2006. Onset and progression in inherited ALS determined by motor 
neurons and microglia. Science. 312, 1389-92. 
Boissonneault, V., Filali, M., Lessard, M., Relton, J., Wong, G., Rivest, S., 2009. Powerful 
beneficial effects of macrophage colony-stimulating factor on beta-amyloid deposition 
and cognitive impairment in Alzheimer's disease. Brain. 132, 1078-92. 
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A.J., Dake, B., Murugaiyan, G., Doykan, C.E., 
Wu, P.M., Gali, R.R., Iyer, L.K., Lawson, R., Berry, J., Krichevsky, A.M., Cudkowicz, 
M.E., Weiner, H.L., 2012. Modulating inflammatory monocytes with a unique 
microRNA gene signature ameliorates murine ALS. J Clin Invest. 122, 3063-87. 
Cheah, B.C., Vucic, S., Krishnan, A.V., Kiernan, M.C., 2010. Riluzole, neuroprotection and 
amyotrophic lateral sclerosis. Curr Med Chem. 17, 1942-199. 
Chekulaeva, M., Filipowicz, W., 2009. Mechanisms of miRNA-mediated post-transcriptional 
regulation in animal cells. Curr Opin Cell Biol. 21, 452-60. 
Chen, K., Rajewsky, N., 2006. Natural selection on human microRNA binding sites inferred 
from SNP data. Nat Genet. 38, 1452-6. 
Chi, S.W., Zang, J.B., Mele, A., Darnell, R.B., 2009. Argonaute HITS-CLIP decodes 
microRNA-mRNA interaction maps. Nature. 460, 479-86. 
Chio, A., Logroscino, G., Traynor, B.J., Collins, J., Simeone, J.C., Goldstein, L.A., White, L.A., 
2013. Global epidemiology of amyotrophic lateral sclerosis: a systematic review of the 
published literature. Neuroepidemiology. 41, 118-30. 
27 
Chiu, I.M., Chen, A., Zheng, Y., Kosaras, B., Tsiftsoglou, S.A., Vartanian, T.K., Brown, R.H., 
Jr., Carroll, M.C., 2008. T lymphocytes potentiate endogenous neuroprotective 
inflammation in a mouse model of ALS. Proc Natl Acad Sci U S A. 105, 17913-8. 
Chiu, I.M., Morimoto, E.T., Goodarzi, H., Liao, J.T., O'Keeffe, S., Phatnani, H.P., Muratet, M., 
Carroll, M.C., Levy, S., Tavazoie, S., Myers, R.M., Maniatis, T., 2013. A 
neurodegeneration-specific gene-expression signature of acutely isolated microglia from 
an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385-401. 
Ciura, S., Lattante, S., Le Ber, I., Latouche, M., Tostivint, H., Brice, A., Kabashi, E., 2013. Loss 
of function of C9orf72 causes motor deficits in a zebrafish model of amyotrophic lateral 
sclerosis. Ann Neurol. 74, 180-7. 
Crooke, S.T., 2004. Progress in antisense technology. Annu Rev Med. 55, 61-95. 
Damiano, M., Starkov, A.A., Petri, S., Kipiani, K., Kiaei, M., Mattiazzi, M., Flint Beal, M., 
Manfredi, G., 2006. Neural mitochondrial Ca2+ capacity impairment precedes the onset 
of motor symptoms in G93A Cu/Zn-superoxide dismutase mutant mice. J Neurochem. 
96, 1349-61. 
De Vos, K.J., Chapman, A.L., Tennant, M.E., Manser, C., Tudor, E.L., Lau, K.F., Brownlees, J., 
Ackerley, S., Shaw, P.J., McLoughlin, D.M., Shaw, C.E., Leigh, P.N., Miller, C.C., 
Grierson, A.J., 2007. Familial amyotrophic lateral sclerosis-linked SOD1 mutants perturb 
fast axonal transport to reduce axonal mitochondria content. Hum Mol Genet. 16, 2720-8. 
Dean, N.M., Bennett, C.F., 2003. Antisense oligonucleotide-based therapeutics for cancer. 
Oncogene. 22, 9087-96. 
del Aguila, M.A., Longstreth, W.T., Jr., McGuire, V., Koepsell, T.D., van Belle, G., 2003. 
Prognosis in amyotrophic lateral sclerosis: a population-based study. Neurology. 60, 813-
9. 
Diserbo, M., Agin, A., Lamproglou, I., Mauris, J., Staali, F., Multon, E., Amourette, C., 2002. 
Blood-brain barrier permeability after gamma whole-body irradiation: an in vivo 
microdialysis study. Can J Physiol Pharmacol. 80, 670-8. 
Donnelly, C.J., Zhang, P.W., Pham, J.T., Heusler, A.R., Mistry, N.A., Vidensky, S., Daley, E.L., 
Poth, E.M., Hoover, B., Fines, D.M., Maragakis, N., Tienari, P.J., Petrucelli, L., Traynor, 
B.J., Wang, J., Rigo, F., Bennett, C.F., Blackshaw, S., Sattler, R., Rothstein, J.D., 2013. 
RNA toxicity from the ALS/FTD C9ORF72 expansion is mitigated by antisense 
intervention. Neuron. 80, 415-28. 
Ebert, M.S., Neilson, J.R., Sharp, P.A., 2007. MicroRNA sponges: competitive inhibitors of 
small RNAs in mammalian cells. Nat Methods. 4, 721-6. 
Ebert, M.S., Sharp, P.A., 2010. MicroRNA sponges: progress and possibilities. RNA. 16, 2043-
50. 
Engelhardt, J.I., Tajti, J., Appel, S.H., 1993. Lymphocytic infiltrates in the spinal cord in 
amyotrophic lateral sclerosis. Arch Neurol. 50, 30-6. 
Evans, M.C., Couch, Y., Sibson, N., Turner, M.R., 2013. Inflammation and neurovascular 
changes in amyotrophic lateral sclerosis. Mol Cell Neurosci. 53, 34-41. 
28 
Ferraiuolo, L., Kirby, J., Grierson, A.J., Sendtner, M., Shaw, P.J., 2011. Molecular pathways of 
motor neuron injury in amyotrophic lateral sclerosis. Nat Rev Neurol. 7, 616-30. 
Friedman, R.C., Farh, K.K., Burge, C.B., Bartel, D.P., 2009. Most mammalian mRNAs are 
conserved targets of microRNAs. Genome Res. 19, 92-105. 
Ginhoux, F., Greter, M., Leboeuf, M., Nandi, S., See, P., Gokhan, S., Mehler, M.F., Conway, 
S.J., Ng, L.G., Stanley, E.R., Samokhvalov, I.M., Merad, M., 2010. Fate mapping 
analysis reveals that adult microglia derive from primitive macrophages. Science. 330, 
841-5. 
Goldmann, T., Wieghofer, P., Muller, P.F., Wolf, Y., Varol, D., Yona, S., Brendecke, S.M., 
Kierdorf, K., Staszewski, O., Datta, M., Luedde, T., Heikenwalder, M., Jung, S., Prinz, 
M., 2013. A new type of microglia gene targeting shows TAK1 to be pivotal in CNS 
autoimmune inflammation. Nature Neuroscience. 16, 1618-26. 
Gordon, P.H., Moore, D.H., Miller, R.G., Florence, J.M., Verheijde, J.L., Doorish, C., Hilton, 
J.F., Spitalny, G.M., MacArthur, R.B., Mitsumoto, H., Neville, H.E., Boylan, K., 
Mozaffar, T., Belsh, J.M., Ravits, J., Bedlack, R.S., Graves, M.C., McCluskey, L.F., 
Barohn, R.J., Tandan, R., 2007. Efficacy of minocycline in patients with amyotrophic 
lateral sclerosis: a phase III randomised trial. Lancet Neurol. 6, 1045-53. 
Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Caliendo, 
J., Hentati, A., Kwon, Y.W., Deng, H.X., et al., 1994. Motor neuron degeneration in mice 
that express a human Cu,Zn superoxide dismutase mutation. Science. 264, 1772-5. 
Haidet-Phillips, A.M., Hester, M.E., Miranda, C.J., Meyer, K., Braun, L., Frakes, A., Song, S., 
Likhite, S., Murtha, M.J., Foust, K.D., Rao, M., Eagle, A., Kammesheidt, A., 
Christensen, A., Mendell, J.R., Burghes, A.H., Kaspar, B.K., 2011. Astrocytes from 
familial and sporadic ALS patients are toxic to motor neurons. Nat Biotechnol. 29, 824-8. 
He, M., Liu, Y., Wang, X., Zhang, M.Q., Hannon, G.J., Huang, Z.J., 2012. Cell-type-based 
analysis of microRNA profiles in the mouse brain. Neuron. 73, 35-48. 
Hebert, S.S., Horre, K., Nicolai, L., Papadopoulou, A.S., Mandemakers, W., Silahtaroglu, A.N., 
Kauppinen, S., Delacourte, A., De Strooper, B., 2008. Loss of microRNA cluster miR-
29a/b-1 in sporadic Alzheimer's disease correlates with increased BACE1/beta-secretase 
expression. Proc Natl Acad Sci U S A. 105, 6415-20. 
Henkel, J.S., Beers, D.R., Zhao, W., Appel, S.H., 2009. Microglia in ALS: the good, the bad, and 
the resting. J Neuroimmune Pharmacol. 4, 389-98. 
Ilieva, H., Polymenidou, M., Cleveland, D.W., 2009. Non-cell autonomous toxicity in 
neurodegenerative disorders: ALS and beyond. J Cell Biol. 187, 761-72. 
Janssen, H.L., Reesink, H.W., Zeuzem, S., Lawitz, E., Rodriguez-Torres, M., Chen, A., Davis, 
C., King, B., Levin, A.A., Hodges, M.R., 2011. A Randomized, Double-Blind, Placebo 
(Plb) Controlled Safety and Anti-Viral Proof of Concept Study of Miriversen (Mir), an 
Oligonucleotide Targeting Mir-122, in Treatment Naive Patients with Genotype 1 (Gt1) 
Chronic Hcv Infection. Hepatology. 54, 1430a-1430a. 
 
29 
Janssen, H.L., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der 
Meer, A.J., Patick, A.K., Chen, A., Zhou, Y., Persson, R., King, B.D., Kauppinen, S., 
Levin, A.A., Hodges, M.R., 2013. Treatment of HCV infection by targeting microRNA. 
N Engl J Med. 368, 1685-94. 
Jopling, C.L., Yi, M., Lancaster, A.M., Lemon, S.M., Sarnow, P., 2005. Modulation of hepatitis 
C virus RNA abundance by a liver-specific MicroRNA. Science. 309, 1577-81. 
Kang, S.H., Li, Y., Fukaya, M., Lorenzini, I., Cleveland, D.W., Ostrow, L.W., Rothstein, J.D., 
Bergles, D.E., 2013. Degeneration and impaired regeneration of gray matter 
oligodendrocytes in amyotrophic lateral sclerosis. Nature Neuroscience. 16, 571-9. 
Kim, D.Y., Hong, G.U., Ro, J.Y., 2011. Signal pathways in astrocytes activated by cross-talk 
between of astrocytes and mast cells through CD40-CD40L. J Neuroinflammation. 8, 25. 
Kim, J., Inoue, K., Ishii, J., Vanti, W.B., Voronov, S.V., Murchison, E., Hannon, G., Abeliovich, 
A., 2007. A MicroRNA feedback circuit in midbrain dopamine neurons. Science. 317, 
1220-4. 
Kole, R., Krainer, A.R., Altman, S., 2012. RNA therapeutics: beyond RNA interference and 
antisense oligonucleotides. Nat Rev Drug Discov. 11, 125-40. 
Krol, J., Loedige, I., Filipowicz, W., 2010. The widespread regulation of microRNA biogenesis, 
function and decay. Nat Rev Genet. 11, 597-610. 
Kumar, D.R., Aslinia, F., Yale, S.H., Mazza, J.J., 2011. Jean-Martin Charcot: the father of 
neurology. Clin Med Res. 9, 46-9. 
Laaksovirta, H., Peuralinna, T., Schymick, J.C., Scholz, S.W., Lai, S.L., Myllykangas, L., 
Sulkava, R., Jansson, L., Hernandez, D.G., Gibbs, J.R., Nalls, M.A., Heckerman, D., 
Tienari, P.J., Traynor, B.J., 2010. Chromosome 9p21 in amyotrophic lateral sclerosis in 
Finland: a genome-wide association study. Lancet Neurol. 9, 978-85. 
Lanford, R.E., Hildebrandt-Eriksen, E.S., Petri, A., Persson, R., Lindow, M., Munk, M.E., 
Kauppinen, S., Orum, H., 2010. Therapeutic silencing of microRNA-122 in primates with 
chronic hepatitis C virus infection. Science. 327, 198-201. 
Lee, R.C., Feinbaum, R.L., Ambros, V., 1993. The C. elegans heterochronic gene lin-4 encodes 
small RNAs with antisense complementarity to lin-14. Cell. 75, 843-54. 
Leigh, P.N., Meininger, V., Bensimon, G., Cudkowicz, M., Robberecht, W., 2008. Minocycline 
for patients with ALS. Lancet Neurol. 7, 119-20; author reply 120-1. 
Lewis, C.A., Manning, J., Rossi, F., Krieger, C., 2012. The Neuroinflammatory Response in 
ALS: The Roles of Microglia and T Cells. Neurol Res Int. 2012, 803701. 
Liao, B., Zhao, W., Beers, D.R., Henkel, J.S., Appel, S.H., 2012. Transformation from a 
neuroprotective to a neurotoxic microglial phenotype in a mouse model of ALS. Exp 
Neurol. 237, 147-52. 
LifeTechnologies, 2012. New tools for microRNA functional analysis. BioProbes. 67, 20-21. 
Lugli, G., Larson, J., Martone, M.E., Jones, Y., Smalheiser, N.R., 2005. Dicer and eIF2c are 
enriched at postsynaptic densities in adult mouse brain and are modified by neuronal 
activity in a calpain-dependent manner. J Neurochem. 94, 896-905. 
30 
Majounie, E., Renton, A.E., Mok, K., Dopper, E.G., Waite, A., Rollinson, S., Chio, A., 
Restagno, G., Nicolaou, N., Simon-Sanchez, J., van Swieten, J.C., Abramzon, Y., 
Johnson, J.O., Sendtner, M., Pamphlett, R., Orrell, R.W., Mead, S., Sidle, K.C., Houlden, 
H., Rohrer, J.D., Morrison, K.E., Pall, H., Talbot, K., Ansorge, O., Hernandez, D.G., 
Arepalli, S., Sabatelli, M., Mora, G., Corbo, M., Giannini, F., Calvo, A., Englund, E., 
Borghero, G., Floris, G.L., Remes, A.M., Laaksovirta, H., McCluskey, L., Trojanowski, 
J.Q., Van Deerlin, V.M., Schellenberg, G.D., Nalls, M.A., Drory, V.E., Lu, C.S., Yeh, 
T.H., Ishiura, H., Takahashi, Y., Tsuji, S., Le Ber, I., Brice, A., Drepper, C., Williams, 
N., Kirby, J., Shaw, P., Hardy, J., Tienari, P.J., Heutink, P., Morris, H.R., Pickering-
Brown, S., Traynor, B.J., 2012. Frequency of the C9orf72 hexanucleotide repeat 
expansion in patients with amyotrophic lateral sclerosis and frontotemporal dementia: a 
cross-sectional study. Lancet Neurol. 11, 323-30. 
Makeyev, E.V., Maniatis, T., 2008. Multilevel regulation of gene expression by microRNAs. 
Science. 319, 1789-90. 
Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., 2002. Macrophage polarization: 
tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. 
Trends Immunol. 23, 549-55. 
Maragakis, N.J., Rothstein, J.D., 2006. Mechanisms of Disease: astrocytes in neurodegenerative 
disease. Nat Clin Pract Neurol. 2, 679-89. 
McKercher, S.R., Torbett, B.E., Anderson, K.L., Henkel, G.W., Vestal, D.J., Baribault, H., 
Klemsz, M., Feeney, A.J., Wu, G.E., Paige, C.J., Maki, R.A., 1996. Targeted disruption 
of the PU.1 gene results in multiple hematopoietic abnormalities. EMBO J. 15, 5647-58. 
Meister, G., Landthaler, M., Patkaniowska, A., Dorsett, Y., Teng, G., Tuschl, T., 2004. Human 
Argonaute2 mediates RNA cleavage targeted by miRNAs and siRNAs. Mol Cell. 15, 
185-97. 
Melanie Leitner, S.M., Cathleen Lutz 2009. Working with ALS Mice; Guidelines for preclinical 
testing and colony management. Vol., ed.^eds. Prize4Life, Inc. 
Melzer, N., Meuth, S.G., Wiendl, H., 2009. CD8+ T cells and neuronal damage: direct and 
collateral mechanisms of cytotoxicity and impaired electrical excitability. FASEB J. 23, 
3659-73. 
Mildner, A., Schmidt, H., Nitsche, M., Merkler, D., Hanisch, U.K., Mack, M., Heikenwalder, 
M., Bruck, W., Priller, J., Prinz, M., 2007. Microglia in the adult brain arise from Ly-
6ChiCCR2+ monocytes only under defined host conditions. Nature Neuroscience. 10, 
1544-53. 
Miller, T.M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S.H., Andres, P.L., 
Mahoney, K., Allred, P., Alexander, K., Ostrow, L.W., Schoenfeld, D., Macklin, E.A., 
Norris, D.A., Manousakis, G., Crisp, M., Smith, R., Bennett, C.F., Bishop, K.M., 
Cudkowicz, M.E., 2013. An antisense oligonucleotide against SOD1 delivered 
intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, 
randomised, first-in-man study. Lancet Neurol. 12, 435-42. 
Min, H., Yoon, S., 2010. Got target? Computational methods for microRNA target prediction 
and their extension. Exp Mol Med. 42, 233-44. 
31 
Morozova, N., Zinovyev, A., Nonne, N., Pritchard, L.L., Gorban, A.N., Harel-Bellan, A., 2012. 
Kinetic signatures of microRNA modes of action. RNA. 18, 1635-55. 
Moser, J.M., Bigini, P., Schmitt-John, T., 2013. The wobbler mouse, an ALS animal model. Mol 
Genet Genomics. 288, 207-29. 
Mosmann, T.R., Sad, S., 1996. The expanding universe of T-cell subsets: Th1, Th2 and more. 
Immunol Today. 17, 138-46. 
Nagai, M., Re, D.B., Nagata, T., Chalazonitis, A., Jessell, T.M., Wichterle, H., Przedborski, S., 
2007. Astrocytes expressing ALS-linked mutated SOD1 release factors selectively toxic 
to motor neurons. Nature Neuroscience. 10, 615-22. 
Nakajima, K., Honda, S., Tohyama, Y., Imai, Y., Kohsaka, S., Kurihara, T., 2001. Neurotrophin 
secretion from cultured microglia. J Neurosci Res. 65, 322-31. 
Naor, S., Keren, Z., Bronshtein, T., Goren, E., Machluf, M., Melamed, D., 2009. Development of 
ALS-like disease in SOD-1 mice deficient of B lymphocytes. J Neurol. 256, 1228-35. 
Nimmerjahn, A., Kirchhoff, F., Helmchen, F., 2005. Resting microglial cells are highly dynamic 
surveillants of brain parenchyma in vivo. Science. 308, 1314-8. 
Pasinelli, P., Brown, R.H., 2006. Molecular biology of amyotrophic lateral sclerosis: insights 
from genetics. Nat Rev Neurosci. 7, 710-23. 
Philips, T., Robberecht, W., 2011. Neuroinflammation in amyotrophic lateral sclerosis: role of 
glial activation in motor neuron disease. Lancet Neurol. 10, 253-63. 
Prinz, M., Priller, J., 2014. Microglia and brain macrophages in the molecular age: from origin to 
neuropsychiatric disease. Nat Rev Neurosci. 15, 300-12. 
Qiu, H., Lee, S., Shang, Y., Wang, W.Y., Au, K.F., Kamiya, S., Barmada, S.J., Finkbeiner, S., 
Lui, H., Carlton, C.E., Tang, A.A., Oldham, M.C., Wang, H., Shorter, J., Filiano, A.J., 
Roberson, E.D., Tourtellotte, W.G., Chen, B., Tsai, L.H., Huang, E.J., 2014. ALS-
associated mutation FUS-R521C causes DNA damage and RNA splicing defects. J Clin 
Invest. 124, 981-99. 
Reaume, A.G., Elliott, J.L., Hoffman, E.K., Kowall, N.W., Ferrante, R.J., Siwek, D.F., Wilcox, 
H.M., Flood, D.G., Beal, M.F., Brown, R.H., Jr., Scott, R.W., Snider, W.D., 1996. Motor 
neurons in Cu/Zn superoxide dismutase-deficient mice develop normally but exhibit 
enhanced cell death after axonal injury. Nat Genet. 13, 43-7. 
Reid, G., Kirschner, M.B., van Zandwijk, N., 2011. Circulating microRNAs: Association with 
disease and potential use as biomarkers. Crit Rev Oncol Hematol. 80, 193-208. 
Rentzos, M., Evangelopoulos, E., Sereti, E., Zouvelou, V., Marmara, S., Alexakis, T., 
Evdokimidis, I., 2012. Alterations of T cell subsets in ALS: a systemic immune 
activation? Acta Neurol Scand. 125, 260-4. 
Rodriguez, A., Griffiths-Jones, S., Ashurst, J.L., Bradley, A., 2004. Identification of mammalian 
microRNA host genes and transcription units. Genome Res. 14, 1902-10. 
Rosen, D.R., 1993. Mutations in Cu/Zn superoxide dismutase gene are associated with familial 
amyotrophic lateral sclerosis. Nature. 364, 362. 
32 
Rossi, D., Martorana, F., Brambilla, L., 2011. Implications of gliotransmission for the 
pharmacotherapy of CNS disorders. CNS Drugs. 25, 641-58. 
Selbach, M., Schwanhausser, B., Thierfelder, N., Fang, Z., Khanin, R., Rajewsky, N., 2008. 
Widespread changes in protein synthesis induced by microRNAs. Nature. 455, 58-63. 
Simard, A.R., Soulet, D., Gowing, G., Julien, J.P., Rivest, S., 2006. Bone marrow-derived 
microglia play a critical role in restricting senile plaque formation in Alzheimer's disease. 
Neuron. 49, 489-502. 
Smith, R.A., Miller, T.M., Yamanaka, K., Monia, B.P., Condon, T.P., Hung, G., Lobsiger, C.S., 
Ward, C.M., McAlonis-Downes, M., Wei, H., Wancewicz, E.V., Bennett, C.F., 
Cleveland, D.W., 2006. Antisense oligonucleotide therapy for neurodegenerative disease. 
J Clin Invest. 116, 2290-6. 
Tai, H.C., Schuman, E.M., 2006. MicroRNA: microRNAs reach out into dendrites. Curr Biol. 
16, R121-3. 
Tambuyzer, B.R., Ponsaerts, P., Nouwen, E.J., 2009. Microglia: gatekeepers of central nervous 
system immunology. J Leukoc Biol. 85, 352-70. 
Tang, F., Hajkova, P., O'Carroll, D., Lee, C., Tarakhovsky, A., Lao, K., Surani, M.A., 2008. 
MicroRNAs are tightly associated with RNA-induced gene silencing complexes in vivo. 
Biochem Biophys Res Commun. 372, 24-9. 
Town, T., Laouar, Y., Pittenger, C., Mori, T., Szekely, C.A., Tan, J., Duman, R.S., Flavell, R.A., 
2008. Blocking TGF-beta-Smad2/3 innate immune signaling mitigates Alzheimer-like 
pathology. Nat Med. 14, 681-7. 
Trang, P., Wiggins, J.F., Daige, C.L., Cho, C., Omotola, M., Brown, D., Weidhaas, J.B., Bader, 
A.G., Slack, F.J., 2011. Systemic delivery of tumor suppressor microRNA mimics using 
a neutral lipid emulsion inhibits lung tumors in mice. Mol Ther. 19, 1116-22. 
van Es, M.A., Veldink, J.H., Saris, C.G., Blauw, H.M., van Vught, P.W., Birve, A., Lemmens, 
R., Schelhaas, H.J., Groen, E.J., Huisman, M.H., van der Kooi, A.J., de Visser, M., 
Dahlberg, C., Estrada, K., Rivadeneira, F., Hofman, A., Zwarts, M.J., van Doormaal, 
P.T., Rujescu, D., Strengman, E., Giegling, I., Muglia, P., Tomik, B., Slowik, A., 
Uitterlinden, A.G., Hendrich, C., Waibel, S., Meyer, T., Ludolph, A.C., Glass, J.D., 
Purcell, S., Cichon, S., Nothen, M.M., Wichmann, H.E., Schreiber, S., Vermeulen, S.H., 
Kiemeney, L.A., Wokke, J.H., Cronin, S., McLaughlin, R.L., Hardiman, O., Fumoto, K., 
Pasterkamp, R.J., Meininger, V., Melki, J., Leigh, P.N., Shaw, C.E., Landers, J.E., Al-
Chalabi, A., Brown, R.H., Jr., Robberecht, W., Andersen, P.M., Ophoff, R.A., van den 
Berg, L.H., 2009. Genome-wide association study identifies 19p13.3 (UNC13A) and 
9p21.2 as susceptibility loci for sporadic amyotrophic lateral sclerosis. Nat Genet. 41, 
1083-7. 
van Rooij, E., Purcell, A.L., Levin, A.A., 2012. Developing microRNA therapeutics. Circ Res. 
110, 496-507. 
 
 
33 
Volinia, S., Calin, G.A., Liu, C.G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., 
Roldo, C., Ferracin, M., Prueitt, R.L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, 
A., Negrini, M., Harris, C.C., Croce, C.M., 2006. A microRNA expression signature of 
human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 103, 2257-
61. 
Wake, H., Moorhouse, A.J., Jinno, S., Kohsaka, S., Nabekura, J., 2009. Resting microglia 
directly monitor the functional state of synapses in vivo and determine the fate of 
ischemic terminals. J Neurosci. 29, 3974-80. 
Weydt, P., Moller, T., 2005. Neuroinflammation in the pathogenesis of amyotrophic lateral 
sclerosis. Neuroreport. 16, 527-31. 
Williams, A.H., Valdez, G., Moresi, V., Qi, X., McAnally, J., Elliott, J.L., Bassel-Duby, R., 
Sanes, J.R., Olson, E.N., 2009. MicroRNA-206 delays ALS progression and promotes 
regeneration of neuromuscular synapses in mice. Science. 326, 1549-54. 
Winter, J., Jung, S., Keller, S., Gregory, R.I., Diederichs, S., 2009. Many roads to maturity: 
microRNA biogenesis pathways and their regulation. Nat Cell Biol. 11, 228-34. 
Wolf, Y., Yona, S., Kim, K.W., Jung, S., 2013. Microglia, seen from the CX3CR1 angle. Front 
Cell Neurosci. 7, 26. 
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R.M., 
Okamoto, A., Yokota, J., Tanaka, T., Calin, G.A., Liu, C.G., Croce, C.M., Harris, C.C., 
2006. Unique microRNA molecular profiles in lung cancer diagnosis and prognosis. 
Cancer Cell. 9, 189-98. 
Yamanaka, K., Chun, S.J., Boillee, S., Fujimori-Tonou, N., Yamashita, H., Gutmann, D.H., 
Takahashi, R., Misawa, H., Cleveland, D.W., 2008. Astrocytes as determinants of disease 
progression in inherited amyotrophic lateral sclerosis. Nature Neuroscience. 11, 251-253. 
Yamasaki, R., Lu, H., Butovsky, O., Ohno, N., Rietsch, A.M., Cialic, R., Wu, P.M., Doykan, 
C.E., Lin, J., Cotleur, A.C., Kidd, G., Zorlu, M.M., Sun, N., Hu, W., Liu, L., Lee, J.C., 
Taylor, S.E., Uehlein, L., Dixon, D., Gu, J., Floruta, C.M., Zhu, M., Charo, I.F., Weiner, 
H.L., Ransohoff, R.M., 2014. Differential roles of microglia and monocytes in the 
inflamed central nervous system. J Exp Med. 211, 1533-49. 
Yona, S., Kim, K.W., Wolf, Y., Mildner, A., Varol, D., Breker, M., Strauss-Ayali, D., Viukov, 
S., Guilliams, M., Misharin, A., Hume, D.A., Perlman, H., Malissen, B., Zelzer, E., Jung, 
S., 2013. Fate mapping reveals origins and dynamics of monocytes and tissue 
macrophages under homeostasis. Immunity. 38, 79-91. 
Zhao, W., Xie, W., Le, W., Beers, D.R., He, Y., Henkel, J.S., Simpson, E.P., Yen, A.A., Xiao, 
Q., Appel, S.H., 2004. Activated microglia initiate motor neuron injury by a nitric oxide 
and glutamate-mediated mechanism. J Neuropathol Exp Neurol. 63, 964-77. 
Zhu, S., Stavrovskaya, I.G., Drozda, M., Kim, B.Y., Ona, V., Li, M., Sarang, S., Liu, A.S., 
Hartley, D.M., Wu, D.C., Gullans, S., Ferrante, R.J., Przedborski, S., Kristal, B.S., 
Friedlander, R.M., 2002. Minocycline inhibits cytochrome c release and delays 
progression of amyotrophic lateral sclerosis in mice. Nature. 417, 74-8. 
34 
Zu, T., Liu, Y., Banez-Coronel, M., Reid, T., Pletnikova, O., Lewis, J., Miller, T.M., Harms, 
M.B., Falchook, A.E., Subramony, S.H., Ostrow, L.W., Rothstein, J.D., Troncoso, J.C., 
Ranum, L.P., 2013. RAN proteins and RNA foci from antisense transcripts in C9ORF72 
ALS and frontotemporal dementia. Proc Natl Acad Sci U S A. 110, E4968-77. 
 
 
 
 
 
 
 
 
 
 
 
35 
 
 
 
 
 
 
 
 
 
 
 
CHAPTER 2 
 
 
Characterizing microRNA dysregulation in a rodent model of ALS and in 
patient autopsy tissue 
36 
SUMMARY 
microRNAs (miRNAs) are dysregulated in a variety of disease states, suggesting that this 
newly discovered class of gene expression repressors may be viable therapeutic targets. A 
microarray of miRNA changes in ALS model SOD1G93A rodents identified 12 miRNAs as 
significantly upregulated. Six of these miRNAs tested in human ALS tissues were confirmed 
increased. Specifically, miR-155 was increased 5-fold in mice and 2-fold in human spinal cords. 
Three of these well-correlated target miRNAs are robustly increased at 15-18 weeks of age in a 
24-week ALS-mouse model showing the potential of therapeutic intervention. Despite well-
optimizing a miRNA extraction protocol for ALS patient serum, these top miRNA targets, miR-
142-3p, miR-146a, and miR-155, do not appear to be strong serum biomarker candidates at this 
time. 
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INTRODUCTION 
Amyotrophic lateral sclerosis (ALS; also known as Lou Gehrig’s Disease) is a fatal adult-
onset neurodegenerative disease characterized by the selective loss of motor neurons in the 
spinal cord and brain leading to stiffness, severe muscle weakness, and death due to respiratory 
failure typically within 2-4 years of disease onset (Rothstein, 2009). Riluzole, the only FDA 
approved treatment, prolongs survival by only two to three months (Miller et al., 2012). 
Therefore, discovering novel therapeutic targets is of critical importance.  
Since their discovery in 1993 (Lee et al., 1993), miRNAs have emerged as key regulators 
in numerous physiological and pathological processes. miRNAs are highly conserved, single-
stranded, non-coding RNA molecules ~22 nucleotides in length. miRNAs repress gene 
expression by inhibiting translation of and/or facilitating the degradation of their target mRNAs 
via binding to the 3’UTR. Because only partial complementarity is required for miRNA-mRNA 
interactions, a single miRNA can potentially regulate hundreds of mRNA transcripts. Testing the 
potential therapeutic opportunity of dysregulated miRNAs in any particular disease requires a 
careful analysis of the miRNA expression changes in the target tissues. 
Using animal models, miRNAs have been studied as potential therapeutic targets in a 
wide array of diseases, including cancer (Kota et al., 2009), heart failure (Small and Olson, 
2011), blood disorders (Patrick et al., 2010), and multiple sclerosis (O'Connell et al., 2010; 
Ponomarev et al., 2011). Notably, one study of miRNA in disease is now progressing beyond the 
animal model. Santaris Pharma developed an antisense oligonucleotide inhibitor against miR-
122, called Miriversen, found to be critical to hepatitis C viral replications (Lanford et al., 2010). 
The authors have continued to complete a successful Phase I (Janssen et al., 2011) and Phase IIa 
trial (NCT01200420) (Janssen et al., 2013). These clinical trials shows that despite the vast 
38 
number of potential mRNA targets for each miRNA, miRNAs remain both powerful and realistic 
therapeutic targets.  
Studying miRNA dysregulation and ALS, Williams et al discovered that miR-206 is 
critically important in the organization of neuromuscular synapses and that miR-206 knockout 
mice display increased ALS disease acceleration (Williams et al., 2009). However, the authors 
did not study a rescue effect by increasing miR-206, nor did they study the brain or spinal cord. 
Nevertheless, this study demonstrates that one particularly miRNA can clearly affect ALS.   
The SOD1G93A transgenic mouse model was developed by Gurney et al. in 1994 based 
on a dominantly inherited ALS-causing mutation in patients (Gurney et al., 1994). These 
animals overexpress mutant human SOD1 protein with a glycine to alanine switch at position 
93. SOD1G93A mice and rats are born at normal Mendelian ratios and develop normally. At 3 
months of age, SOD1G93A mice and rats begin to lose weight and develop atrophy in hind limb 
muscles. This phenotype progresses rapidly with paralysis typically occurring at 160 days of 
age. For ethical considerations and to allow the collection of tissues, mice are euthanized when 
unable to right themselves within 30 seconds of being placed on their backs. The SOD1WT 
transgenic line has no overt phenotype.   
TDP-43 was identified biochemically as a component of aggregates associated with 
ALS and Frontotemporal Dementia (Neumann et al., 2006). Subsequently, in 2008, an ALS 
causative mutation in TDP-43 was identified, and all TDP-43 mutations are thought to account 
for ~5% of familial ALS (Gitcho et al., 2008; Kabashi et al., 2008). A transgenic mouse line 
was then developed that expresses this human mutation, TDP-43A315T (Wegorzewska et al., 
2009). TDP-43A315T mice develop progressive weakness and difficulty walking associated with 
loss of motor neurons and ubiquitinated inclusions in motor neurons and layer V cortical 
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neurons (Wegorzewska et al., 2009; Wils et al., 2010). Spinal cords and brains from these mice 
show neuron loss, as well as astrocyte and microglial activation (Wegorzewska et al., 2009). 
Due to a gender disparity in survival times, all of our TDP-43 mouse data presented here focus 
on TDP-43 male mice. This line has since come under controversy for having an obstructive 
bowel phenotype that eclipses a phenotype that would result from classical motor neuron loss in 
the brain and spinal cord (Hatzipetros et al., 2013). Therefore, our use of this line is as a second 
confirmation of interesting miRNAs and not as a primary source in generating dysregulation 
lists. By using two genetic models for validation, top priority miRNAs can be more rigorously 
chosen for future large-scale therapeutic experiments that have a greater chance of success for 
translating to ALS patients broadly.   
While a number of drugs tested in the SOD1 model have subsequently failed in human 
clinical trials, we have taken steps to increase the translational potential of our use of this 
preclinical model. We only considered important those miRNAs increased in both the rodent 
ALS model and in patient ALS tissue from both familial and sporadic ALS patients. Also, 
antisense oligonucleotides have been tested in a Phase I trial in SOD1 human ALS, suggesting 
this type of strategy to be safe and realistic (Miller et al., 2013).  
In 2007, miRNAs were found in exosomes which are 50-90 nm vesicles present in 
biological fluids thought to be important in cell signaling (Valadi et al., 2007). Exosomes are 
actively secreted by a myriad of immune and inflammatory cell types including T cells, B cells, 
dendritic cells, and macrophages. miRNAs were soon after identified as potential diagnostic 
molecules in serum, where, for example, miR-141 could distinguish patients with prostate cancer 
from healthy controls (Mitchell et al., 2008). Adding to the usefulness of miRNAs as potential 
biomarkers is their extreme stability in biofluids including protection from repeated freeze thaw 
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cycles (Mitchell et al., 2008) and a high level of reproducibility between individuals and multiple 
extractions (Chen et al., 2008). There have since been a plethora of studies with miRNAs serving 
as potential biomarkers in serum and plasma for various cancers (reviewed: Reid et al., 2011), 
heart disease (Adachi et al., 2010), sepsis (Wang et al., 2010), and multiple sclerosis (Siegel et 
al., 2012).  
In order to confidently determine the ability of our target miRNAs to serve as biomarkers 
in ALS, we had to first identify a reliable method for quantifying miRNAs. Criteria included a 
high yield in extractions, low noise in extractions from the same biofluid source, and an ability to 
successfully measure miRNA levels in a dilution curve experiment. To this end, we compared 
the most popular miRNA extraction methods and performed a methods screen and optimization 
prior to application to ALS serum. 
The young field of miRNA research is quickly becoming a leader in the identification of 
novel disease pathways while identifying promising therapeutic targets (Jackson and Linsley, 
2010; van Rooij et al., 2012). With well-established ALS rodent models and ALS patient autopsy 
tissue banks, the first step to identify miRNAs interesting to ALS mechanistically and 
translationally requires the formation of a well-validated list of dysregulated miRNAs both in the 
rodent model and in patient tissue. Determining the time-course of these miRNA changes will 
inform intervention potential, and miRNA patient biomarker research could potentially identify 
predictive and prognostic biomarkers as exists for various other diseases. 
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MATERIALS AND METHODS 
Animals  
 All animal protocols were approved by the Institutional Animal Care and Use 
Committee of Washington University at St. Louis and adhered to NIH guidelines. Animals were 
provided food and water ad libitum, and cages were changed once a week. All mice were 
maintained in a 12-hour light/12-hour dark cycle and received routine veterinary monitoring. 
TDP-43A315T mice were sacrificed for tissue harvesting at end-stage of disease as evidenced by 
sudden quiescence following touch, typically at ~90 days of age. SOD1G93A mice were sacrificed 
for tissue at either pre-defined time points throughout disease or at end-stage, evidenced by an 
inability to right itself within 30 seconds of being placed on either side. 
 For tissue harvesting, mice were first anesthetized with isoflurane before being 
perfused with 20-30mL of PBS. Whole spinal cords and/or 30mg of cortex were then isolated 
and flash frozen. All mice used in this chapter were on a pure C57BL/6 background.  
LPS  
 Lipopolysacharide from Escherichia coli O111:B4 (LPS, Sigma) was diluted in PBS 
and injected into 10-week nontransgenic male mice at either 0.2mg LPS/kg mouse mass (6x105 
endotoxin units/kg) or 0.1mg/kg (3 x 105 endotoxin units/kg). After 1 hour, mice were sacrificed, 
perfused, and tissue harvested. 
 BV-2 cells were plated at 50% confluency in a T-75 flask before being treated with 
100ng/mL LPS for 24 hours. Cells were lysed in Qiazol and miRNAs were extracted.  
Human tissues 
 Patient tissues were analyzed with approval from the Institutional Review Board from 
Washington University and Massachusetts General Hospital. Spinal cord autopsy tissue was 
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obtained from 16 ALS patients (9 male, 7 female; age range 34-79, mean 64; from Washington 
University School of Medicine, Massachusetts General Hospital) and 12 non-ALS control 
patients (6 male, 6 female; age range 51-80, mean 70; from National Disease Research 
Interchange; clinical information in Table 2.2. Postmortem intervals ranged from 1 to 40 hours.  
miRNA quantification 
 RNA was extracted from flash frozen tissue using miRNeasy kits per manufacturer’s 
instructions (Qiagen). Mouse RNA integrity and yield were assessed by Nanodrop before 
diluting to 150ng/µL for microarray assays and 2ng/µL for miRNA individual assays. miRNA 
microarrays were performed without amplification using low density Rodent MiRNA A+B cards 
sets 3.0 (Life Technologies) using a 7900HT quantitative real time polymerase chain reaction 
(qPCR) machine for 40 cycles. Analysis was conducted on SDSv2.2 software with automatic 
thresholding. Microarray hits were confirmed with individual TaqMan miRNA assays (Life 
Technologies) as per the manufacturer’s instructions. RNA from patient autopsy samples were 
also quantified via Nanodrop and diluted to 2ng/uL. All rodent miRNAs were normalized to 
endogenous U6, and human miRNA values were normalized to total RNA input. qPCR samples 
were quantified in technical duplicates on an Applied Biosystems 7500 fast Real-Time PCR 
System.  
Serum/Biomarker extraction methods 
 For isolating serum, up to 10mL patient blood was collected in a non-additive, silicone-
coated BD vacutainer tube (red cap). Following a 30 minute to 1 hour room temperature rest, 
blood was centrifuged at 2,000g for 15min at 4oC. The top, serum layer was then aliquoted to 
1.5mL microcentrifuge tubes before centrifuging at 2,000g for 3min at 4oC. The supernatant was 
then transferred to a new microcentrifuge tube until being stored at -80oC. Blood was always 
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attempted to be collected from an ALS patient and a non-ALS control volunteer within 10 
minutes for paired processing and analysis. 
 For methods optimization, patient serum was pooled in order to create a homogenous 
mixture, sufficient to serve as input for all methods being compared within a given experiment. 
Four methods were used for miRNA extraction from serum all according to vendor published 
protocols: (1) miRCURY RNA Isolation Kit – Biofluids (Exiqon), (2) mirVana miRNA Isolation 
Kit (Life Technologies), (3) miRNeasy Serum/Plasma Kit (Qiagen), (4) TRIzol LS. 5.6 x 108 
copies of cel-39 spike-in control (Qiagen) was added to each 200uL serum aliquot prior to 
extraction. 1ug MS2 RNA (Roche) was added to 200uL serum input, as indicated, also prior to 
beginning the extraction protocol. For the serum dilution, methods optimization experiment, 
200uL serum was either undiluted or diluted 4:1, 3:2, 2:3, or 1:4 with PBS prior to the addition 
of spike-in and MS2 and prior to commencing the extraction protocol. 
Statistical analysis  
 Data are presented as mean ± SEM. All statistical tests were conducted with Graphpad 
Prism 6 Software. Gene expression data from end-stage tissue was analyzed with a 2-tailed 
Student t test. Quantification of miR-155 in patient populations which was analyzed by ANOVA 
followed by Tukey’s post-hoc test. The time course of miRNA changes were analyzed by 
ANOVA followed by Dunnett’s multiple comparison test.  
 
RESULTS 
6 miRNAs are significantly upregulated in rodent and patient ALS spinal cord tissue.  
To identify miRNA therapeutic targets for ALS, we measured miRNA changes in both 
the rodent ALS model and in human ALS autopsy samples. Using TaqMan miRNA microarrays 
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that assayed 673 miRNAs, we measured miRNA expression levels in both end-stage mouse and 
rat spinal cord tissue as compared to their age matched controls. First, in order to generate a 
manageable list of most significantly and robustly changed miRNAs to carry forward to in vivo 
intervention experiments, we first considered miRNAs either upregulated or downregulated more 
than 2 fold in the ALS-model mice at p<0.05. From the 43 resulting miRNAs, we next only 
considered miRNAs changed more than 1.5 fold at p<0.2 in the ALS-model rats as compared to 
both nontransgenic and SOD1WT controls. 12 miRNA were identified as significantly increased 
in both ALS models (Table 2.1).  
Using individual miRNA assays, 11 miRNAs were confirmed increased in the mouse, 10 
in the rat, and 6 in patient ALS autopsy spinal cord tissues (Fig 2.1A-C). 16 patient ALS autopsy 
samples were compared to 12 controls, whose clinical diagnosis and demographic information is 
detailed in Table 2.2. Specifically, the most researched amongst these hits, miR-155, was 
significantly increased in both familial and sporadic patient ALS spinal cord tissue (Fig 2.1D). 
Total RNA integrity from our autopsy spinal cord samples was poor as determined by Agilent 
Bioanalyzer; however our miRNA experiments showed well-shaped qPCR amplification curves, 
high amplification, low noise, and high consistency between samples and even between multiple 
extractions from the same spinal cord. Furthermore, RNA integrity numbers (RIN) did not well 
correlate with miRNA qPCR counts (Fig 2.2). This is in agreement with published data showing 
miRNAs to be stable despite extensive degradation of mRNA (Hall et al., 2012). 
Among the list of dysregulated miRNAs in ALS model mice and human ALS samples, 
miR-155 appeared to be an excellent first therapeutic target because of its abundance and fold 
change in ALS and extensive prior work linking miR-155 with immunity and inflammation 
(Landgraf et al., 2007; O'Connell et al., 2007; Wang et al., 2009). To further validate and 
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characterize this targets, we continued analysis from the SOD1G93A ALS-model rodent model to 
the TDP-43A315T ALS/FTD mouse model. miR-155 was increased 1.8 fold in TDP-43A315T mouse 
spinal cords as compared to nontransgenic age-matched controls (p<0.05) (Fig 2.3).  
miR-155 expression levels increase upon LPS treatment, both in the mouse cortex and in 
microglia culture. 
Next, to test if miR-155 upregulation might be a result of inflammation in the central 
nervous system as is true in the periphery (O'Connell et al., 2007), we injected adult 
nontransgenic mice with two doses of LPS. After one hour, their perfused brain was collected, 
and miR-155 was significantly increased. Finally, to determine if this increase could be 
contributed by microglial cells, we treated BV-2, an immortalized murine microglia cell line, 
with LPS for 24 hours and found a robust 14-fold increase in miR-155 levels. (Fig 2.3). 
miR-142-3p, miR-146a, and miR-155 are upregulated at a mid-disease stage in SOD1G93A 
mice and are all well correlated. 
Three of the miRNAs identified to be robustly and significantly increased in end-stage 
ALS-model rodent tissue and in ALS patient autopsy tissue (Fig 2.1) were further evaluated to 
determine when this upregulation occurs in disease. For this, miRNA levels were measured from 
the spinals cords from 3 male and 3 female perfused mice at 9, 12, 15, 18, and 21 weeks of age 
with an additional set of spinal cords collected at end-stage (approximately 24 weeks of age). For 
all 3 miRNAs, a small trending increase was observed at 15 weeks of age (1.4-1.8 fold increase 
over 9 weeks) with robust differences were observed at 18 weeks of age (2.5-3.4 fold increases) 
(Fig 2.4).  
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 Pearson correlation values were then determined for each pairing of these 3 miRNAs 
using the 36 spinal cords from the time course study. miR-142-3p, miR-146a, and miR-155 had a 
near perfect correlation with Pearson Correlation values ranging from 0.98 and 1.0. (Fig 2.5). 
miRNEasy provides highest yield and least noise in quantifying miRNAs from patient 
serum, but 3 target miRNAs remain unchanged in ALS serum. 
Three distinct experiments were conducted in order to find the optimal method for 
miRNA extractions from patient serum. For each, patient serum aliquots were combined to 
create a homogenous pool of serum sufficient to be input for all extractions. First, triplicate 
extractions were performed for 4 methods with and without the RNA carrier MS2: Trizol LS 
(non-column based), miRCury, miRNeasy, and miRVana. Two miRNAs, miR-24, and miR-
196b, were quantified using Taqman primers. miRVana extractions resulted in the highest level 
of noise (Fig 2.6 A-D) and also the lowest yield (E,F) and was therefore no longer considered in 
methods optimization. Next, the remaining best 5 methods were compared again in their yield 
and noise in performing 4 extractions from the same pool of patient serum. Trizol extractions 
without the aid of a purification column resulted in the most noise and lowest yield relative to 
miRNEasy and miRCury. Furthermore, the RNA Carrier MS2 served to increase yield and 
reduce noise (Fig 2.7). 
The final two methods, miRNEasy + MS2 and miRCury + MS2 were compared in three 
ways: 1) their ability to accurately measure a dilution series; 2) their noise between duplicate 
extractions; 3) their miRNA yield. For this, patient serum was again pooled, but also diluted in 
PBS to create 100%, 80%, 60%, 40%, 20%, and 0% serum in PBS aliquots. Three miRNAs were 
quantified from duplicate extractions from each of these dilutions for both methods. The 
measured amount of miRNA from miRNEasy + MS2 extractions much more closely followed 
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the predicted values with less noise (Fig 2.8). Furthermore, miRNEasy + MS2 resulted in 
roughly twice the yield of miRCury (Fig 2.9) and was therefore chosen as the method to measure 
miRNA in ALS patient serum. 
miR-142-3p, miR-142-5p, and miR-155 levels were measured in serum from 27 ALS 
patients and 17 controls using the miRNEasy + MS2 extraction method. miR-103 was also 
measured to be tested as a putative control. While miR-103 normalization did reduce overall 
noise, regardless, all 3 target miRNAs showed no significant or even trending difference in ALS 
serum as compared to controls (Fig 2.10 A,C). For 17 ALS patients, blood was also collected 
from a healthy volunteer at the same time in order to control for any variations in the handling of 
the serum or the time to processing. When measuring these three target miRNAs in a paired 
analysis, the signal remained consistent between ALS patients and controls (B, D) showing these 
three miRNAs to not be suitable ALS serum biomarkers at this time.  
 
DISCUSSION 
To determine the therapeutic potential of targeting miRNAs in ALS, we first generated a 
list of miRNAs changed in the SOD1G93A rodent model. Six of these miRNAs identified in the 
ALS rodent model are also upregulated in familial and sporadic human ALS spinal cord. 
Interestingly, all 6 of the patient-confirmed upregulated miRNAs (miR-24-2*, miR-142-3p, miR-
142-5p, miR-146a, miR-146b, and miR-155) are well studied in the context of immunity and 
inflammation. Each of these targets may be potential candidates for therapies for 
neurodegenerative disease and testing them will require a similar approach to that highlighted in 
chapters 4 and 5 for miR-155. Given the high level of correlation for at least 3 of these targets, 
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the most potent effect on modulating disease phenotype and underlying mechanism may be a 
combinatorial strategy in which multiple related miRNAs are modulated in concert. 
Quantifying when dysregulation begins for our target miRNAs in the ALS model is 
important for two reasons. First, it can help inform the underlying mechanism that drives the 
upregulation. This concept is further discussed in chapter 5. Second, if the miRNA is a negative 
regulator of disease, it is important to know when to target it in any future intervention 
experiment. For the three miRNAs measured, an increase in expression is seen at 15 weeks of 
age that becomes robust at 18 weeks of age with typical survival being 24 weeks. This affords a 
broad time range for potential therapeutic intervention.  
While forming a list of dysregulated miRNAs in ALS is mostly descriptive, some insight 
into underlying mechanism driving these expression changes can be garnered by correlating the 
data with the timing of various pathways in ALS pathogenesis (Turner and Talbot, 2008). These 
pathogenic correlations will be further addressed in chapter 5, but the miRNA time course 
changes are being presented here as they also inform the therapeutic intervention potential and 
the identification of interesting dysregulated miRNAs. In developing a list of our best candidates 
for future intervention studies, we wanted to ensure that miRNAs of interest changed at an early 
or mid-disease point in our mouse model of ALS.  For miR-142-3p, miR-146a, and miR-155, 
upregulation occurs at a mid-disease stage roughly one month before the end-stage of disease.  
This is a sufficiently long window to allow for therapeutic experiments using miRNA inhibitors 
in vivo. 
Interestingly, all three miRNAs for which time course data were generated showed a near 
perfect correlation. This suggests that these miRNAs, while located on separated chromosomes, 
likely result from the same pathological change during ALS. Our best predication of this driving 
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force is the influx and activation of inflammatory mediators (Chiu et al., 2008; Chapter 5). These 
data also suggest that the most robust effect in intervention studies may arise from a multi-target 
approach to prevent compensatory effects of these tightly regulated miRNAs; however, these 
ambitious multi-target experiments are beyond the scope of this dissertation. 
Growing controversy exists on the usefulness of the ALS-rodent model as more clinical 
trials fail to translate rodent targets to patients (Benatar, 2007; Perrin, 2014). This may be due to 
the single genetic mutation, SOD1G93A, most often being studied in mice to then apply to patients 
who 98% do not harbor this mutation. Also, many targets found in the rodent are not validated as 
applicable to patients. We aimed to strengthen our target list in two ways against these justified 
concerns. First, we used the TDP-43A315T mouse line as a second validator of our top miRNA hit 
before deciding to continue with more ambitious intervention experiments. Second, we used 
human autopsy tissue from both familial and sporadic ALS patients to validate our miRNAs of 
interest. The stringency used in identifying dysregulated miRNAs in ALS potentially caused 
some interesting miRNAs to be overlooked but served to increase confidence and reduce the 
number of false positive targets, which is an important consideration given the climate of failed 
clinical trials based on rodent research.  
Research into the usefulness of miRNAs diagnostic and prognostic biomarkers has been 
rapidly expanding. In 2012, it was shown that miR-155 is increased in peripheral monocytes 
(CD14+,CD16+) from ALS patients compared with controls (Butovsky, 2012). These data 
independently corroborate the increased miR-155 levels that we found in human ALS spinal 
cords. One exciting feature of a miR-155 focused trial is the ability to define patients for whom 
miR-155 is clearly increased prior to enrolling in the clinical trial. Since this may be a key 
component of inclusion criteria for clinical trial, it will be important to independently confirm 
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these data. However, serum is experimentally easier and faster to isolate than peripheral blood 
mononuclear cells. The ability to use serum would allow us to greatly expand the number of 
patients/correlations because we could rely on >1000 banked serums. For these reasons, we 
performed a careful experiment to optimize miRNA extraction from serum. After finding a very 
good method that showed great reproducibility and low noise, we screened 27 ALS patient 
samples and 17 controls for three of our miRNA hits. While discouraging that our top targets 
appear unchanged in serum, we may be able to better rely on peripheral blood mononuclear cells 
for future miR-142, miR-146, and miR-155 studies. In the meantime, there may be novel miRNA 
targets from the serum that were eclipsed in our spinal cord tissue based analysis. We are now 
well equipped to study this with the methods and biofluids available. 
 
CONCLUSION 
We have successfully generated a well-validated list of miRNAs robustly changed in the 
rodent ALS-model and in patient autopsy spinal cord tissue. These miRNAs appear changed in 
mid- to late-disease stage and are well correlated. Despite not being a robust biomarker in ALS 
serum at this point in time, these targets remain exciting targets for ALS research going forward 
given their abundance, their fold change, and their corroboration across ALS models. miR-155 
specifically was increased 5-fold in the SOD1G93A ALS model mice, 2-fold in the TDP-43A315T 
ALS-FTD model mice, and 2-fold in human spinal cords, and this microRNA served as our 
priority therapeutic target moving forward to intervention experiments in ALS-model mice. 
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Figure 2.1: miRNA array changes were confirmed in mouse, rat, and human spinal cord 
tissues. (A) Using individual TaqMan miRNA assays, 11 out of the 12 miRNA microarray hits 
were confirmed significantly increased in end-stage mouse spinal cord tissue (n=5-6). (B) In rat 
lumbar spinal cord tissue, 10 out of the 12 miRNAs tested were increased in end-stage SOD1G93A 
rats over nontransgenic and overexpressing SOD1WT age-matched controls (n=4,4,4). (C) In 
autopsy spinal cord samples from 16 ALS patients and 12 non-ALS controls, 6 miRNAs assayed 
were significantly increased in the ALS tissue. (D) Specifically, both sporadic and familial ALS 
patients showed a significant increase in miR-155 (n=12 controls; 1.7x increase in n=11 sporadic 
ALS; 1.7x increase in n=5 familial ALS; ANOVA with Tukey’s post-hoc test). (RQ=relative 
quantification. SC = spinal cord. *p<0.05, **p<0.01, ***p<0.001.) 
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Figure 2.2: miRNA abundance is not well correlated with total RNA Integrity. RNA was 
extracted from 28 patient autopsy spinal cord tissues and analyzed by Agilent Bioanalyzer to 
determine RNA integrity numbers (RIN). ALS samples had an average RIN of 4.0 (SE = 0.28), 
and control samples had an average RIN of 4.9 (SE = 0.38). miRNA abundance for all 
microarray hits were determined by qPCR and normalized to respective biogroup (non-ALS 
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controls or ALS). RIN values were correlated with the relative expression of microarray miRNA 
hits, showing poor correlation between RNA integrity and miRNA abundance. (RQ=relative 
quantification) 
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Figure 2.3: miR-155 is increased in an ALS-FTD mouse model and following LPS challenge 
in vivo and in vitro. (A) 4 TDP-43A315T mice showed a 1.8 fold increase of miR-155 in spinal 
cord tissue as compared to nontransgenic age-matched controls (p<0.05). (B) 10-week 
nontransgenic male mice showed a step-wise increase of miR-155 in cerebral cortex one-hour 
after an intraperitoneal LPS injection (n=3 per group; LPS full dose = 0.2mg/kg, 6x105 
endotoxin units/kg, from Escherichia coli, p<0.05 for full LPS compared to saline). (C) LPS 
treatment (24 hours, 100ng/mL) increased miR-155 14.3 fold in an immortalized microglia cell 
line (BV2).  (RQ = relative quantification.) 
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Figure 2.4: Expression levels for miR-142-3p, miR-146a, and miR-155 significantly increase 
in SOD1G93A C57BL/6 mice between 15 and 18 weeks of age. Whole spinal cords were 
collected from 3 male and 3 female perfused mice at 9, 12, 15, 18, 21 weeks of age and at end-
stage (approximately 24 weeks of age). Taqman miRNA RT-qPCR primers were then used to 
determine the time course for upregulation of 3 key miRNAs. While a slight trend towards 
upregulation is seen at 105 days, robust differences are observed starting at 126 days of age. End 
stage tissues were collected when the mouse was unable to right itself within 30 seconds of being 
placed on either side.  (ANOVA with Dunnett’s multiple comparison test; all comparisons 
against 63-day data. (mean +/- SE; *p<0.05, ***p<0.001, ****p<0.0001.)) 
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Figure 2.5: Upregulation of miR-142-3p, miR-146a, and miR-155 is very well correlated in 
SOD1G93A mice. 36 mice at various stages in disease progression had their miRNA expression 
levels quantified in ALS-model spinal cord tissue and compared. For all 3 miRNAs tested in this 
fashion, expression levels were tightly correlated with the Pearson Correlation between 0.98 and 
1 for the 3 pairwise comparisons. 
57 
E
 
F
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Figure 2.6: Trizol, miRCury, and miRNEasy extraction methods result in lower coefficients 
of variation following miRNA extraction from serum as compared to miRVana. Patient 
control serum was pooled, mixed, and aliquoted for miRNA extraction using 7 methods in 
triplicate. The use of an RNA carrier, MS2, generally resulted in lower coefficients of variation 
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58 
between triplicates. (A-D) miRVana had the greatest level of noise and was therefore ruled out as 
an optimal extraction method going forward. Relative expression levels are shown where each 
extraction method is normalized to itself such that noise is displayed independent of yield. (E,F) 
Relative expression is shown relative to miRVana, whose average from triplicate extractions is 
set to 1. Trizol, miRCury, and miRNEasy extraction methods result in much greater yield 
following miRNA extraction from serum as compared to miRVana. For two example miRNAs, 
miR-24, and miR-196b, miRVana resulted in 20-50 fold less yield as compared to other miRNA 
extraction methods. Trizol + MS2 extraction method resulted in the greatest yield. (c.v. = 
coefficient of variance; mean +/- SE) 
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Figure 2.7: miRNEasy + MS2 and miRCury + MS2 extraction methods resulted in the 
greatest yield and least noise when used to extract miRNA from patient serum. To further 
optimize miRNA extraction from serum, the best 5 methods were compared again in their yield 
and noise in performing 4 extractions from the same pool of patient serum. Trizol extractions 
without the aid of a purification column resulted in the most noise and low yield relative to 
miRNEasy and miRCury. Furthermore, the RNA Carrier MS2 served to increase yield and 
reduce noise. (mean +/- SE) 
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Figure 2.8: miRNA expression from miRNEasy extractions best follows predicted values 
from diluted patient control serum. The best two methods were compared in their ability to 
quantify 3 miRNAs from pooled patient serum that was diluted in PBS in the designated 
amounts, performed in duplicates. Red dots show expected values. For all 3 miRNAs, miRNEasy 
values more closely matched the expected quantification. Expression levels are normalized to 
undiluted serum input for each method such that noise and expected values are shown, but not 
overall yield. (mean +/- SE) 
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Figure 2.9: miRNEasy serum miRNA extractions result in two fold greater yield as 
compared to miRCury. Relative quantification values are shown for miR-24, miR-103, and 
miR-191 following duplicate patient serum miRNA extractions at the designated dilution 
amounts. Data is shown relative to undiluted miRNEasy extractions for each miRNA. miRcury 
extractions resulted in lower yields for all 3 miRNAs measured. (mean +/- SE) 
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Figure 2.10: No significant changes in key dysregulated miRNAs are observed in ALS 
patient serum as compared to controls. miRNA was extracted from 27 ALS patients and 17 
controls using the miRNEasy + MS2 extraction method. miR-103 was also quantified as a 
putative miRNA control. (A) miR-142-3p, miR-142-5p, and miR-155 all show similar levels in 
ALS patients and in controls. (B) For 17 ALS patients, serum was collected from a healthy 
volunteer at the same time in order to control for any potential variation in extraction methods. 
ALS patient miRNA levels were then normalized to their matched control. No significant or 
trending changes were observed for the 3 miRNAs of interest. (C, D) Noise was reduced 
following normalization to miR-103 showing this to be a potentially valid control, but no 
significant or trending changes in miRNA expression levels were observed in ALS patients. 
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  Mouse Rat 
  
RQ: 
SOD1G93A/NonTG T-test 
RQ: 
SOD1G93A/NonTG T-test 
RQ: 
SOD1G93A/SOD1WT T-test 
miR-17 2.66 0.00 1.99 0.04 11.58 0.00 
miR-19b 2.51 0.00 1.99 0.10 9.20 0.02 
miR-20a 2.33 0.01 1.79 0.10 20.60 0.01 
miR-24-2-5p 2.44 0.02 1.78 0.06 3.22 0.00 
miR-106a 2.59 0.01 2.11 0.01 11.14 0.00 
miR-142-3p 3.36 0.04 3.81 0.06 24.84 0.02 
miR-142-5p 3.27 0.05 10.61 0.17 2.94 0.34 
miR-146a 8.86 0.00 3.89 0.02 8.79 0.01 
miR-146b 3.02 0.01 1.84 0.04 2.95 0.01 
miR-155 2.08 0.01 20.08 0.20 58.75 0.19 
miR-223 3.52 0.05 1.89 0.14 10.25 0.02 
miR-338-3p 2.27 0.01 1.75 0.16 5.33 0.03 
 
Table 2.1: 12 miRNAs are altered in end-stage ALS mouse and rat spinal cords by 
microarray. miRNAs were isolated from end-stage SOD1G93A mouse and rat spinal cords and 
from age-matched non-transgenic (NonTG) controls (n=3-4). For rats, miRNAs were also 
isolated from age-matched SOD1WT control spinal cords (n=3). 673 miRNAs were assayed using 
Applied Biosystem’s TaqMan Rodent Array A+B Cards v3.0. 434 miRNAs amplified and were 
quantified. For mice, 6 miRNAs were decreased and 37 miRNAs were increased greater than 2 
fold at p<0.05. From these 43 miRNAs, 12 were also changed >50% in the rat samples at 
p<0.20. RQ = relative quantification.  
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Table 2.2: Clinical diagnoses and basic demographics for patient controls. Autopsy spinal 
cord tissues were obtained from 12 non-ALS control patients for miRNA analysis (provided by 
NDRI). Males and females were equally represented, and ages ranged from 59 to 80 years of 
age. 
 
 
Age Sex Cause of death Other diagnoses 
59 F Colon cancer with mets Hypertension 
60 F Diabetic ketoacidosis 
Coronary artery disease, diabetes, hypertension, 
depression, stroke  
69 F 
Chronic obstructive 
pulmonary disease none 
71 F Dementia Hypertension, depression, osteoporosis 
79 F Renal failure 
Coronary artery disease, hypertension, stroke, 
COPD, Emphysema 
80 F Pulmonary fibrosis Hypertension, Epilepsy, Asthma,  
59 M Respiratory failure 
Myocardial infarction, hypertension, Diabetes 
Type II, stroke,  
63 M Stroke Hypertension, stroke, myocardial infarction 
66 M Heart Failure 
Congestive heart failure, myocardial infarction, 
rheumatoid arthritis 
72 M Failure to thrive 
Cirrhosis of liver presumed secondary to 
alcohol, hypertension 
79 M Respiratory failure 
COPD, Diabetes Type II, Atrial Fibrillation, 
Congestive Heart Failure 
79 M Stroke Alzheimer's disease 
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CHAPTER 3 
 
 
Developing a high-throughput method to determine cell-type specific 
expression of microRNAs in glial and neuronal cell types in vivo 
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SUMMARY 
 In order to understand the regulatory role of microRNAs (miRNAs) in the brain and 
spinal cord, it is first necessary to know their cellular expression levels. We have adapted the 
miRAP system to quantify miRNAs in neurons, motor neurons, astrocytes, and microglia in a 
high-throughput and physiologically relevant method in vivo. By generating mice that express a 
GFP-myc-tagged miRNA binding protein, Ago2, using cell type specific promoters, we were 
able to isolate active miRNAs from specific cell populations by performing anti-myc 
immunoprecipitation. These experiments have allowed the generation of large datasets of 
endogenous controls, brainstem specific vs spinal cord enriched miRNAs, and neuronal vs. glial 
enriched miRNAs. We have applied this system to inform our previously identified dysregulated 
miRNAs in ALS and found miR-142-3p, miR-142-5p, miR-146a, and miR-155 to be highly 
enriched in microglia in vivo. Specifically, miR-155 was 326 times more abundant in spinal cord 
microglia over spinal cord motor neruons. These data inform our future mechanistic experiments 
on the role of anti-miR-155 treatment in mice, describes expression patterns for hundreds of 
miRNAs, and may serve as a resource in the study of numerous physiological and pathological 
cellular processes. 
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INTRODUCTION  
miRNAs are recently-discovered, small, non-coding RNAs that regulate translation of 
coding RNAs. Typically, miRNAs direct translational repression by binding to the 3’UTR of 
mRNAs after first being incorporated into Argonaute2 (Ago) containing RNA-induced silencing 
complexes (RISC) (Gregory et al., 2005). Although emerging data clearly suggest miRNAs can 
be powerful regulators of physiological and pathological cellular processes, the role of most 
miRNA remains relatively undescribed, and how these miRNAs affect neurodegenerative 
diseases remains unexplored. Our own recent research demonstrates that miR-155 is particularly 
important for the progression of ALS, a severe, rapidly progressive neurodegenerative disease 
that disproportionately impacts motor neurons in the spinal cord (Koval et al., 2013). One of the 
major hurdles to understanding the role of miR-155 and other miRNAs in the disease process is 
the lack of basic information about which miRNAs are expressed in which cell types in the 
central nervous system.  
 Obtaining cell type specific miRNA information is challenging. The most popular current 
methods for achieving this are fluorescence activated cell sorting (FACS), laser capture 
microdisections (LCMs), cell culture models, and in situ histology; however, each of these 
methods has significant limitations. For both FACS and LCM, oftentimes only the neuronal cell 
body is acquired at a loss of miRNAs present in the synapses (Lugli et al., 2005) and the 
dendrites (Tai and Schuman, 2006).  Furthermore, both of these methods require cell 
manipulations ex vivo that are inherently stressful and will create cell damage and alter gene 
expression. Next, cell culture models, while convenient, often lack physiological relevance. 
Finally, in situ’s are difficult, expensive, and only serve to assay a single miRNA at a time.  
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 Due to these limitations in current methods, we were motivated to translate the novel 
BAC-TRAP method of isolating mRNAs to the isolation of miRNAs.  With BAC-Translating 
Ribosome Affinity Purification (TRAP), mice were generated using BAC constructs that express 
EGFP-L10a, a ribosomal protein, under control for specific cell-promoters. Since most active 
mRNAs are coupled with the ribosome, immunoprecipitating (IP'ing) GFP (tagged to ribosomal 
protein) from brain tissue pulled down active mRNA from only that specific cell population 
(Dougherty et al., 2010; Doyle et al., 2008; Heiman et al., 2008). We were interested in adapting 
this methodology to miRNAs. 
 Since most miRNAs in a cell are linked to the miRNA processing protein Ago2 
(Hammond et al., 2001), affinity purification via antibodies to Ago2 can be used to capture 
miRNAs from tissue lysates (Chi et al., 2009). Furthermore, by expressing a GFP-myc-tagged 
version of Ago2 only in a particular cell type such as motor neurons, we can use myc or GFP 
antibodies to isolate the miRNAs from just this particular cell type. While we were generating 
BAC transgenic mice that expressed GFP-Ago2 behind cell type specific promoters, He et al. 
developed a method to achieve GFP-Ago2 expression within particular cell types using a Cre-
Lox system. They coined this method miRAP, miRNA tagging and affinity purification. Cre 
recombinase is an enzyme that can recognize a pair of LoxP sequences in the genome and 
recombine them to excise the intervening DNA. By crossing various neural Cre recombinase- 
expressing mice (Camk2α, Gad2, PV, SST, L7) to their newly generated lox-stop-lox-GFP-myc-
Ago2 mice, the authors were able to express GFP-myc-Ago2 in specific glutamatergic and 
GABAergic cell populations. Following lysing and immunoprecipitating whole mouse brains, 
the authors were able to define a list of miRNAs with differential expression patterns in distinct 
neuronal cell sub-types (He et al., 2012).  
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 In order to test miRNA expression levels in neuronal vs glial cell populations, we created 
double transgenic mice that express lox-stop-lox-GFP-myc-Ago2-GFP and cell-specific Cre 
drivers using the following promoters: Synapsin1 (Syn) to label neurons, Choline 
acetyltransferase (ChAT) to label all cholinergic neurons including motor neurons, glial fibrillary 
acidic protein (GFAP) to label astrocytes, and lysozyme 2 (Lyz2) to label myeloid cells 
including microglia in the brain and spinal cord (Table 3.1). With these experiments we were 
able to generate a database of miRNAs enriched in glial vs neuronal cell types that will aid 
research in physiological and pathological roles of miRNAs. 
 
Materials and Methods 
Animals 
 All animal protocols were approved by the Institutional Animal Care and Use 
Committee of Washington University at St. Louis and adhered to NIH guidelines. Animals were 
provided food and water ad libitum, and cages were changed once a week. All mice were 
maintained in a 12-hour light/12-hour dark cycle and received routine veterinary monitoring.  
 All mice were on a bred on a B6 background. To generate cell-specifc GFP-Ago2 
expressing mice, a homozygous (ROSA)26Sortm1(CAG-GFP/EiF2c2)Zjh mouse (Jax ID: 017626) was 
bred to one of four-cre lines: Syn-Cre (Jax ID: 004781), ChAT-Cre (Jax ID: 006410), GFAP-Cre 
(Jax ID: 004600; previously back-crossed into C57BL/6), Lyz2-Cre (Jax ID: 004781). Mice used 
in experiments were heterozygous for CAG-GFP/Eif2c2 and for a cell-specific Cre driver. 
 For tissue harvesting, mice were first anesthetized with isoflurane before being perfused 
with 20-30mL of PBS. Whole spinal cords, whole brainstem and/or 30mg of relevant tissue were 
then isolated and flash frozen. Spleens were isolated prior to the perfusion. 
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Histology: miRNA in situ and double label cell-type expression 
 5µm sections of all spinal cords mounted on Superfrost slides and baked at 60°C for 30 
minutes. Sections were deparaffinized for 5 minutes in xylene, immersed in 100% ethanol for 5 
minutes then treated with protease (1.5 mg/ml pepsin - DAKO) for 30 minutes at room 
temperature. The sections were washed and allowed to air-dry. Two LNA miRNA probes, mmu-
miR-155 and scrambled-miR, were prepared according to the manufacturer’s recommended 
conditions (Exiqon), and each was labeled at the 5’ end with digoxigenin (DIG). Probes were 
diluted to 1.5 pmol/uL in Exiqon hybridization buffer. Probe solutions were placed on tissue 
sections, covered with polypropylene coverslips and heated to 60°C for 5 minutes, followed by 
hybridization at 37°C overnight. Sections were treated with anti-digoxigenin – alkaline 
phosphatase conjugate (1:150 dilution in pH 7 Tris buffer; Roche) at 37°C for 30 minutes. 
Development was carried out with NBT/BCIP (180 µl of Roche solution was added to 15 ml of 
titrated alkaline phosphatase detection solution adjusted to pH 9 to 9.5). Development was 
closely monitored and stopped when the control sections appeared light blue. In all cases, the 
development time with the chromogen was from 30-60 minutes. Sections were counterstained 
with nuclear fast red for 3 to 5 minutes, rinsed and mounted with coverslips. For double-label 
experiments, Optimal immunohistochemistry for FOX3 was defined as a dilution range of 1:500 
to 1:1000 using heat-mediated antigen retrieval for FOX3. Following a 30-minute incubation 
with biotinylated secondary antibody, slides were rinsed and incubated in streptavidin-HRP in 
PBS for 30 minutes. Following two washes in TBS, slides were incubated in DAB solution for 
approximately one-minute – until color development occurred and before significant signal in 
control samples. Sections were washes, dehydrated, and coverslipped. Nuance imaging system 
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was used to convert brightfield images to fluorescent images to improve ability to determine 
double labeling. 
 For cell-specific determination, free-floating 40uM sections of brain and spinal cord 
were washed in PBS and blocked in 5% normal donkey serum, 0.1% triton, in PBS for one hour. 
Rabbit-anti-ChAT (1:100, Millipore AB143) or mouse anti-NeuN antibody (1:200, MAB377, 
Millipore, MAB377), both with chicken-anti-GFP (1:1000) in blocking solution were applied to 
the tissues overnight at 25oC. AlexaFluor488-conjugated donkey anti-goat (A11062, Life 
Technologies) was added with either AlexaFluor 594 goal anti-rabbit or goat anti-chicken 
(ab150169, Abcam) in blocking buffer to the tissue for one hour. Slides were washed 3 times in 
PBS, mounted on superfrost slides, and coverslipped with Vectashield with DAPI (Vector 
Laboratories). All slides were observed at 4x, 10x, and 20x objectives using a Nikon Eclipse 80i 
microscope fitted with a Photometrics CoolSnap EZ camera. All images were taken at ambient 
temperature with a Cy3 or FITC filter. For image acquisition and formatting, NIS Elements 3.0 
(Nikon) and Adobe Photoshop v12.0 were used.  
FACS/LPS 
 Lipopolysacharide from Escherichia coli O111:B4 (LPS, Sigma) was diluted in PBS 
and injected into the peritoneum of one CX3CR1-GFP positive adult male mouse at 5mg/kg 
(1.5x107 endotoxin units/kg) while a second CX3CR1-GFP mouse received a saline injection. 
After 4 hours, mice were sacrificed, perfused, and brain and spinal cord tissues were harvested. 
Following dissociation with a dounce homogenizer in homogenization buffer, cells were pelleted 
and resuspended in 37% Percoll in HBSS. A Percoll gradient was then poured with the desired 
cells being located between the 70% and 37% Percoll layers. These isolated cells were then 
pelleted and resuspended in Fc-block in FACS buffer. Cells were next incubated in the viability 
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marker propidium iodide, anti-CD11b-PE and anti-CD45-cy7 before being washed and sorted 
with a BD FACSAria machine directly into Qiazol. 
Cell lines 
  Primary microglia and astrocyte cultures were prepared from P1 mouse pup cortex as 
described by others (Skaper et al., 2012; Tamashiro et al., 2012). Briefly, cerebral hemispheres 
were collected minus the cerebellum, brainstem, meninges, and hippocampus. Following mild 
dissociation, cells were allowed to grow for 2 weeks before undergoing isolation via differential 
adherence where following a 2 hour shake, the supernatant contained the desired microglia and 
the astrocytes retained adherence. These isolated cell types were then allowed to grow for an 
addition 48 hours before being collected for miRNA isolation. 
 NSC34 cells were transfected with a GFP-Ago2 construct using Lipofectamine 2000 
for 24 hours. After an additional 24 hours, transfected NSC34 cell, untransfected NSC34 cells, 
and BV2 cells were washed, collected, and counted with a hemocytometer. Cells were diluted in 
PBS and combined to create 4 cell solutions: 100% BV2, 50% BV2/50% transfected NSC34, 
100% transfected NSC34, 100% untransfected NSC34. Cells were lysed in cold lysis buffer and 
half of the mixture was loaded onto an anti-GFP conjugated beads and the other half onto mouse-
anti-Ago2 conjugated magnetic beads (2E12-1C9; Anova). See miRAP for further details. 
Immunoprecipitation/miRAP 
 (Adapted from He et al, 2013.) Brainstem and spinal cords from 63 day-old male mice 
were harvested and flash frozen in liquid nitrogen and stored at -80º C. For array experiments, 
IP’s were conducted on 3 double positive mice from each of the 4-cre driver lines and from an 
additional 3 nontransgenic controls at the same time for a given tissue type. Whole brainstem or 
spinal cord was lysed in 1mL of ice-cold lysis buffer (10 mM HEPES [pH 7.4], 100 mM KCl, 5 
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mM MgCl2, 0.5% NP-40, 1 mM DTT, 100 U/mL RNasin Plus (Promega), and EDTA-free 
protease inhibitors (Roche)). Tissue was lysed using a hand blender before centrifuging at +4º C 
for 30 min at 13,000 g. 10ug of mouse-anti-Myc (sc-40; Santa Cruz Biotechnology) or mouse-
anti-Ago2 (2E12-1C9; Anova) in 350µL of PBS-Tween was conjugated to 50µL of protein G 
Dynabeads (Invitrogen) for 45 min, rotating at RT. Antibody-conjugated beads were washed 
three times with 1mL of PBS-Tween to remove any excess antibody. A BCA assay was 
performed on all tissue homogenates to normalize input to the lowest protein concentration. 
850µL of supernatant or supernatant diluted with lysis buffer were applied to the antibody-
conjugated beads and incubated at +4º C for 4 hours with end-over-end rotation. Beads were 
washed twice with low-salt buffer (50mMTris-HCl [pH 7.5], 150mM NaCl, 1mM MgCl2, 0.5% 
NP-40, 1mM DTT, 100U/mL RNasin Plus) and twice with high-salt buffer (50mMTris-HCl [pH 
7.5], 600 mM NaCl, 1 mM MgCl2, 0.5% NP-40, 1 mM DTT, 100 U/ml RNasin Plus). 700µL of 
Qiazol was added directly to the beads, and samples were vortexed for 30 sec and stored at -20º 
C. The Qiagen miRNeasy kit was used to isolate miRNA. 
miRNA Extraction and quantification 
 RNA was extracted from flash frozen tissue, cells, or immunoprecipitation using 
miRNeasy kits per manufacturer’s instructions (Qiagen). For tissue and cells, muse RNA 
integrity and yield were assessed by Nanodrop before diluting to 2ng/µL for miRNA individual 
analysis using Taqman miRNA probes (Life Technologies). qPCR samples were quantified in 
technical duplicates on an Applied Biosystems 7500 fast Real-Time PCR System and normalized 
to endogenous U6.  
 For immunoprecipitations, extracted miRNA was used in quantification assays without 
dilution. miRNA microarrays were performed with amplification using low density Rodent 
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MiRNA A+B cards sets 3.0 (Life Technologies) using a 7900HT quantitative real time 
polymerase chain reaction (qPCR) machine for 40 cycles. Analysis was conducted on SDSv2.2 
software with automatic thresholding.  
Data analysis and stats 
 Data are presented as mean ± SEM. All statistical tests were conducted on either excel 
or with Graphpad Prism 6 Software. Array data was normalized by a geometric mean of 9 
endogenous controls using invariant set normalization. miRNAs were globally compared 
between data sets and outliers were excluded following each comparison until 21 miRNAs were 
identified. The 9 with the least amount of noise between samples following a first-pass 
normalization were then used as a final normalization set for all microarray data. miRNAs were 
listed as enriched if they were highly expressed (CT<33 for all 3 mice in a biological group), 
consistently expressed (<2CT variation in any biological group), and changed greater than 10 
fold at p<0.01. Significance of miR-155 in different cell types was determined using the Kruskal-
Wallis non-parametric test at p<0.05.  
 
RESULTS: 
miR-155 is expressed in glial cells as determined by FACS and cell culture, and in neurons 
as determined by in situ. 
 First, to determine if miR-155 is dynamically expressed in microglia, one CX3CR1-
GFP mouse was given an intraperitoneal injection (5mg/kg) while another mouse received a 
saline injection. 4 hours later, CD11bhi-CD45hi , GFP+ cells were FACS sorted and quantified 
for miR-155 expression (Fig 3.1A). The mouse that received the LPS injection had about a 20-
fold increase in miR-155 levels (Fig 3.1B). Therefore, miR-155 is likely present in microglia 
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cells and is dynamically expressed following immune cell activation. Next to contrast miR-155 
expression across different CNS cell types, miR-155 was quantified in primary cortical neurons, 
in an immortalized mouse motor-neuron like cells (NSC-34), and in primary microglia and 
astrocytes. It was found that miR-155 has about a 500-fold increase in expression in the glial cell 
types over the neuronal cell types (Fig 3.1C).  
 However, upon performing miR-155 in situ’s in human ALS spinal cords, it was found 
that miR-155 colocalizes with Fox3, a neuronal marker. Specifically, large alpha motor neurons 
were found to be positive for miR-155 (Fig 3.2). No double labeling of miR-155 was observed in 
GFAP+ or Iba1+ cells (data not shown).  
miRAP: preliminary in vitro experiments and generation of mice 
 Combining the strategies to pull-down miRNAs with Ago2 immunoprecipitation and 
the strategy to quantify mRNA in specific cells by IP of GFP-tagged ribosomes, we developed a 
method for quantifying miRNAs using GFP-tagged Ago2 in specific cell populations. To test the 
potential of this methodology, we first performed an IP experiment in BV2 and NSC-34 cell 
lines. We first identified 2 miRNAs that are relatively specific for cultured microglia like cells, 
BV2 (miR-155) and cultured NSC-34 cells (miR-676), (Fig 3.3A-B).  With these two pieces of 
data, we tested the ability of a GFP IP to enrich for miRNAs bound to Ago2 only in the cells 
expressing the Ago2-GFP construct.  To test the cell type specific pull down of miRNA, we 
transfected NSC-34 cells with a GFP-Ago2 construct. Both miRNAs should be associated with 
Ago2, but only the miR-676 (NSC-34 cell specific miRNA) should be associated with GFP since 
only the NSC-34 cells were transfected with GFP-tagged Ago2.   We first IP’d this combined 
lysate with Ago2 antibody and compared miR-676 and miR-155 levels with levels from the 
individual lysates (Fig 3.3C).  As expected, the levels of each miRNA were roughly equivalent 
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compared with the individual lysates.  We next immunoprecipitated this same lysate with a GFP 
antibody.  In this setting we pulled down only 13% of the miR-155 and 600% of miR-676.  
Overall, this represents a 44 fold enrichment of the NSC-34 cell specific miR-676 compared to 
miR-155 (Fig 3.3D). 
 Having validated the ability of IP to pull down tagged Ago2 in mixed cell systems, we 
generated four mouse lines that express GFP-myc-Ago2 in specific cell populations. The four 
Cre-recombinase lines used are used is this study that are specific for 1) all neurons (Syn); 2) 
cholinergic neurons/motor neurons (ChAT); 3) astrocytes (GFAP); 4) myeloid cells/microglia 
(Lyz2) (Table 3.1). Syn, ChAT, and GFAP are very popular and well characterized Cre drivers 
that are specific and consistently expressed in their relevant cell types. Lyz2, however, has had 
mouse-to-mouse variability reported and mosaic expression in some hematopoietic-derived cells 
(Clausen et al., 1999; Faust et al., 2000). Despite this, Lyz2 is widely considered the best 
available driver for studying myeloid cells. The myeloid cells remaining in the perfused brain 
and spinal cord are microglia along with in disease, infiltrating macrophages. These Cre 
recombinase expressing mice were crossed into loxp-stop-loxp-GFP-myc-Ago2 generated mice 
by He et al., 2013 (Fig 3.4). Upon generation of double positive transgenic mice, Cre 
recombinase is expressed behind these cell-type specific promoters and serves to excises the 
floxed stop sequence resulting in expression of GFP-myc-Ago2 in only the specific cell type.  
 Having established double positive mice that should theoretically express GFP-myc-
Ago2 in only neurons, only motor neurons, only astrocytes, or only microglia/myeloid cells, we 
performed double-label histology to observe GFP expression patterns throughout the brain and 
spinal cord. The Synapsin-Cre double positive mouse showed strong expression of GFP in 
NeuN+ cells throughout the brain and spinal cord including in the hippocampus and the spinal 
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cord (Fig 3.5A-B). ChAT-Cre double positive mice, however, did not show any expression of 
GFP in the hippocampus. Instead, GFP expression was isolated to the habenula, brainstem motor 
nuclei, and spinal motor neurons. Two brainstem motor nuclei with clear GFP labeling are 
shown in Fig 3.5C-D. For both of these lines, GFP expression appeared cytoplasmic and not 
nuclear, in agreement with known Ago2 localization. While the GFAP-Cre line showed faint 
double labeling of GFP and GFAP, GFP was undetectable in Lyz2-Cre by histology. We are 
actively trying to improve our methods to detect faint GFP. GFP expression in these mouse lines 
has been confirmed instead by RNA (data not shown) and by immunoprecipitation experiments. 
GFP-myc-Ago2 cell specific expression successfully allows for the determination of cell-
enriched miRNAs. 
 Before performing miRNA microarrays, we tested the ability to accurately determine 
predicted miRNA cell specific expression patterns by the double positive transgenic mice (cell 
specific-Cre+ and loxp-stop-loxp-GFP-myc-Ago2+). For this, we isolated spinal cords from Chat-
Cre+ double transgenic and negative littermate controls. Following an Ago2 IP, we measured 
relatively equal amounts of presumed glial (miR-155, miR-142) and neuronal (miR-124, miR-
676, miR-196b) miRNAs between the mice, as expected (Fig 3.6A). However, upon an anti-Myc 
IP, miR-124, miR-676 and miR-196b were highly enriched in only the Chat-Cre+ mice while 
presumed glial miRNAs remained at a baseline level of noise (Fig 3.6B). These data demonstrate 
that the predicted in vivo enrichment of motor neuron miRNAs is performing as predicted and 
confirms our ability to technically complete the experiment. 
 Having validated our mice and our immunoprecipitation methods, we performed 
TaqMan miRNA microarrays (rodent v3.0) in 3 mice from each of the four Cre-driver lines using 
both brainstem and spinal cord tissue independently. Each array set consists of 2 microfluid 
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cards in order to increase the number of miRNAs measured. All 24 arrays sets (48 cards) showed 
strong expression levels overall. First, because miRNA yield is too low following 
immunoprecipitation to be measured by nanodrop, Agilent small RNA chips, or Qubit, we relied 
on the identification of endogenous controls within each microarray card to normalize the data. 
Upon comparing all 24 data sets to one another, it was clear that miRNAs were normally 
distributed with the majority of miRNAs being equally changed between samples with a left- and 
right-tail. These outliers were systematically removed until putative endogenous controls 
remained. Following normalization of each putative control to a geomean of the set of controls, 
the 9 miRNAs with the lowest coefficient of variation were considered the best final endogenous 
controls. All miRNAs measured in all samples were therefore normalized to the geometric mean 
of these 9 controls: miR-24, miR-26a, miR-29a, miR-29c, miR-30a-3p, miR-30e, miR-191, miR-
221, and miR-708. Interestingly, one of these miRNAs, miR-191, was a control recommended by 
Exiqon for its stable expression across various tissues. 
 miRNA expression levels were quantified in both a pan-neuronal Cre line (Syn) and in 
a motor neuron specific Cre line (ChAT). In comparing miRNAs in the brainstem and the spinal 
crods of these mice, over 300 miRNAs were able to be accurately quantified. In the brainstem, 9 
miRNAs were identified as significantly diminished in the ChAT mice whereas 12 miRNAs 
were highly enriched (Fig 3.7A), and 16 were de-enriched, 9 enriched in ChAT+ cells in the 
spinal cord (Fig 3.7B). See the discussion section for further information on some of these 
targets. 
 Next, miRNA expression was compared between neuronal and glial cells. Because the 
miRNAs isolated by the IP were assayed in these arrays without dilution or normalization, a 
careful survey of endogenous controls was necessary. Upon locating the 9 controls, it was 
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discovered that miRNA signal in the Lyz2+ tissues were roughly 6.8CT translated representing 
~100 fold decrease in overall miRNA levels. This was not surprising as double label histology 
had previously proven difficult in these mice. Also, microglia contain less cytoplasm and are 
greatly outnumbered by other cell types in the brain and spinal cord. Nonetheless, upon 
application of the endogenous controls, many miRNAs were found to be significantly increased 
in only neuronal cells or only glial cells. Some of these were previously validated by others 
while others are newly discovered here. Please see the discussion section for further information. 
In the brainstem, 18 miRNAs were found to be robustly and significantly enriched in neurons 
over both astrocytes and microglia. In contrast, only 2 miRNAs were identified as glial enriched 
(Fig 3.8). It should be noted that these lists merely comprise the most striking ‘hits’ from the 
array and are not a complete list. In contrast, 8 miRNAs were identified as neuronal enriched 
whereas 17 miRNAs were found to be microglia enriched in the spinal cord (Fig 3.9). 
 We contrasted neuron, motor neuron, astrocyte, and microglia expression between the 
brainstem and the spinal cord. Several examples of internal consistency were observed including 
that one miRNA significantly increased in spinal cord microglia over brainstem microglia (Fig 
3.10), miR-2134, was determined to be upregulated in microglia over neurons and astrocytes 
only in the spinal cord (Fig 3.8-3.9), showing consistency across our data. More so, the miR-10 
family and miR-196 family were consistently shown to be enriched in cell types in the spinal 
cord over the brainstem (Fig 3.10). To further test miR-196 expression, we isolated miRNA 
across different tissues in both a nontransgenic mouse and in autopsy tissue from a patient with 
ALS. For both of these tissue sets, miR-196 showed a remarkable enrichment selective to the 
spinal cord and muscle. Also, lower spinal cord sections showed higher levels of miR-196 over 
the cervical spinal cord. Both miR-196a and miR-196b showed similar expression patterns (Fig 
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3.11). These data are in agreement with the cell-specific array data from the various cell lines 
that show miR-196 to be consistently increased in the spinal cord cells over brainstem for each 
cell type.  
 In applying the miRNA array data from the GFP-myc-Ago2 specific cell type 
expressing mice, we aimed to further understand our previous 6 miRNA targets found to be 
dysregulated in ALS. Most miRNAs showed similar expression levels while most of our six ALS 
target miRNAs showed a trend towards being enrichmed in astrocytes and microglia for both the 
braintem and the spinal cord (Fig 3.12). Paricularly, miR-142-3p had the most marked 
enrichment in astrocytes and microglia compared to neruons, especially in the spinal cord tissue. 
Likewise, in the spinal cord, miR-155 was robustly increaed in both astrocytes and microglia 
over neurons. While miR-24-2* showed consistent expression across cell types and miR-146b 
only showed mild enrichment in microglia, miR-142-3p, miR-142-5p, miR-146a, and miR-155 
were highly enrichmed in microglia in both the brainstem (Fig 3.13A) and the spinal cord (Fig 
3.13B). This is consistent with Chapter 2 data showing miR-142-3p, miR-146a, and miR-155 to 
be tightly correlated in their dynamic expression throughout the ALS disease time course. 
 Of particular interest, miR-155 was found to be upregulated 28 fold in brainstem 
astrocytes over neurons and 78 fold in the spinal cord. However, the strongest expression was 
clearly in microglia with a 146 fold enrichment in the brainstem and a 326 fold enrichment in the 
spinal cord.  
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DISCUSSION 
 In order to understand the physiological and pathological role of miRNAs, it is first 
necessary to know their cellular expression patterns. The most popular current methods for 
achieving this are FACS, LCMS, cell culture models, and in situ staining; however, each of these 
methods has significant limitations. First, both fluorescence activated cell sorting, FACS, and 
laser capture microdisection, LCM, is low yield and requires dissociation and staining steps in ex 
vivo cells that raises levels of cell stress and therefore makes measures of stress and activation 
pathways potentially inaccurate (Avvisato et al., 2007). Cell culture models often do not 
accurately describe the nature of in vivo cells, and miRNA in situ are technically very difficult, 
expensive, and low throughput, only testing a single miRNA per experiment.  
 miRAP has several advantages over traditional methods to quantify miRNAs from 
specific cell populations. First, one major benefit of a miRAP approach is that once the tissue of 
interest is isolated from the mouse, the first experimental step is to lyse the cells. This allows the 
RNA that is isolated to closely mimic its native state. This is especially important for 
neuroinflammatory regulators that quickly change expression based on their environment. 
Second, this method allows for miRNAs throughout the cell to be isolated, including in dendrites 
and synapses that were previously hard to isolate with conventional methods. Third, unlike in 
situ’s that test one miRNA at a time, miRAP is a highthouput method allowing for quantification 
of hundreds of miRNAs. Finally, by isolating miRNAs bound to Ago2, we are isolating the 
“active” miRNAs that have been incorporated into RISC.  
 One concern with the miRAP method is that cells may behave abnormally and exhibit 
altered miRNA levels upon expressing an extra copy of Ago2 in specific cell types. However, 
this issue was addressed by He et al for various neuronal cells in the cortex (He et al., 2012). 
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They found that the transgenic Ago2 was expressed in significantly lower amounts than 
endogenous Ago2. Furthermore, the combined levels of transgenic and endogenous Ago2 
equaled that of Ago2 in nontransgenic mice suggesting overall Ago2 levels are tightly regulated 
by the cell. Therefore, expression of transgenic Ago2 is not thought to alter cellular function, but 
we will also quantify Ago2 expression levels in our mice using western blots in neural tissues. 
 Following discrepant data on miR-155 expression following FACS and in situ 
experiments, we developed miRAP mice that express tagged-Ago2 in 4 specific cell types: 
neurons, motor neurons, astrocytes, and myeloid cells/microglia. Our microarray datasets 
unearthed many predicted and novel cell-type enriched miRNAs. The confirmation of predicted 
targets allows for increased confidence in the accuracy of our dataset. For example, miR-219 was 
the most significantly miRNA enriched in all neurons (Syn+) cells over motor neurons (ChAT+) 
and was found in both the brainstem and spinal cord screen. This miRNA has been well studied 
as an important modulator of NMDA receptor signaling cascades (Kocerha et al., 2009) – a 
function not relevant to motor neurons.  Also, miR-218, found to be significantly enriched in 
motor neurons has been previously identified by in situ to be localized to motor neurons in the 
brainstem and spinal cord (Kapsimali et al., 2007).  As a third example, we found miR-223 to be 
23,000 times more abundant in microglia than neurons in the spinal cord. This miRNA has been 
well researched as specific to hematopoietic cells and functions to regulate myeloid 
differentiation and proliferation (Chen et al., 2004; Sun et al., 2010). These examples of 
confirmed miRNA cell specific expression using our miRAP method is as exciting as the 
identification of several novel cell-specific miRNAs. 
 These methods and our data set have many potential ramifications. First, by comparing 
the miRNA microarray data to existing datasets on mRNA from astrocytes, neurons and motor 
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neurons already generated by Joe Dougherty (Doyle et al., 2008) and others (Cahoy et al., 2008), 
it may be able to gain insight into miRNA control over regulatory networks. Furthermore, these 
double transgenic mice can be adapted to have implications in studying various disease 
networks.  Please see chapter 6 for a discussion on these and other future experiments. 
 For the miRNAs we found to be dysregulated in ALS, we found a striking enrichment 
of miR-142-3p, miR-142-5p, miR-146a, and miR-155 in microglia. Specifically, while miR-155 
was 28 times more abundant in brainstem astrocytes over neurons (78 times in the spinal cord), 
the most drastic upregulation was in microglia. miR-155 was 146 times more abundant in 
brainstem microglia over neurons, and 326 times more abundant in spinal cord microglia over 
spinal cord motor neruons, although all cell types did show a real signal of miR-155. We are 
excited that while we are able to apply the information learned about miR-155 using this dataset, 
many other researchers will be able to similarly inform their research for their particular 
microRNAs of interest as well.  From these data, we will focus our analysis on changes in 
microglia gene expression and neuroinflamatory pathways overall following miR-155 inhibition 
in vivo. 
 
CONCLUSIONS 
 We have developed an exciting new method for quantifying miRNA enrichment in 
specific neuronal and glial cell populations in the brain and spinal cord. By expressing GFP-
myc-Ago2 protein in only neurons, motor neurons, astrocytes, or microglia, we have generated 
datasets that identify several confirmed and novel cell-specific miRNAs. By applying these 
methods to our ALS targets, we have identified miR-142, miR-146, and miR-155 as enriched in 
astrocytes and especially in microglia in the brainstem and spinal cord over neruonal cell types. 
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These data will inform our analysis of the role of these miRNAs and the mechanism of 
therapeutic intervention moving forward. 
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Figure 3.1: miR-155 is upregulated in CX3CR1+ cells following LPS activation in vivo and 
is enriched in glial subtypes. (A) CD11bhi-CD45hi/GFP+ cells were collected from one 
CX3CR1-GFP mouse given a saline IP (top row) and a mouse given a 5mg/kg LPS IP.  
CD11b/CD45 gating are show in first column, and GFP gating is shown in the second column. 
(B) Following miRNA extraction, miR-155 levels were quantified. miR-155 in GFP+ monocytes 
derived from the mouse that received an LPS injection was 20-fold increased over cells derived 
from the control mouse. (C) miRNA was extracted from four distinct cell lines. NSC-34 are an 
immortalized mouse motor-neuron like cell line. Primary cultured neurons were gifted from Dr. 
Jeffrey Millbrandt’s lab from p1 mouse pups. Primary microglia and primary astrocytes were 
purified by differential centrifugation described by others (Skaper et al., 2012). While miR-155 
was detectible in all cell lines, expression was much greater in the glial lines (708x microglia, 
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593x in astrocytes over NSC-34). No statistical data is possible as all experiments in this figure 
were conducted with an n=1.concusions are therefore possible.  
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Figure 3.2: miR-155 co-expresses with Fox3 in human ALS spinal cords. (A) miR-155 
positive cells were observed with miRNA in situ’s using a diogoxigenin-conjugated miR-155 
probe developed with anti-digoxigenin – alkaline phosphatase conjugate and NBT/BCIP. These 
cells are identified as large alpha motor neurons with Fox3 staining (B) and by morphology. (C) 
Fox3+ cells clearly double label for miR-155 in blue; overlap shown in yellow. (D) Brightfield 
illumination showing miR-155 labeling in blue and Fox3 labeling in brown. 
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Figure 3.3: Immunoprecipitation with GFP pulls down NSC-34 cell specific miRNA. (A) 
miR-155 was identified as expressed in BV2 cells and not NSC-34 cells. (B) In contrast, miR-
676 was only detectible in NSC-34 cells. miR-676 expression was similar following transfection 
with an Argonaute2-GFP (Ago2-GFP) construct. (C) Separate lysates from untransfected BV2 
cells and transfected NSC-34 cells or a combination of NSC-34 cells and BV2 lysates were 
immunoprecipitated with an Ago2 antibody. Only miR-155 was detectable in the BV2 cell lysate 
and miR-676 from the NSC-34 cell lysate input. However, a mixed cell lysate yielded both miR-
155 and miR-676. (D) Following a GFP immunoprecipitation of BV2 cell lysate, miRNAs were 
not detectable. In contrast, miR-676 was isolated from NSC-34 cell transfected with a GFP-Ago2 
construct. Upon applying the mixed cell lysate, the GFP immunoprecipitation pulled down miR-
676 selectively. 
A B 
C D 
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Figure 3.4: Schematic of miRAP mouse model design. Upon generation of double positive 
transgenic mice, Cre recombinase causes a recombination and removal of the floxed stop 
sequence resulting in expression of GFP-myc-Ago2 in only the specific cell type.  
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Figure 3.5: Mice double positive for cell-type specific Cre expression successfully express 
GFP protein in the target cell types. An adult mouse that is Syn-Cre+ and loxP-stop-loxP-GFP-
myc-Ago2+ has robust GFP staining (green) in NeuN+ cells (red) in both the hippocampus (A) 
and in the spinal cord (B) (merge shown in yellow; 10x).  (C,D) An adult mouse that is ChAT-
Cre+ and loxP-stop-loxP-GFP-myc-Ago2+ has robust GFP staining (green) in ChAT+ cells (red) 
in two distinct brainstem nuclei (merge shown in yellow; 20x).   
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Figure 3.6: Myc-IP from ChAT specific GFP-myc-Ago2 mice enriches for neuronal 
miRNAs. Spinal cords were isolated and homogenized from mice expressing lox-stop-lox-GFP-
myc-Ago2 and Cre recombinase under the motor neuron specific ChAT promoter. (A) An IP of 
Ago2 yields relatively equal amounts of presumed glial (miR-155, miR-142) and neuronal (miR-
124, miR-676, miR-196b) miRNAs from spinal cords from a nontransgenic (NonTG) mouse and 
the ChAT-Cre+ mouse. (B) An IP with anti-myc antibody greatly enriches for neuronal miRNAs 
in the lox-stop-lox-GFP-myc-Ago2/ChAT-Cre mouse and not in the non-transgenic mouse. (RQ 
= relative quantification) 
 
RQ 
RQ 
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Figure 3.7: TaqMan microarrays identify several miRNAs enriched in either neuronal or 
motor neuron cells from the brainstem and spinal cord. Brainstems and spinal cords were 
isolated from mice expressing lox-stop-lox-GFP-myc-Ago2 and Cre recombinase under either 
the pan-neuronal promoter (Syn) or the motor neuron specific promoter (ChAT). Following a 
myc-conjugated immunoprecipitation, miRNAs were quantified using TaqMan rodent v3.0 A 
and B microarray cards (n=3 group). miRNAs were analyzed if and only if all 3 mice had a 
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corrected CT count less than 33 that also showed stable expression, defined as <2 CT variation 
between mice. Following a normalization to 9 identified control miRNAs, miRNAs were listed if 
changed more than 10 fold at a p<0.01 for either tissue. (A) In the brainstem, 333 miRNAs met 
the expression criteria to be analyzed for significant variation between cell-type specific 
expression. 9 miRNAs were identified as significantly de-enriched in motor neurons over all 
neurons, and 13 miRNAs were identified as enriched. (B) In the spinal cord, out of 337 miRNAs 
compared, 16 miRNAs were de-enriched in motor neurons and 9 were enriched. 
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Figure 3.8: miRNA enrichment in neuronal and glial cell types from whole brainstem 
tissue. Several predicted and novel neuron-enriched miRNAs were discovered in the brainstem. 
Out of 750 miRNAs quantified, only miRNAs that were highly expressed and were consistent in 
one or more biological group were considered. 271 miRNAs were thusly quantified in 
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comparison of neuronal (Syn) vs microglia (Lyz2) expression; 387 in comparing neurons to 
astrocytes (GFAP); and 254 in comparison microglia to astrocytes. Listed are the most robust 
and significant miRNAs with cell-type specificity. Specifically, 18 miRNAs were identified as 
neuronal enriched and 2 miRNAs were identified as glia enriched.  
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Figure 3.9: In spinal cord tissue, 8 miRNAs are significantly enriched in neurons and 17 in 
microglia. Following the same rigid standards for expression and noise previously explained, 
374 miRNAs were compared in expression levels between astrocytes (GFAP) and neurons (Syn), 
213 for comparing microglia (Lyz2) and neurons, and 155 for comparing microglia and 
astrocytes. From these, several altered expression patterns were observed with the most robust of 
these being highlighted here. We identified 8 miRNAs significantly increased in neurons over 
both astrocytes and microglia. In contrast, 17 miRNAs were found to be expressed in much 
greater levels in microglia over both neurons and astrocytes. 
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Figure 3.10: Particular miRNAs have altered expression levels in the brainstem compared 
to spinal cord tissue within distinct cell types. Mice were generated that expressed GFP-myc-
Ago2 protein in specific cell types: all neurons (Syn), motor neurons (ChAT), astrocytes 
(GFAP), and microglia/myeloid cells (Lyz2). Following a myc-IP, 3 brainstems and 3 spinal 
cords were compared for each line to determine differential expression between tissue types for a 
given cell type. The overlapping number shown for each comparison describes the number of 
miRNAs that had a CT<33 for all 3 mice in either tissue as well as less than a 2 CT count 
variation between mice. Tissue-enriched miRNAs were identified for each cell type. Highlighted 
here are those changes greater than 5 fold that were significant at p<0.01. Of particular note, the 
miR-10 family and miR-196 family were consistently shown to be enriched in cell types in the 
spinal cord over the brainstem. 
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Figure 3.11: miR-196 is highly enriched in descending spinal cord and muscle. miR-196a 
and miR-196b levels were quantified in various tissues in a nontransgenic adult mouse and in 
human ALS autopsy tissue. (A) Very little expression of miR-196 was observed in the frontal 
cortex (cx), parietal cortex, midbrain, cerebellum, liver, spleen heart, or lung. However a robust 
increase was observed in the spinal cord that was greatest in the lumbar section (32x cervical SC, 
166x thoracic SC, 534x lumbar SC over frontal cortex). The quadriceps and tail muscles also had 
robust increase in expression (1320x, 475x respectively). These same expression patterns were 
observed for miR-196b as well (B). (C) In the autopsy tissue for an ALS patient, miR-196 again 
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showed increasing expression in the SC that was greatest in the lumbar region (54x, 76x, 110x 
over motor cortex for cervical, thoracic, lumbar SC respectively). The quadriceps muscle showed 
the greatest level of miR-196 at a 143 fold enrichment over the brain. (D) miR-196b expression 
mirrored the trends observed with miR-196a. 
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Figure 3.12: Target miRNAs dysregulated in ALS are glial enriched. Mice were generated 
that expressed GFP-myc-Ago2 in only neurons (Syn), motor neurons (ChAT), astrocytes 
(GFAP), or microglia/myeloid cells (Lyz2). miRNAs were isolated from a myc-IP and quantified 
on TaqMan microarrays. Following normalization to a geometric mean of 9 identified 
endogenous controls, miRNA expressions were plotted as the fold difference in average 
expression between each cell type. The x-axis denotes the index of miRNAs quantified with the 
y-axis showing the average fold change of motor neurons, astrocytes, or microglia over the 
average synapsin expression (from average of n=3). Because sensitivity in the assay is not yet 
know, the values between 10 fold de-enrichment and enrichment have been shaded.  While our 
six ALS dysregulated miRNAs showed a trend towards glial enrichment for both the braintem 
and the spinal cord, miR-142-3p had the most marked enrichment in astrocytes and microglia 
compared to neruons, especially in the spinal cord tissue. Likewise, in the spinal cord, miR-155 
was robustly increaed in both astorcytes and microglia over neurons. 
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Figure 3.13: 4 out of 6 ALS dysregulated miRNA targets are highly enriched in glia cell 
types. Following a myc-IP that pulls down GFP-myc-Ago2 in specific cell types (Syn: neurons; 
ChAT: motor neurons; GFAP: astorcytes; Lyz2: microglia/myeloid cells) miRNAs were 
quantified by a TaqMan microarray. Following normalization, the expression levels of the six 
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dysregulated miRNAs were quantified in both brainstem and spinal cord tissue from 3 mice 
each. miR-24-2* showed consistent expression across all four cell types assayed. miR-146b only 
showed mild enrichment in microglia. miR-142-3p, miR-142-5p, miR-146a, and miR-155, 
however, show high enrichment in microglia in both the brainstem (A) and the spinal cord (B). 
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Figure 3.14: miR-155 is moderately enriched in astrocytes over neurons and robustly 
enriched in microglia. Following the cell-type specific pull-down of miRNAs in specific cell 
types (neurons, motor neurons, astrocytes, and microglia/myeloid cells using the Syn, ChAT, 
GFAP, or Lyz2 promoter respectively), miR-155 levels were analyzed in the brainstem and 
spinal cord from 3 mice for each cell-type as part of a larger TaqMan microarray. Although 
underpowered, miR-155 levels from the Lyz2 brainstem and spinal cord were found to be 
significantly increased over Syn (* p<0.05; Kruskal-Wallis test). 
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Table 3.1. Four Cre-recombinase drivers are used is this study that are specific for distinct 
glial and neuronal cell types.  Detailed are the cells identified to express Cre recombinase for 
each driver and the promoter’s biological function. The four promoters used are specific for 1) 
all neurons; 2) cholinergic neurons/motor neurons; 3) astrocytes; 4) myeloid cells/microglia. All 
mice were acquired from Jax with the exception of GFAP which were a gift from Dr. David 
Gutmann at Washington University School of Medicine. While the Jax mice are carried on the 
FVB mouse background, these GFAP mice had been backcrossed onto a pure B6 background. 
 
 
Cell Promoter Targeted Cells Promoter Function Jax # 
Synapsin1  
(Syn) 
Pan neuronal(Hilfiker et al., 1999) Regulates synaptic vesicles, 
neurotransmitter release 
(Hoesche et al., 1993) 
003966 
Choline acetyltransferase 
(ChAT) 
Cholinergic neurons including all motor 
neurons(Rotolo et al., 2008) 
Enzyme necessary for synthesis of 
neurotransmitter acetylcholine 
006410 
Glial fibrillary acidic protein 
(GFAP) 
Astrocytes, oligodendroglia, ependyma, 
and few neurons(Zhuo et al., 2001) 
Intermediate filament (cytoskeletal 
protein) 
004600 
Lysozyme 2  
(Lyz2, aka LysM) 
Myeloid cells including monocytes, 
microglia, macrophages, granulocytes 
Glycoside hydrolases, innate 
immune response 
004781 
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CHAPTER 4 
 
 
Global microRNA inhibition throughout the rodent central nervous system 
using antisense oligonucleotides 
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SUMMARY 
Having previously identified microRNAs (miRNAs) significantly increased in ALS 
spinal cords in both patient autopsy tissue and in the rodent model, we required a technique to 
modulate these miRNAs in vivo in order to determine their mechanism of action and the effect of 
therapeutic intervention. Antisense oligonucleotides are short DNA-like synthetic molecules that 
inhibit a target sequence through Watson-crick base pairing. We created a novel anti-miR-155 
capable of robustly inhibiting miR-155 as evidenced by derepression of miR-155 target mRNAs. 
Following treatment in non-transgenic mice with 4-week continuous infusion of anti-miRs 
directly into the cerebral lateral ventricles, we confirmed broad distribution of the anti-miR by 
both histology and by RNA analysis of confirmed miRNA targets. With this technique, we are 
now able to test the effect of miRNA inhibition in our ALS-mouse model. 
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INTRODUCTION 
miRNAs (miRNAs) are a recently discovered regulatory-class of RNA molecules. These 
short single-stranded molecules inhibit as many as hundreds of mRNAs through partial 
complimentary with the seed region (2-8nt) of the miRNA considered the most important in 
directing the binding to target mRNAs (Hall et al., 2012). miRNAs are dysregulated in a variety 
of diseases and have proven themselves to be viable therapeutic targets (Janssen et al., 2013a; 
Miller et al., 2013). After screening miRNAs in SOD1G93A and control rodent spinal cords, we 
discovered miR-155 to be robustly and significantly upregulated in ALS. We also confirmed 
miR-155 to also be significantly increased in ALS human autopsy spinal cord tissue as compared 
to controls. Testing the potential therapeutic opportunity of dysregulated miRNAs in any 
particular disease requires not only a careful analysis of the miRNA expression changes in the 
target tissues but also a method to modulate miRNA function in disease models. 
Antisense oligonucleotides (ASOs, oligos) are synthetic DNA-like single stranded 
molecules that can be used to inhibit mRNA/miRNA function by binding tightly to their target 
through Watson-Crick base pairing. Their mode of action can either be inhibition through steric 
blocking of translation or degradation through recruitment of RNaseH, depending on the 
modifications on the phosphodiester backbone and at the 2’-sugar position. While the precise 
mechanism of distribution and uptake by cells is not known, it is believed that ASOs are actively 
brought into cells by absorptive endocytosis and fluid phase pinocytosis (Dias and Stein, 2002). 
Once in cells, ASOs may have very long half-lives, on the order of a few to several months (Hua 
et al., 2010; Kordasiewicz et al., 2012). 
There are four common phosphate backbone modifications that aim to increase 
specificity and affinity for target RNA, increase uptake into cells, and extend half-life via 
118 
protection from endogenous nucleases. First, the most popular modification remains the 
phosphorothioate modification (PS) which involves replacing the non-bridging phosphate 
oxygen with sulfer. This modification typically involves recruitment of RNAseH and improves 
serum binding (Magen and Hornstein, 2014). Unfortunately, these backbones are thought to have 
sequence-independent effects though affinity for heparin-binding growth factor and other 
heparin-binding molecules (Dias and Stein, 2002). In an attempt to prevent these off-target 
effects, three more modifications arose that are RNAse-independent. The thiophosphoramidate 
modification (NPS) refers to an alternating replacement of the phosphate oxygen atom with 
sulfer and nitrogen (Gryaznov, 1999). This modification aids in nucleic acid resistance. Next, the 
peptide nucleic acid modification (PNA) and the phophorodiamidate morpholino (PMO) both 
involve replacement of the ribose nucleic acid backbone with either peptide nucleic acid or a six-
membered morpholine ring, respectively (Magen and Hornstein, 2014). These final two 
modifications promote RNaseH-independent inhibition and are also highly resistant to nucleases 
(Summerton, 1999). 
There are also multiple common 2’-sugar ring modifications that aim to enhance target 
binding while also conferring nuclease resistance. The 2’-O-methyl (ME) and 2’-O-
methoxyethyl (MOE) are the most common. However, the bridging locked nucleic acid (LNA) 
design is thought to improve binding and nuclease resistant but also may incur more toxicity 
(Swayze et al., 2007). Additionally, fluoro modifications have increased thermal stability over 
2’-O-methyl substitutions while also conferring nuclease resistance but may increase oligo-
mediated toxicity as well (Akhtar, 1995; Kawasaki et al., 1993). Following an unpublished 
screen of various phosphate backbone and 2’-sugar modifications for anti-miR-155 ASOs, our 
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oligos here tested were synthesized with a full phosphorothioate backbone with alternating 
blocks of 2’-MOE and 2’fluoro sugar-modified nucleosides. 
The strategy of using ASOs to target miRNAs has been successful in recent rodent 
experiments and even in a limited number of clinical trials.  Following the discovery that miR-
122, a liver specific miRNA, drives the replication of the hepatitis C virus (HCV) (Jopling et al., 
2005), Santaris Pharma developed an antisense oligonucleotide inhibitor against miR-122, called 
Miriversen. Following successful chimpanzee studies (Lanford et al., 2010), the authors have 
continued to complete a successful Phase I (Janssen et al., 2011) and Phase IIa trial 
(NCT01200420) (Janssen et al., 2013). Hepatitis C patients that received Miriversen reported no 
significantly greater number of adverse events over placebo, and their viral titer counts were 
robustly and significantly reduced, even at the lowest dosage level tested, 3mg/kg. Reduced 
HCV RNA was observed over 3 months beyond the last injection. This clinical trial shows that 
despite the vast number of potential mRNA targets for each miRNA, miRNAs remain both 
powerful and realistic therapeutic targets. 
While ASO-mediated miRNA inhibition strategies have been successful in the periphery, 
they have not been readily applied to the CNS. ASOs are highly charged molecules and do not 
readily cross the blood-brain barrier (BBB). Peripheral dosing would have to be approximately 
100-fold higher than a direct CNS delivery to equal the same level of tissue concentration (Banks 
et al., 2001). Therefore, to target miRNAs in the CNS, we delivered anti-miRs directly to the 
cerebral spinal fluid as previously described for mRNA inhibitors (Smith et al., 2006). Alzet 
osmotic pumps are small implantable pumps that sit in a sub-cutaneous pocket in the back of the 
mouse. These pumps absorb fluid from the surrounding tissue to then promote the fluid within 
the pump to travel up through the tubing and into a catheter that we place directly into the lateral 
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cerebral ventricles. CSF circulates from the ventricles to all CNS tissue, making it an excellent 
drug delivery vehicle. Using this method, we demonstrate here the ability of these anti-miRs to 
inhibit their cognate miRNA target throughout the CNS.  
Among the list of dysregulated miRNAs in ALS model mice and human ALS samples, 
miR-155 appeared to be an excellent first therapeutic target because of its abundance and fold 
change in ALS, reproducibility across species and various ALS models, and extensive prior work 
linking miR-155 with immunity and inflammation (Landgraf et al., 2007) (O'Connell et al., 
2009) (Wang et al., 2009). More intensive background on miR-155 is available in Chapter 5.  
 
MATERIALS AND METHODS 
Animals  
 All animal protocols were approved by the Institutional Animal Care and Use Committee 
of Washington University at St. Louis and adhered to NIH guidelines. Animals were provided 
food and water ad libitum, and cages were changed once a week. All mice were maintained in a 
12-hour light/12-hour dark cycle and received routine veterinary monitoring. Post-surgical mice 
were single-housed as to protect the sutures and tubing. 
anti-miR sequences 
All anti-miRs were synthesized with a full phosphorothioate backbone with alternating 
blocks of 2’-MOE and 2’fluoro sugar-modified nucleosides. Sequences are denoted in Table 4.1.  
Alzet osmotic pump surgeries 
Osmotic pumps were prepared per manufacturer protocol (pump model 2004 for 28 day 
experiments; Alzet). For implantation, mice were anesthetized in a chamber with 5% 
isoflurane/oxygen mixture and confirmed to be unconscious before being placed in Kopf Model 
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940 small animal stereotaxic apparatus, fitted with ear bars (Miller, 2013). The catheter was 
oriented at 2.00mm lateral and 1.1mm posterior to bregma.  
mRNA quantification 
For mRNA Affymetrix microarray and Sylamer analysis, RNA, extracted with 
miRNEasy, was diluted to 100ng/µL and sent to Expression Analysis, Inc for running the 
Affymetrix Mouse Genome 430 2.0 array. Analysis was then conducted as previously described 
by others (van Dongen et al., 2008). For RT-qPCR of mRNA targets, RNA was normalized to 
20ng/µL using Nanodrop. Primers and probes for mRNA targets were purchased from Integrated 
DNA Technologies and are detailed in Table 4.1. For let-7 target analysis, 40ng total RNA was 
quantified with Express One-Step Superscript Kits (Invitrogen) as per the manufacturer’s 
protocol. For miR-155 targets, 40ng total RNA was quantified with Power SYBR Green RNA-
to-CT 1-Step Kit (Life Technologies) as per the manufacturer’s protocol. One-step qRT-PCR 
was conducted on a 7500 fast Real Time PCR System (Applied Biosystems). RNA was 
quantified as technical duplicates and normalized to GAPDH. 
miR-155 target array  
RNA from treated nontransgenic mouse cortex was profiled for miR-155 target 
engagement using a 2-step RT/qPCR method. First, cDNA was created from 300ng total RNA 
extracted using miRNEasy kits (Qiagen) using Qiagen’s RT2 First Strand Kit according to 
vendor protocols. Next, cDNA was amplified and quantified on an ABI 7900 fast machine using 
miR-155 target arrays plates (RT2 profiler PCR Array Format E 384 (4x96), Catalog No. 
PAMM-6002ZE-4, Qiagen) according to the vendor protocol. Four samples were run on each 
plate with at least one sample being from a saline treated, a scrambled treated, and an anti-miR-
155 treated mouse (20ug/day, 4 week treatment, 2 week washout). Array data was normalized to 
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a geometric mean of 4 endogenous controls: Actb, Gapdh, Gusb, and Hsp90ab1. Primers for the 
14 most derepressed mRNAs in the anti-miR-155 treated samples were then ordered (IDTDNA, 
Table 4.1), and individual RT/qPCR assays were performed with 40ng total RNA using the 
Power SYBR Green RNA-to-CT 1-Step Kit (Life Technologies) as per the manufacturer’s 
protocol. 
anti-miR-155 in vitro luciferase assay 
miRNA antisense oligonucleotides were screened for in vitro function as described 
previously (Esau, 2008). Briefly, Hela cells were co-transfected with a miR-155 expressing 
plasmid and with a luciferase reporter with perfect 2x miR-155 complementary sequences at the 
3’UTR. 4 hours later, anti-miR-155 was added to the media at concentrations ranging from 1 to 
200nM. 24 hours later, luciferase activity was determined and plotted. 
Isolation of peritoneal macrophages 
Adult C57BL/6 mice were given an intraperitoneal (IP) injection of thioglycollate 
followed by 3 daily IPs of 25mg/kg anti-miR or saline. On day 4, peritoneal macrophages were 
isolated, plated, and stimulated with LPS for 24 hours (20ng/mL). RNA was then extracted and 
analyzed by Sylamer analysis. 
Cy3-anti-miR-155 histology  
Adult C57BL/6 mice were implanted with a subdermal Alzet osmotic pump to deliver 
10ug/day of cy3-labeled anti-miR-155 (Regulus Therapeutics) directly into the lateral ventricle. 
After 2 weeks of treatment, mice were perfused with phosphate buffered saline (PBS) and 4% 
paraformaldehyde (PFA). Brain and spinal cord tissues were post-fixed in PFA for 48 hours and 
then submerged in 30% sucrose for 2 days. The spinal cord was embedded in O.C.T. (VWR) 
123 
before it and the brain were sliced at 40um. Tissue for distribution analysis was then washed in 
PBS and mounted with Fluoromount G (Southern Biotech) before being coverslipped.  
For cell-specific determination, tissues were washed in PBS and blocked in 5% natural 
horse serum in PBS for 30 minutes. A dilution of 1:1000 of chicken-anti-GFAP polyclonal 
antibody (ab4674, Abcam), 1:1000 goat-anti-Iba1 polyclonal antibody (ab5076, Abcam) or 
1:200 mouse anti-NeuN antibody (MAB377, Millipore, MAB377) in blocking buffer was then 
applied to the tissues overnight at 4oC. Tissues were then washed with PBS and blocked with 5% 
natural horse serum for 30 minutes before incubating in their relevant 1:1000 AlexaFluor488-
conjudated secondary antibody for 1 hour (goat anti-chicken (ab150169, Abcam), donkey anti-
goat (ab150129, Abcam), or goat anti-mouse (35502, Thermo Scientific, Waltham, MA)). All 
slides were observed at 4x, 10x, and 20x objectives using a Nikon Eclipse 80i microscope fitted 
with a Photometrics CoolSnap EZ camera. All images were taken at ambient temperature with a 
Cy3 or FITC filter. For image acquisition and formatting, NIS Elements 3.0 (Nikon) and Adobe 
Photoshop v12.0 were used.  
Statistical analysis  
 Data are presented as mean ± SEM. All statistical tests were conducted with Graphpad 
Prism 6 Software. All gene expression data were analyzed with a 2-tailed Student t test. 
 
RESULTS 
Anti-let-7 delivered through ventricular osmotic pumps successfully derepresses its targets 
individually and globally.  
To determine whether anti-miRs could inhibit targets broadly in the CNS, we used a 
miRNA inhibitor of let-7. We first assayed anti-let-7 because this oligonucleotide is known to be 
124 
a potent miRNA inhibitor in the periphery (Esau, 2010). let-7 is not known to be important in 
ALS and is best known for its role in cell cycle regulation, cell differentiation, and cancer 
(Androsavich et al., 2012). After treating animals with anti-let-7 via an osmotic pump directed 
into the lateral ventricles (Fig 4.2A), mRNAs with 3’-UTR let-7 binding sites were globally 
derepressed in cortical tissue (Fig 4.2B). Further Sylamer analysis was conducted for these mice 
in various brain regions including the cortex, striatum, and hippocampus (Fig 4.3). After 
confirming the suitability of GAPDH as an endogenous control (Fig 4.1), analysis of a subset of 
these mRNAs demonstrated derepression of targets in the parietal cortex, midbrain, occipital 
cortex, cerebellum, cervical and lumbar spinal cord (Fig 4.2C,D). 
A novel anti-miR-155 derepresses predicted targets globally in the periphery and 
individually in the brain and spinal cord.  
Having established that anti-miRs can target the CNS including the spinal cord, we 
developed an anti-miR-155 oligonucleotide to test whether this inhibitor would affect the ALS 
rodent model. First, miR-155 targets had not been previously described in the brain and spinal 
cord. Therefore an array containing 46 confirmed and 38 predicted miR-155 direct targets was 
conducted on 16 cortex RNA samples from adult nontransgenic mice treated with either saline 
(n=5), scrambled-anti-miR (n=5), or anti-miR-155 pumps (n=6) at 20ug/day for 4 weeks 
followed by a 2 week washout prior to harvesting tissue. 45 biologically confirmed targets and 
31 predicted targets amplified on these arrays. Of these 76 targets measured, 66 were increased 
20% or more in the anti-miR-155 treated mice over both saline and scrambled treated mice. 
48/76 were increased more than 50%, and 24/76 were increased more than 100% (Fig 4.4).  
The top 14 targets from the array (Fig 4.5A) were then assayed individually in a pooled 
analysis by biogroup in order to identify the best miR-155 targets to follow for target 
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engagement (Fig 4.5B). From this, Card11 and Cyr61 were added to previously identified miR-
155 targets PU.1 and SHIP1 as top markers for anti-miR-155 target engagement. 
In Hela cells transfected with miR-155 and a luciferase reporter containing a 3’UTR 
recognized by miR-155, the novel anti-miR-155 derepressed luciferase and led to increased 
luciferase activity (Fig 4.6A). To test efficacy of miR-155 inhibition peripherally in vivo, we 
administered three daily IP injections of anti-miR-155 in non-transgenic mice. An mRNA profile 
from lipopolysaccharide (LPS)-stimulated peritoneal macrophages from anti-miR-155 treated 
mice showed global derepression of mRNAs with a miR-155 3’-UTR binding site (Fig 4.6B). 
Finally, to test efficacy in CNS tissue, we implanted 28 day osmotic pumps with saline, 
scrambled control, or anti-miR-155 that infused directly into the lateral ventricles. We confirmed 
4 known and/or predicted miR-155 mRNA targets (O'Connell et al., 2009; Vigorito et al., 2007; 
Xu et al., 2010; Zhang et al., 2010) to be derepressed in the cortex following anti-miR-155 
treatment (Fig 4.6C). Furthermore, quantification of one of these targets, SHIP1, across the CNS 
demonstrated a significant increase over saline in all areas assayed (Fig 4.6D).  
Cy3-labeled anti-miRs infused into the cerebral lateral ventricles distribute throughout the 
brain and spinal cord and are incorporated neurons, astrocytes, and microglia. 
In a separate experiment, mice treated with cy3-labeled anti-miR-155 osmotic pumps for 
two weeks demonstrated clear cellular uptake throughout the brain and spinal cord (Fig 4.7). 
More so, double-label histology showed cy3-anti-miR-155 to be incorporated into distinct cell 
types including neurons (NeuN+), microglia (Iba1+), and astrocytes (GFAP+) (Fig 4.8).  
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DISCUSSION 
Antisense oligonucleotides can function as potent inhibitors of miRNAs (anti-miRs), but 
it remained unclear whether these inhibitors could achieve broad CNS distribution similar to 
antisense oligonucleotide inhibitors of mRNA (Smith et al., 2006). We first assayed anti-let-7 
because this oligonucleotide is known to be a potent miRNA inhibitor in the periphery (Esau, 
2010). let-7 is not known to be important in ALS and is best known for its role in cell cycle 
regulation, cell differentiation, and cancer (Androsavich et al., 2012). Following a 28-day 
infusion of anti-let-7 into the cerebral lateral ventricle in mice, we saw robust derepression of let-
7 targets throughout the brain and spinal cord as determined by both global Sylamer analysis and 
targeted mRNA assays. While other studies have demonstrated anti-miR function in limited 
sections of cortical tissue (Lee et al., 2012; Selvamani et al., 2012), these data establish a method 
of widespread inhibition of miRNAs and are the first to show inhibition of miRNAs in the spinal 
cord.  
Next, we developed a novel anti-miR against miR-155, previously identified as 
significantly upregulated in ALS. We screened candidate anti-miR-155 molecules in a luciferase 
assay where luciferase was fused to a 3’UTR that contained a miR-155 binding site. 
Derepression of luciferase following transfection with anti-miR-155 was a sign of a functional 
anti-miR.  
In progressing to in vivo studies, we had to first define miR-155 targets. Because our 
anti-miRs are not designed to necessarily degrade their target miRNA, we instead measured 
target engagement by quantifying derepression of the miRNA’s target mRNAs. miR-155 has 
been well studied in the periphery (Faraoni et al., 2009; Vigorito et al., 2013), but no study has 
yet defined miR-155 targets in the brain and spinal cord. Therefore, we performed a miR-155 
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target array to measure derepression following anti-miR treatment from the perfused mouse 
cortex. As our goal was to identify mRNAs to track as opposed to exhaustively identifying novel 
mRNA targets, we only confirmed the most upregulated mRNA targets of miR-155. From this, 
we identified Card11 and Cyr61 as miR-155 targets in the central nervous system. Card11 was 
previously only a bioinformatically predicted target, but Cyr61 had been previously 
experimentally verified as a direct target in the periphery (Zhang et al., 2010). The caspace 
recruitment domain (CARD) family protein Card11 is essential for protein kinase c-mediated 
cytokine production in T and B cells (Hara et al., 2003), and cytoseine-rich protein 61 
(Cyr61/CCN1) is a secreted signaling protein that regulates cell adhesion, proliferation, and 
differentiation (Han et al., 2003). These two novel targets were added to our previously 
identified miR-155 targets, PU.1 and SHIP1, to allow us to well track anti-miR-155 efficacy in 
vivo. 
Our novel anti-miR-155 also showed widespread functional distribution in both the 
peripheral and central compartments. We measured this both through derepression of mRNAs 
and through histology. By infusing a cy3-labeled anti-miR-155, we were able to track its uptake 
throughout the brain and spinal cord and into neurons, microglia, and astrocytes. Given the 
importance of miR-155 in the periphery (Akhtar, 1995; Faraoni et al., 2009) and its abundance in 
microglia (Figure 3.14), we considered it essential that our anti-miR-155 reach the dominant 
immune cell of the brain, microglia.  The distribution of anti-miR-155 throughout the brain and 
spinal cord and its uptake by cells known to be critical to ALS disease pathogenesis, we were 
prepared to continue on to testing the therapeutic potential of anti-miR-155 in the ALS mouse 
model.  
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Anti-miRs have been used safely and effectively in the periphery in recent human clinical 
trials (NCT00688012 and NCT00979927); (Janssen et al., 2013b) and CSF infusion of antisense 
oligonucleotides designed to lower mRNA have recently been applied to patients with ALS 
(Miller et al., 2013). Thus, CSF delivery of anti-miRs has the real potential for utility in clinical 
trials.  
 
CONCLUSION 
We have demonstrated a therapeutically relevant method to inhibit miRNAs broadly in 
the brain and spinal cord for the first time. Our novel anti-miR-155 robustly derepresses PU.1, 
SHIP1, Cyr61, and novel, Card11. We confirmed broad distribution of anti-miRs following 
infusion into the lateral cerebral ventricles by both histology and global RNA readout. With this 
method, we are able to test the role of dysregulated miRNAs in ALS-model rodent spinal cords 
in vivo. 
 
129 
 
 
 
Figure 4.1: GAPDH does not vary between samples or between treatment groups. RNA was 
extracted and diluted to 20ng/uL before qPCR amplification. GAPDH was run on each plate as 
the endogenous control, and its cycle threshold did not significantly vary between samples within 
groups or between treatment groups (n=5-6 per group). 
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Figure 4.2: let-7 anti-miR distributes throughout CNS and derepresses target mRNAs.    
(A) Saline, scrambled anti-miR control, or anti-let-7 was infused directly to the lateral ventricle 
for 28 days with an osmotic pump. At 42 days, RNA was extracted. (B) Using Affymetrix 430 
2.0 mouse gene arrays and Sylamer software analysis, cortical mRNA with let-7 binding sites 
(blue and red lines denoting mRNAs that contain the 1-7nt, or 2-8nt miRNA seed region 
compliment respectively) were enriched among the upregulated (derepressed) mRNAs for anti-
let-7 treated mice as normalized to scrambled treated mice. (C,D) mRNA of two confirmed let-7 
targets (TGFBR1, NRAS) were significantly increased in anti-let-7 treated mice in all regions 
assayed (p<0.05 TGFBR1; p<0.01 NRAS).  
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Figure 4.3: let-7 anti-miR distributes from lateral ventricle infusion to globally derepress 
target mRNAs throughout brain. Using Affymetrix 430 2.0 mouse gene arrays and Sylamer 
software analysis, anti-let-7 treatment globally derepressed mRNAs that contain the 1-7nt, or 2-
8nt miRNA seed region compliment in various brain regions including the cortex, hippocampus, 
and striatum. 
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Figure 4.4: miR-155 target mRNAs are derepressed in anti-miR-155 treated mouse cortex. 
A miR-155 target array (Qiagen) assayed 76 confirmed and predicted miR-155 targets. Mice 
were treated for 4-weeks with osmotic pumps directed to their cerebral lateral ventricles 
containing either saline (n=5), scrambled anti-miR (n=5), or anti-miR-155 (n=6). Data are here 
presented as the average of anti-miR-155 treated mice compared to the average of scrambled 
anti-miR treated mice. Of these 76 targets measured, 66 were increased 20% or more in the anti-
miR-155 treated mice over both saline and scrambled treated mice. 48/76 were increased more 
than 50%, and 24/76 were increased more than 100%.  
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Figure 4.5: miR-155 target array identified several putative mRNAs to track for anti-miR-
155 target engagement including Card11 and Cyr61. (A) The top 14 hits are shown from the 
miR-155 target array that assayed 76 mRNAs with proven or predicted miR-155 binding sites. 
(B) The RNA from treated mouse cortices was pooled by treatment group and analyzed by Sybr 
Green RT/qPCR. Card11 and Cyr61 were clearly derepressed (3.9x and 3.2x respectively) 
following anti-miR-155 treatment and were chosen as target mRNAs for the study of anti-miR-
155 target engagement. 
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Figure 4.6: anti-miR-155 successfully derepresses miR-155 targets in vitro, in the periphery 
in vivo, and in the central nervous system. (A) Hela cells were transfected with a miR-155 
expression plasmid and a luciferase reporter containing two miR-155 binding sites. After 4 
hours, either anti-miR-155 or a scrambled control anti-miR was transfected into cells (1 to 
200nM). Quantified 24 hours later, luciferase levels were increased in anti-miR-155 treated cells, 
indicating inhibition of miR-155. (B) After 3 daily IP injections of either anti-miR-155 or 
scrambled anti-miR control, peritoneal macrophages were isolated from adult mice, stimulated 
with LPS, and RNA was extracted. An Affymetrix microarray of mRNA followed by Sylamer 
analysis shows derepression of mRNAs that contain the heptamer seed region compliment to 
miR-155 (blue line denotes 1-7nt miRNA heptamer compliment, red for 2-8nt heptamer).        
(C) anti-miR-155 was infused into the lateral ventricles of adult mice for 4 weeks. 2 weeks later, 
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mRNA was extracted. mRNA levels of 4 confirmed and/or predicted miR-155 targets were 
significantly increased in anti-miR-155 treated mice over both saline and scrambled treated mice 
(SHIP1 p<0.001, PU.1 p<0.001; Card11 p<0.01, Cyr61 p<0.001). (D) SHIP1, a confirmed miR-
155 target, was significantly increased in anti-miR-155 treated mice in all regions assayed 
(p<0.05). 
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Figure 4.7: cy3-anti-miR-155 distributes from lateral cerebral ventricle throughout brain 
and spinal cord. Mice were treated for 2 weeks with an osmotic pump delivering 10ug/day cy3-
labeled anti-miR-155 directly into the lateral ventricle. Anti-miR-155 distributes throughout the 
(A) subventicular zone (4x), (B) cortex (4x), (C) hippocampus (10x), and (D) spinal cord (10x). 
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Figure 4.8: cy3-anti-miR-155 distributes into neurons, microglia, and astrocytes. Mice were 
treated for 2 weeks with an osmotic pump delivering 10ug/day cy3-labeled anti-miR-155 directly 
into the lateral ventricle (B,E,H). 40um brain slices were collected, and cell specific antibodies 
were used against NeuN to mark neurons (A), Iba1 to mark microglia (D), and GFAP to mark 
astrocytes (G). cy3-anti-miR-155 is present in all cell types assayed (C, F, I, arrowheads mark 
examples of double positive cells) (20x, scale bar = 100um). 
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Forward Reverse 
Arid2 CAGCCCAGCAACCATTTTCC TTTCCCTGACTCACAGTCGC 
Card11 CACTGGATGCGTGCACAAAA AGATGTTCAGGTTCAGGCGG 
Cebpb CTTATAAACCTCCCGCTCGGC TGGCCACTTCCATGGGTCTA 
Cyr61 AGAGGCTTCCTGTCTTTGGC CCAAGACGTGGTCTGAACGA 
Fadd CTCATTTCCTGCTCCCTGCT CAACAATGCGGAAGGCGATT 
Ifngr1 ACAGCTCTCCGTCCTCGTAT GGATCTCCCCACTCCGGTTA 
Ikbke CCACGTCTTTTCCCTACCCC GCTCAAGGACACAAGGGTGA 
Irak3 GCTGGCTGCATATTTCACGG TGATTCGAACGTGCCAGGAA 
Mafb GTAGTGTGGAGGACCGCTTC CTTCTGCTTCAGGCGGATCA 
Msh2 TAAGGCTTCTCCCGGCAATC CAAGCCTAGCTTCCTCTGGG 
Rhoa AGGATTGGCGCTTTTGGGTA TTCCCACGTCTAGCTTGCAG 
Ripk1 CGGGAGGTTGGACTCTTCTT GTCTTCTCCAGCAGGTCACT 
Socs1 GCTCACTGCCTCTGTCTCC GGTTGCGTGCTACCATCCTA 
Trp53inp1 CTCACGGGCACAGAAATGGA TTTATCCACTGGGAAGGGCG 
Hsp90ab1 AGGAAGTGCACCATGGAGAG AGAGATCAACTCGCGGAGGA 
GAPDH GGTTGTCTCCTGCGACTTCA TAGGGCCTCTCTTGCTCAGT 
anti-miR-155 CCCCUAUCACAATUAGCAUUAA N/A 
anti-let-7 AACUAUACAACCTACUACCUCA N/A 
Scrambled anti-miR CCCCAUUACCAATTACGUAATA N/A 
 
 
  
Table 4.1: Primer and antisense oligonucleotide sequences. 
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CHAPTER 5 
 
 
Inhibition of microRNA-155 significantly extends survival in a mouse model 
of ALS & further insights into neuroinflammation in ALS 
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SUMMARY 
ALS is a fatal, adult onset neurodegenerative disease characterized by the selective loss 
of motor neurons in the brain and spinal cord. MicroRNAs (miRNAs) are a new class of 
translational repressors shown to be viable therapeutic targets in mouse models for multiple 
sclerosis (Ponomarev et al., 2011) and in patients for Hepatitis C treatment (Janssen et al., 2013). 
Having previously identified dysregulated miRNAs in the mouse model and in patient autopsy 
samples and having developed a method to inhibit miRNAs broadly and globally in the central 
nervous system using antisense oligonucleotides, we next aimed to test the therapeutic potential 
of miRNA modulation in a mouse model of ALS. We found that inhibition of miR-155, 
previously identified to be enriched in immune and inflammatory cell types, resulted in a 
significant extension in survival and a 38% increase in disease duration. While the end-stage 
mice in this treatment experiment showed no altered neuroinflammatory transcripts in their 
spleens or spinal cords, a separate cohort of treated ALS-model mice sacrificed at a mid-disease 
stage had a significant increase in 6 distinct inflammatory cellular and molecular markers. While 
it is unclear if these observations are related the mechanism driving the survival benefit, miR-
155 clearly remains an exciting target for neurodegenerative research. 
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INTRODUCTION 
 ALS is a fatal adult-onset neurodegenerative disease with no adequate therapies despite 
being first characterized in 1869 (Cleveland and Rothstein, 2001). Therefore, innovative 
approaches for the discovery of therapeutic targets is necessary. miRNAs are a newly discovered 
class of translational repressors that have the power to regulate entire cellular networks 
(Makeyev and Maniatis, 2008). Antisense oligonucleotides are synthetic DNA-like molecules 
that can specifically inhibit an mRNA or miRNA through Watson-Crick base pairing. Having 
previously defined 6 miRNAs significantly changed in both the ALS-mouse model and in ALS 
patient autopsy tissues and having established a method to modulate these miRNAs in vivo, we 
next studied the therapeutic potential and the role of miR-155 in a mouse-model of ALS. 
Among the list of dysregulated miRNAs in ALS model mice and human ALS samples, 
miR-155 appeared to be an excellent therapeutic target because of its abundance and fold change 
in ALS, reproducibility across species and various ALS models, and prior work linking miR-155 
with immunity and inflammation. miR-155 is highly expressed in hematopoietic cells including 
T cells and monocytes (Landgraf et al., 2007) and can serve to promote pro-inflammatory 
pathways through targeted repression of anti-inflammatory mediators including SHIP (O'Connell 
et al., 2009) and SOCS (Wang et al., 2009). Immune system involvement is important in ALS 
(Beers et al., 2008; Boillee et al., 2006; Zhu et al., 2002), and recent data suggest that miR-155 is 
increased in peripheral monocytes from ALS model mice and ALS patients (Butovsky et al., 
2012). However, as with many changes in the ALS model, whether the miR-155 increase 
positively or negatively affects ALS remained untested and required development of a method to 
inhibit miRNAs both in peripheral blood cells as well as in the central nervous system (CNS). 
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miR-155 is located within an exon of the non-coding B-cell Integration Cluster (BIC) 
gene on chromosome 21 (Eis et al., 2005). miR-155 is highly homologous in many species 
including human, dog, rat, mouse, zebrafish, and xenopus (miRBase v20.0). This miRNA is 
expressed in lymphoid and myeloid cells and plays important roles in haematopoesis, 
inflammation, and immunity (Faraoni et al., 2009). miR-155 has been shown to be upregulated 
in patient tissues in a variety of diseases including rheumatoid arthritis (Stanczyk et al., 2008), 
multiple sclerosis (MS) (Stanczyk et al., 2008), cystic fibrosis (Bhattacharyya et al., 2011), 
and several cancers including leukemia (Eis et al., 2005), breast cancer (Iorio et al., 2005), 
colon cancer (Volinia et al., 2006), and lung cancer (Yanaihara et al., 2006). Recently, miR-
155 knockout mice were shown to be significantly protected against a model for two of these 
diseases: experimental autoimmune encephalomyelitis (EAE, a mouse-model of multiple 
sclerosis) (O'Connell et al., 2010) and collagen induced arthritis (Bluml et al., 2011).  
miR-155 is especially well-studied in the context of macrophages and microglia. 
Macrophages are white blood cells derived from monocytes, and microglia are the resident 
macrophages in the brain and spinal cord. These cells play important roles in innate and acquired 
immunity. In the context of neurodegeneration, microglia are typically thought of as existing in 
one of two polarized states. When primed by interferon gamma and activated by T-helper cell 
Type I-cytokines, these cells may enter their classically activated M1 state. In this state, 
macrophages serve to destroy the surrounding insult and amplify tissue damage by releasing 
reactive oxygen species, nitric oxide, and pro-inflammatory cytokines like TNF-α, Il-1β, and Il-
6. When exposed to T-helper cell Type II-cytokines, macrophages can become alternatively 
activated (M2). In the M2 state, macrophages are thought to reduce inflammation, promote cell 
growth, and aid with tissue repair by releasing anti-inflammatory cytokines and trophic factors 
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(Classen et al., 2009). However, there is a new controversy in the polarization of microglia in 
ALS. Recently, publications have argued for the M2/M1 role of microglia in ALS (Beers et al., 
2011) (Kobayashi et al., 2013). In contrast, it has also been recently reported that a ‘good’ vs 
‘bad’ microglia is not an accurate description; instead, microglia in ALS express concurrently a 
mix of anti-inflammatory and pro-inflammatory factors. For example, cytotoxic CD8+ T cells 
are typically considered to cooperate with M1, toxic microglia, but it was found that CD8 T cells 
can drive the phagocytic properties known to be beneficial/protective in some diseases (Chiu et 
al., 2013). While the field continues to resolve these discrepancies, there remains a consensus 
that microglia are powerful modulators of disease course and may be viable therapeutic targets. 
 Several studies have suggested that microglia are important for disease pathogenesis in 
ALS. In 2002, Zhu et al. showed that minocycline significantly delayed ALS onset and extended 
survival in the mouse model (Zhu et al., 2002). Minocycline is a tetracycline derivative that 
inhibits microglial activation and cytokine release. However, in a Phase 3 clinical trial, ALS 
patients declined more rapidly with minocycline (Gordon et al., 2007)). Many consider the 
problem to lie in the dosage of 400mg/day, an amount that some consider to be neurotoxic 
(Leigh et al., 2008). Beers et al. transplanted bone marrow from either SOD1G93A or WT mice 
into PU.1 knockout ALS mice, which lack macrophages from birth (Beers et al., 2006). Boillee 
et al. created a mouse line with a floxed mutant SOD1 protein and with cre recombinase under 
the microglia specific CD11b promoter (Boillee et al., 2006). In both of these studies, removing 
SOD1G93A from microglia alone was sufficient to significantly extend survival. More recently, an 
appreciation for the beneficial role of lymphocytes in ALS has emerged. It was found that 
removing T cell infiltration in a mouse model of ALS was detrimental while transplantation of 
T-regulatory cells into a mouse model of ALS robustly extended survival (Beers et al., 2011). 
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With information gathered from these and other studies, many consider the best therapeutics that 
target neuroinflammation won’t be immune suppressors, but instead will be immune modulators.  
A new variant in a myeloid cell activating receptor has recently been identified as a risk 
factor for both Alzheimer’s disease (Guerreiro et al., 2013) and ALS (Cady et al., 2014). This 
p.R47H variant in the triggering receptor on myeloid cells 2, TREM2, confers a single amino 
acid substitution on the extracellular domain of a receptor. Upon activation, TREM2 forms a 
signaling complex with its binding partner TYROBP, also known as DAP12 (Kierdorf and Prinz, 
2013) which typically leads to increased phagocytosis and a blunting of inflammation. 
(Takahashi et al., 2005). While it us unknown how the p.R47H variant affects the function of 
TREM2, it has been found that a truncation mutation leading to a loss-of-function in TREM2 is 
sufficient to cause early onset frontotemporal-like dementia known as polycystic 
lipomembranous osteodysplasia with sclerosing leukoencephalopathy (PLOSL or Nasu-Hakola 
Disease) (Paloneva et al., 2000; Paloneva et al., 2002). Therefore, many consider this variant to 
also confer a loss-of-function mutation that diminishes the neuroprotective role of microglia in 
neurological disease (Guerreiro et al., 2013; Jonsson et al., 2013). These TREM2 mutations serve 
to strengthen the motivation for translational research in neuroinflammation in 
neurodegenerative diseases. 
For our miRNA intervention experiments, we used the Gurney SOD1G93A transgenic 
mouse model that overexpress an ALS-causing human SOD1 mutation (Gurney et al., 1994). 
These mice recapitulate the ALS phenotype with progressive muscle weakness and paralysis 
followed by death. Onset and survival time course is dependent on the mouse strain. Here, we 
are using the B6/SJL hybrid background. These mice typically begin losing weight at 90-100 
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days with a reported median survival of 128.9 (Leitner, 2009). The animals are euthanized 
when unable to right themselves within 30 seconds of being placed on their backs.  
Mouse models of ALS are attracting increased controversy as more trials that amelerate 
symptoms in the mouse fail to translate to patients (Perrin, 2014). For these reasons, we have 
taken steps to increase the translational potential of our research. First, we are only considering 
miRNAs that are increased in both the rodent model and in human ALS autopsy tissue. Because 
miR-155 levels are increased in peripheral blood cells in ALS patients (Butovsky et al., 2012), 
enrollment for a clinical trial might be determined by elevated miR-155 levels. Similarly, the 
efficacy of this targeted miR-155 therapy can be read out in peripheral cells throughout 
treatment. Finally, antisense oligonucleotides have been tested in a Phase I trial in SOD1 human 
ALS, suggesting this type of strategy to be safe and realistic (Miller et al., 2013).  
Furthermore, most therapeutic studies in the mouse model prolong survival by delaying 
onset of the disease rather than slowing progression of the disease (Benatar, 2007). However, 
patients enter the clinic already sick. Therefore, an important metric for success is an extension 
in disease duration as opposed to a delay in symptom onset. With the growing understanding of 
the importance of neuroinflammation on disease pathogenesis and on miRNAs in diseases, the 
work detailed here aims to further characterize the role of inflammatory mediators in ALS while 
also testing the therapeutic potential of dysregulated miRNAs in ALS. 
 
MATERIALS AND METHODS 
Animals  
 All animal protocols were approved by the Institutional Animal Care and Use 
Committee of Washington University at St. Louis and adhered to NIH guidelines. Animals were 
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provided food and water ad libitum, and cages were changed once a week. All mice were 
maintained in a 12-hour light/12-hour dark cycle and received routine veterinary monitoring. 
Post-surgical mice were single-housed as to protect the sutures and tubing. 
Alzet osmotic pump surgeries 
 Osmotic pumps were prepared per manufacturer protocol (pump model 2004 for 28 day 
experiments; 2006 for 42 day experiments; Alzet). For implantation, mice were anesthetized in a 
chamber with 5% isoflurane/oxygen mixture and confirmed to be unconscious before being 
placed in Kopf Model 940 small animal stereotaxic apparatus, fitted with ear bars (Miller, 2013). 
The catheter was oriented at 2.00mm lateral and 1.1mm posterior to bregma.  
Treatment and analysis of B6/SJL SOD1G93A ALS mice 
 All B6/SJL SOD1G93A were gifted from Prize4Life and were previously confirmed to 
have high and consistent SOD1G93A copy counts. Mice were implanted with osmotic pumps at 60 
days of age containing 20ug/day anti-miR-155, 20ug/day scrambled control, or saline. Pumps 
were removed at 102 days. Weekly IP injections (25mg/kg) began at 60 days of age and 
continued until the mouse reached end-stage. For the first two weeks only, mice received an 
additional weekly IP injection. Mice were weighed and assessed for neurological score biweekly 
in blinded fashion starting at 60 days. A neurological score of 1 was given when 1) when the 
mouse was no longer able to fully extend its legs; 2) when the mouse could no longer spread its 
legs past midline when lifted by its tail; or 3) when significant hind limb tremors were present. 
End-stage was defined as when the mouse was no longer able to right itself after being placed on 
either side within 30 seconds. All involved in the administration and monitoring of the animals 
were blinded with separate people involved in injecting and scoring the mice. Blinding was 
broken only once all analyses were completed. 
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Treatment and analysis of FVB SOD1G93A ALS mice 
 B6.FVB SOD1G93A mice were implanted with osmotic pumps at 80 days of age 
containing 20ug/day anti-miR-155, 20ug/day scrambled control, or saline. Weekly IP injections 
(25mg/kg) began at 60 days of age and continued until the mice were sacrificed. For the first two 
weeks only, mice received an additional weekly IP injection. At 117 days mice were 
anesthetized, euthanized, and tissue was harvested and flash frozen. 
Human tissues 
 Patient tissues were analyzed with approval from the Institutional Review Board from 
Washington University and Massachusetts General Hospital. Spinal cord autopsy tissue was 
obtained from 16 ALS patients (9 male, 7 female; age range 34-79, mean 64; from Washington 
University School of Medicine, Massachusetts General Hospital) and 12 non-ALS control 
patients (6 male, 6 female; age range 51-80, mean 70; from National Disease Research 
Interchange; clinical information in Table 2.2). Postmortem intervals ranged from 1 to 40 hours.  
miRNA quantification 
 RNA was extracted from flash frozen tissue using miRNeasy kits per manufacturer’s 
instructions (Qiagen). Mouse RNA integrity and yield were assessed by Nanodrop before 
diluting to 2ng/µL for miRNA individual analysis. All rodent miRNAs were normalized to 
endogenous U6. qPCR samples were quantified in technical duplicates on an Applied 
Biosystems 7500 fast Real-Time PCR System.  
mRNA quantification 
For RT-qPCR of mRNA targets, RNA was normalized to 20ng/µL using Nanodrop. 
Primers and probes for mRNA targets were purchased from Integrated DNA Technologies 
(Coralville, IA). 40ng total RNA was quantified with either Express One-Step Superscript Kits 
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(Invitrogen, Carlsbad, CA) or Power SYBR Green RNA-to-CT 1-Step Kit (Life Technologies, 
Carlsbad, CA) as per the manufacturer’s protocol. Rodent RNA was quantified as technical 
duplicates and normalized to GAPDH. 
For TREM2 expression analysis in patients, extracted RNA was quantified and 40ng was 
used as input for the Express One-Step Superscript qRT-PCR Universal (Invitrogen: 11781-200) 
with validated Taqman assays for human TREM2 and three endogenous controls, GAPDH, 
PPIA, and RPLPO (Applied Biosystems 4331182, 4333764F, 4333763F, 4333761F 
respectively). Reactions were run in duplicate on an ABI 7500 fast thermocycler. TREM2 
expression was normalized to the geometric mean of the three endogenous controls.  
For TREM2 expression analysis in mice, total RNA was extracted from saline-perfused 
and snap-frozen spinal cords of 8 end-stage SOD1G93A transgenic mice (Jackson Lab B6.Cg-
Tg(SOD1*G93A)1Gur/J) and 6 negative littermate controls. TREM2 expression was quantified 
using a mouse-specific TREM2 TaqMan assay (Applied Biosystems; 4331182) and normalized 
to the endogenous control SMRT using primers and probe from IDT DNA (Probe: 
AGACGTCTCACACAAGGAAGGACTCGCC, Forward primer: GGGTATATTTTTGATA-
CCTTCAATGAGTTA, Reverse primer TCTGAAACAGTAGGTAGAGACCAAAGC). 
Reactions were run in duplicate on an ABI 7500 fast thermocycler. 
Statistical analysis  
 Data are presented as mean ± SEM. All statistical tests were conducted with either 
Graphpad Prism 6 Software or R version 3.0.1. Fisher’s exact test was used to compare 
proportions of p.R47H carriers in cases and controls. Comparisons of TREM2 expression 
utilized student t-tests, while correlations between TREM2 expression and subject characteristics 
utilized Spearman correlations (continuous variables) or Mann-Whitney U (dichotomous 
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variables).  All neuroinflammation gene expression data were analyzed by ANOVAs followed 
by Durnette’s post-hoc test. All survival and onset data were analyzed using both the Mantel-
Cox Log-Rank test and the Gehan-Breslow-Wilcoxon test. 
 
RESULTS 
anti-miR-155 significantly extends survival and disease duration in the SOD1G93A mouse 
model. To test the therapeutic potential of antagonizing miR-155 in ALS, we treated a large 
cohort of SOD1G93A mice at 60 days of age with continuous intraventricular infusion of anti-
miR-155 (n=22), scrambled control anti-miR (n=21), or saline (n=20). To account for any 
peripheral role of miR-155, we supplemented the CNS treatment with weekly anti-miR or saline 
IP injections (Fig 5.1A). 
 Beginning at 60 days of age, weights and neurological scores (Leitner, 2009) were 
recorded biweekly. Onset was determined in two ways: age when weight peaked and age when a 
neurological score of 1 was observed marking abnormal hind limb motility. Treatment and 
monitoring continued until the animal reached end-stage, defined as when the animal was unable 
to right itself within 30 seconds after being placed on its side (Fig 5.1B). There was no 
significant change in disease onset as defined by either a neurological score of 1, although a 
trending delay in neurological score 2 and 3 occurrence marking mid- and late- disease 
phenotypes was observed in the anti-miR-155 treated mice (Fig 5.2). Likewise, no change in 
onset as defined by age at weight peak was observed as well (Fig 5.3). However, survival was 
significantly increased in only the anti-miR-155 treated mice (Fig 5.4A). These mice had a 9.5 
day extension in survival over saline treated mice (p=0.006). There was no significant difference 
in survival between scrambled treated and saline treated animals (Table 5.1). Our controls 
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agreed with published survival data for SOD1G93A B6/SJL animals (129.5 vs 128.9 days) 
(Leitner, 2009). Furthermore, disease duration was only significantly increased in the anti-miR-
155 treated animals (Fig 5.4B). These mice had a disease duration 14.5 days longer than saline 
(38% extension, p=5.0x10-4) and 11 days longer than scrambled (27% extension, p=2.7x10-3). 
There was no significant difference in disease duration between scrambled treated and saline 
treated animals (Table 5.1).  
Neuroinflammation Analysis in ALS-model mice and ALS Patient Autopsy Spinal Cord 
Tissue 
 In the end-stage spinal cord tissue from four SOD1G93A C57BL/6 mice compared to four 
littermate, non-transgenic controls, pro-inflammatory cytokines assayed showed marked 
upregulation of their RNA transcripts (15 fold increase in IL-1β, 20 fold increase in TNFα) (Fig 
5.5A). Furthermore, in a panel of seven chemokine ligands and four chemokine receptors, we 
observed a drastic and highly significant increase in only two of the ligands (CCL2, CXCL10) 
and one of the receptors (CXCR4) (Fig 5.5B).  
 Following the identification of a TREM2 risk allele by Janet Cady et al., (2014), I 
examined spinal cord expression of TREM2 in lumbar spinal cord sections from 18 subjects with 
ALS and found a 2.8-fold upregulation compared to controls (p=2.8x10-4; Fig 5.6A). Expression 
levels did not correlate with age of onset, site of symptom onset, or presence of a known disease-
causing mutation (data not shown). However, the degree of upregulation showed a modest 
inverse correlation with disease survival that was not statistically significant after correction for 
multiple comparisons. Because markers of microglial activation are also upregulated in models 
of SOD1 ALS (Hall et al., 1998), we evaluated TREM2 expression in SOD1G93A transgenic mice 
and found a 13-fold increase compared to non-transgenic littermates (p=2.8x10-9; Fig 5.6B). 
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 Next, we measured when these and other neuroinflammation markers change during 
disease progression by measuring mRNA in spinal cord tissue from 6 SOD1G93A C57BL/6 mice 
and 6 non-transgenic controls at 3-week time point intervals between 9 weeks and end-stage 
(~24 weeks). Most neuroinflammation markers, both cellular and molecular, were well 
correlated and showed a small trending increase in expression as early as measured that became 
robust and significant between 15 and 18 weeks of age (Fig 5.7). Of note, GFAP was 
significantly increased by 2.2 fold at 15 weeks, and microglia/macrophage markers CD68 and 
Iba1 were increased 2.6 fold by 18 weeks (p<0.001. Typical survival is 24 weeks of age.  The 
pan T cell marker, CD3, was more variable in expression and only reached significance at end-
stage. The 12 mice in the dynamic range of miR-155 expression, between 105 and 126 days of 
age in the SOD1G93A C57/BL6 mouse model, showed strongest correlation with Iba1 and GFAP 
over CD3; however, there was a correlation with all pro-inflammatory markers assayed (Fig 5.8). 
anti-miR-155 treatment in SOD1G93A mice correlates with a distinct set of 
neuroinflammatory markers in the mid-disease state, but not at end-stage. 
 To test if anti-miR-155 altered cellular or molecular inflammatory transcripts, we 
quantified 16 immune and inflammation mRNAs in the end-stage spleen and 19 in the end-stage 
spinal cord from 6 SOD1G93A B6/SJL mice per treatment group. In a mostly pooled analysis, 
there was no robust change observed for any of these markers in end-stage mice. This included 
markers for astrocytes (GFAP), microglia/macrophages (CD68, Iba1), lymphocytes (CD3, CD8, 
TBX21), pro-inflammatory cytokines (IL1β, IL8, and TNFα), anti-inflammatory cytokines (IL4, 
IL10), chemokines (CCL2, CXCL10, CXCR4) and growth factors (GDNF, IGF1, and IGFBP2) 
(Fig 5.9). 
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 The lack of observable changes in neuroinflammatory transcripts in end-stage mice could 
be attributed to a difference in survival/age upon harvesting tissue or to an overwhelming 
increase in neuroinflammatory transcripts at the end-stage of disease that ultimately obscured 
any subtle effect of our treatment. Therefore, we treated a separate cohort of ALS-model mice 
and scarified them at a mid-disease stage to try to assess changes in immune cell number and 
activation. In this second intervention experiment, we treated SOD1G93A FVB mice with either 
saline, scrambled oligo, or anti-miR-155 oligo with osmotic pumps (20ug/day) and IP injections 
(25mg/kg). This treatment lasted from 80 days of age until 117 days of age at which point all 
mice were sacrificed and spinal cord tissues were harvested (n=7/group). In these mice, a panel 
of 18 neuroinflammatory markers were measured by RT/qPCR. Of these, 6 targets were 
significantly increased in only the anti-miR-155 treated mice over both saline treated and 
scrambled treated mice. These included the pan T cell marker (CD3) a cytotoxic T cell marker 
(CD8), a pro-inflammatory T-helper cell marker (TBX21), the pro-inflammatory cytokine (IL6), 
and 2 chemokine ligands, CCL2 and CXCL10. Interestingly, previously correlated 
neuroinflammatory markers including two other pro-inflammatory cytokines (TNFα, IL1β), an 
astrogliosis marker (GFAP), and the chemokine ligand (CXCR4) were not significantly 
upregulated (Fig 5.10). 
 
DISCUSSION 
 To determine the therapeutic potential of targeting miRNAs in ALS, we first generated a 
list of miRNAs changed in the SOD1G93A rodent model. Six of these miRNA changes are also 
upregulated in familial and sporadic human ALS spinal cord. However, for each of these 
miRNAs, whether the change contributes to disease progression or represents a 
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compensatory/beneficial response remained unclear. To test the importance of the miRNA in 
disease, we developed an antisense oligonucleotide strategy to inhibit miRNAs in the brain and 
spinal cord.  
 We treated a large cohort of ALS-model mice with our novel anti-miR-155. Mice treated 
with anti-miR-155 lived 10 days longer and had a 38% extension in disease duration. Therefore, 
our data establish that the increased miR-155 negatively contributes to ALS disease progression 
in the SOD1G93A mouse model. While it is self-evident that patients present after onset of 
disease, the fact that miR-155 inhibition slowed disease progression may suggest that this 
preclinical drug trial is particularly relevant for therapies. The majority of drugs tested in the 
rapidly progressive SOD1G93A model prolong survival by delaying onset of the disease rather 
than slowing progression of the disease. Of those studies that have reported extended disease 
duration in the mouse model, the weighted mean difference in a meta-analysis was 10%, while 
we here report a 38% extension in disease duration (Benatar, 2007). For further context, a 
previous study using antisense oligonucleotides against SOD1 in rats did not significantly alter 
onset, but extended survival by 10 days and extended disease duration by 37% (Smith et al., 
2006).  
 While a number of drugs tested in the SOD1 model have subsequently failed in human 
clinical trials, we have taken steps to increase the translational potential of this preclinical model. 
In order to have a validated in vivo experimental system for targets applicable to ALS patients, 
we focused on miRNAs changed in both the rodent ALS model and in patient ALS tissue from 
both familial and sporadic ALS patients. Because miR-155 levels are increased in peripheral 
blood cells in some ALS patients (Butovsky et al., 2012), enrollment for a clinical trial could be 
determined by elevated miR-155 levels. Similarly, the efficacy of this targeted miR-155 therapy 
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can be read out in peripheral cells throughout treatment. Finally, antisense oligonucleotides have 
been tested in a Phase I trial in SOD1 human ALS, suggesting this type of strategy to be safe and 
realistic (Miller et al., 2013).  
 Our data clearly identify miR-155 as a promising therapeutic target for ALS and may 
potentially apply more broadly to neurological disorders where miR-155 is increased including 
multiple sclerosis (Junker et al., 2009) and in glioblastoma (D'Urso et al., 2012). However, as an 
ALS therapeutic, some key preclinical issues still need to be addressed. It will be important to 
test how CNS inhibition alone or peripheral blood cell inhibition alone affects survival in this 
model since this will have direct implications for which compartment is the most important to 
target with an anti-miR-155 therapy. In addition, how the timing of miR-155 inhibition will 
affect survival needs to be examined. Also, our data defines other miRNAs that are increased in 
ALS spinal cord tissue. Interestingly, all 6 of the patient-confirmed upregulated miRNAs (miR-
24, miR-142-3p, miR-142-5p, miR-146a, miR-146b, and miR-155) are well studied in the 
context of immunity and inflammation (Pedersen and David, 2008; Sonkoly et al., 2008). Each 
of these targets may be potential candidates for therapies for neurodegenerative disease and 
testing them will require a similar approach to the one taken here. Another miRNA identified 
here may have a more potent effect either alone or in concert with other miRNA targets.  
 Neuroinflammation has long been recognized to be an important component to disease 
progression in ALS (Beers et al., 2006; Boillee et al., 2006) and in other neurological diseases 
including Alzheimer’s disease (Hirsch and Hunot, 2009) and Parkinson’s disease (Eikelenboom 
et al., 2006). Given the increased expression of our top miRNA targets in inflammatory cell 
types, we were interested in better defining neuroinflammation events in ALS and in measuring 
the role of our anti-miRs on these pathways.  
158 
After finding that this same TREM2 variant, p.R47H, confers a 3 fold increased risk of 
ALS, we studied the expression levels of TREM2 in patient autopsy tissue and in our ALS-
model mice. We found a 2.8-fold increase in TREM2 expression in the ALS spinal cord tissue, 
and a 13 fold increase in the ALS-mouse model. Interestingly, higher TREM2 expression in 
patient tissue correlated with shorter survival. These data support the recent finding that higher 
levels of microglia activation correlated with the amount of upper motor neuron symptoms and 
correlated with a more rapid disease progression (Brettschneider et al., 2012). These data further 
suggest that studies of microglial activation and their phagocytic function may provide insights 
relevant to human ALS. 
As further characterization of neuroinflammation in ALS, we measured several pro- and 
anti-inflammatory markers in the ALS-mouse model throughout various disease stages. In 
agreement with published work (Beers et al., 2011), we found significant increases in pro-
inflammatory cellular and molecular markers at a mid-disease stage that were well correlated. 
Specifically, we observed robust increases in markers for astrogliosis, microgliosis, and T cell 
infiltration. We further defined 3 chemokines as enriched in the ALS-model mouse spinal cords. 
CCL2, CXCL10, and CXCR4 were selectively increased out of the 7 chemokine ligands and 4 
receptors quantified. Because several neuroinflammatory markers were highly correlated in our 
panels, we were unable to discern if one cell type or signal best characterizes the increase in 
miR-155 levels, either by cause or by consequence. For future study, we would like to isolate 
RNA and protein from particular cell types at various disease stages and correlate the change in 
expression of inflammatory markers with miR-155. This can be achieved by either FACS or with 
our miRAP method characterized in chapter 3. To this end, we are currently generating triple-
transgenic mice in which selective neuronal or glial subtypes express GFP-tagged miRNA 
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processing proteins in the ALS-mouse model. Please see chapter 6 for more details for this 
experiment.  
While all SOD1G93A treated mice had markedly similar quantities of neuroinflammation 
specific transcripts in end-stage spinal cord tissue independent of anti-miR treatment, these data 
may not be indicative of a lack of mechanism of our oligos on neuroinflammation. Instead, it is 
possible that difference in survival/age upon harvesting tissue negated any delay or alteration in 
neuroinflammatory pathways, and/or that the immune system ultimately overwhelms the tissue at 
the end-stage of disease making it difficult to observe any subtle effect of our treatment. 
Therefore, we treated a separate cohort of ALS-model mice and scarified them at a mid-disease 
stage to try to assess changes in immune cell recruitment and activation. We performed these 
subsequent experiments on the FVB background due to mouse availability, and we therefore 
attempted to scale the ages to correlate to our B6/SJL treatment experiment. While B6/SJL ALS-
model mice live on average to 128.9 days (Melanie Leitner, 2009), our FVB mice live to 149 
days on average. We therefore delayed treatment commencement from 60 days to 80 days. 
Likewise, because miR-155 is increased between 105 and 126 days in the C57BL/6 line whose 
typical survival is 157 days (Melanie Leitner, 2009), we collected spinal cord tissue from the 
FVB mice at 117 days.  
In SOD1G93A FVB mice treated with anti-miR-155, interestingly, we observed a 
significant increase in 6 transcripts from our neuroinflammation panel. These included the pan T-
cell marker (CD3) a cytotoxic T-cell marker (CD8), a pro-inflammatory T-helper cell marker 
(TBX21), the pro-inflammatory cytokine (IL6), and 2 chemokine ligands, CCL2 and CXCL10. 
Of note, while these neuroinflammatory markers were previously shown to be well correlated in 
the ALS-mouse models with several other assayed neuroinflammation transcripts, only these 
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particular markers were increased following our anti-miR treatment. For example, while IL6 was 
robustly increased in anti-miR-155 treated ALS-model mice, three other typically well-correlated 
cytokines, TNFα IL1β, and IL8, were unchanged following miR-155 inhibition. Likewise, while 
the two chemokine ligands previously identified as increased in ALS were increased, the 
chemokine receptor CXCR4 was not significantly different between treatment groups. The 
specificity of these 6 neuroinflammatory changes in responses to miR-155 inhibition suggest 
against an off-target, oligo toxicity response. Furthermore, our scrambled oligo is synthesized 
with an identical backbone to account for off-target and toxic effects. Nonetheless, these data are 
counterintuitive given the work by others in the periphery and in vitro showing miR-155 to be a 
pro-inflammatory mediator (Androulidaki et al., 2009; Kurowska-Stolarska et al., 2011). 
However, these discrepancies may be explained by tissue specific differences or by a more 
complex role for miR-155 in particular. For example, miR-155 has an almost perfect correlation 
with miR-146a, thought to be an anti-inflammatory mediator (Bhaumik et al., 2009; Lu et al., 
2010).  Multiple miRNAs may be tightly regulated such that modulating one effects the 
expression and function of other correlated miRNAs leading to coordinated and complex results.  
Therefore, as performed here, it is important to measure the effect of miRNA modulation in the 
state of the cell downstream of direct miRNA-mRNA targets.   
Typically, microglia are thought to enter an alternatively activated state (M2) early in 
disease that confers protection and then switch to a pro-toxic and deleterious classically activated 
state (M1) later in disease (Beers et al., 2011). M1 microglia are characterized with toxic 
cytokines including IL-6 and TNF-α whereas M2 microglia are characterized by anti-
inflammatory cytokines including IL-4 and IL-10 (Mantovani et al., 2002). However, a recent 
study suggested that ALS microglia differ from this strict M1/M2 paradigm (Chiu et al., 2013). 
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That is, ALS microglia concurrently express factors thought to suppress neurodegeneration 
including IGF-1 and progranulin as well as factors thought to be neurotoxic including Nox2. In 
fact, cytotoxic CD8+ T cells were found to potentially stimulate phagocytosis in microglia, long 
considered to be a beneficial role of microglia (Rogers et al., 2002). Overall, it remains difficult 
to attribute a beneficial or determinate role of microglia to a polarized phenotype (ie M1 vs M2) 
or with specific markers of neuroinflammation, including these six altered neuroinflammatory 
markers following anti-miR-155 treatment.  Therefore, unbiased approaches to modulate 
microglia number and activation states paired with behavioral and survival readouts remain 
important in order to gain insight into the complex role of immune cells in ALS. 
While these data may be considered supportive for a role in increasing microglia and 
lymphocyte activation and recruitment in the ALS-mouse model, it is unclear if this is the 
mechanism of action for our anti-miR treatment. In data presented in Chapter 3, we saw a 
reduced but real signal of miR-155 in neurons, and in Chapter 4, we showed that anti-miR-155 is 
taken up by neurons, microglia, and astrocytes. We do not know if there is one cell type that is 
critical to the ameliorating effect of anti-miR-155 in the ALS-mouse model or which cell type 
this may be. One possible future experiment to discern this would be a peripheral vs central 
treatment experiment, further detailed in the Chapter 6.  
 
CONCLUSION 
We have demonstrated a therapeutically relevant method to inhibit miRNAs broadly in 
the brain and spinal cord for the first time. We have also supplied the first published list of 
altered miRNAs in ALS spinal cord tissue, and we have demonstrated that miRNA inhibition can 
prolong survival in a neurodegeneration model. Anti-miR-155 treatment extended survival in a 
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mouse-model of ALS by 10 days, corresponding to a 38% increase in disease duration. Given the 
putative role of miR-155 in immune cells, we characterized neuroinflammatory pathways in 
ALS-model mice and again in our anti-miR treated mice. Among the characterized targets, 
TREM2 and distinct chemokines were found to be upregulated in ALS.  While our end-stage 
anti-miR treated ALS-model mice showed no alterations in a mRNA neuroinflammation panel, a 
separate cohort of treated mice sacrificed at a mid-disease stage showed a striking increase in 6 
specific inflammatory markers. However, it remains unclear if this observation represents the 
mechanism through which anti-miR-155 extended survival. miRNA inhibition, and miR-155 
specifically, remain exciting avenues for ALS research as potential therapeutic targets. 
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Figure 5.1: anti-miR-155 treatment and observation experiment overview in SOD1G93A 
mice. (A) SOD1G93A B6/SJL mice were treated with osmotic pumps directed to the cerebral 
lateral ventricle and with weekly intraperitoneal (IP) injections (25mg/kg) starting at 60 days of 
age (n=21/group). Osmotic pumps contained either saline, scrambled oligo, or anti-miR-155 
(20ug/day). For the first two weeks, mice received an additional IP injection. At 102 days, the 
osmotic pumps were removed, but the catheter and tubing remained intact, and the weekly IP 
injections continued. (B) Mice were weighed and neurological scores were determined biweekly. 
A score of 1 marked onset and was characterized by the following: 1) failure to fully extend legs 
when lifted by tail; 2) failure to spread legs past midline when lifted by tail; or 3) marked tremors 
when lifted by tail. Mice were euthanized when unable to right itself within 30 seconds of being 
placed on either side. Age at weight peak until end stage gave an overall measure of disease 
duration. 
A 
B 
continuous infusion 
age (weeks) ES (~19) 
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Figure 5.2: No significant change in neuroscore onsets occurred for any treatment group. 
The ALSTDI neurological scoring system was used to track disease onset and progression. A 
score of 1 defines onset and marks 1) failure to fully extend legs when lifted by tail; 2) failure to 
spread legs past midline when lifted by tail; or 3) leg tremors when lifted by tail. A neuroscore of 
2 is given when a mouse’s toes curl under twice in walking 2 cage lengths. A neuroscore of 3 is 
assigned when either leg is fully paralyzed and not used to generate any forward movement. (A) 
Saline, scrambled, and anti-miR-155 treatment groups all showed similar ages at time of onset, 
defined by reaching a neuroscore of 1 (median age: 115, 115, 113 days respectively). (B,C) Time 
to mid- and late- disease stages, defined by neuroscores of 2 and 3 respectively, were similar 
between treatment groups with anti-miR-155 group beginning to show a non-significant trend in 
delay (median NS2: 124, 127, 131 days; median NS3: 129, 134, 138 days for saline, scrambled 
and anti-miR-155 groups respectively). 
       Saline 
       Scrambled 
       anti-miR-155 
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Figure 5.3: Weight peak, as an alternative measure of disease onset, was also insignificantly 
changed between treatment groups for both genders. Saline, scrambled, and anti-miR-155 
treatment groups showed no significant change in weight peak (A) which was true when only 
females were analyzed (B) and only males (C). Median values for weight peak were not 
significantly changed for any treatment group (saline: 91.5 days, scrambled: 90 days, anti-miR-
155: 87 days) (D). 
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Figure 5.4: Survival, but not onset, is extended in anti-miR-155 treated ALS mice. Anti-
miR-155 treated mice had a significant extension in survival and a 38% extension in disease 
duration over saline. (median values shown, log-rank test, *p<0.01, **p<0.01, ***p<0.001).  
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Figure 5.5: Distinct cytokines and chemokines are robustly increased in end stage ALS-
model mice. RNA was extracted from whole spinal cords from 4 end-stage SOD1G93A mice and 
4 littermate controls and analyzed for expression of neuroinflammatory mediating signaling 
transcripts. (A) Two pro-toxic cytokines, IL-1β and TNFα, were robustly increased in the ALS-
model mice, 15 fold and 20 fold respectively. (B) A Panel of 7 chemokine ligands showed CCL2 
to be significantly increased 15 fold and CXCL10 by 10 fold. All other chemokine ligands were 
insignificantly changed. One receptor, CXCR4, was significantly increased by 4 fold as well. 
(*** p<0.001) 
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Figure 5.6: TREM2 expression is increased in human ALS and in SOD1G93A mouse spinal 
cord. (A) TREM2 expression was measured by qPCR in patient autopsy spinal cord tissue from 
18 ALS subjects and 12 controls and normalized to the geometric mean of three endogenous 
control genes, GAPDH, PPIA, and RPLPO, and was found to be significantly increased by 2.8-
fold. (B) In mice, expression was measured in spinal cords from 8 SODG93A mice and 6 wild-
type littermate controls with normalization to an endogenous control, U6, and was found to be 
significantly increased by 13-fold. P-values were calculated using two-tailed student’s t-test. 
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Figure 5.7: Several cellular and molecular markers for neuroinflammation are well 
correlated and robustly increase at a mid-disease stage. Spinal cords were harvested from 6 
SOD1G93A mice every 3 weeks from 9 weeks until end-stage in disease, and extracted mRNA 
was quantified via qPCR. Cellular markers for astrocytes (A) is significantly increased by 105 
days of age (2.2 fold increase over 63-days, p<0.01). CD68 (B) and Iba1 (C), two markers for 
microglia and macrophages, are both significantly increased by 126 days (2.6 fold increase, 
p<0.001). (D) Cybb, a maker for pro-inflammatory M1 macrophages/microglia, was 
undetectable until 126 days, in a pooled analysis. (E,F) Two activation markers, Trem2 and 
CD39, likewise show large enrichment starting at 126 days, by pooled analysis. (G) CD3, a pan 
T-cell marker, had inconsistent expression between mice during each time point and only 
reached a significant level of increase at end-stage (6.7 fold increase, p<0.05) but showed a 
trending increase at 126 days. (H) CD8, a marker for cytotoxic T cells, begins increasing 
expression at 10 days by pooled analysis. (I) IL-1β, a pro-inflammatory cytokine, is undetectable 
until 105 days, whereas TNFα (J), also a pro-inflammatory cytokine, is upregulated beginning at 
126 days. (K-M) 3 chemokines previously identified as increased in end-stage ALS tissue are all 
mildly increased at 126 days with robust upregulation occurring at 146 days by pooled analysis. 
Statistics determined by ANOVA with Dunnett’s multiple comparison post-hoc test. 
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Figure 5.8: Markers for microgliosis and astrogliosis more closely correlate with miR-155 
levels over a marker for T Cells. Because miR-155, miR-146a, and miR-142-3p begin 
upregulation at 105 days that becomes robust and significant at 126 days (Chapter 2, Figure 5.4), 
we correlated inflammatory cell specific transcripts in the 12 ALS-model mice whose spinal 
cords were collected between these time points. While many neuroinflammatory markers showed 
correlations with miR-155 levels, Iba1 and GFAP were particularly well correlated with miR-
155 expression (r=0.84 and 0.83 respectively).  
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Figure 5.9: No significant changes in a panel of neuroinflammatory markers were observed 
in end-stage B6/SJL SOD1G93A mice treated with saline, scrambled, or anti-miR-155 oligo. 
Spinal cord RNA from 6 SOD1G93A mice from each treatment group and from non-transgenic 
mice were quantified by qPCR in a panel of neuroinflammatory markers. These markers include 
those for astrogliosis (GFAP), microglia activation and proliferation (CD68, Iba1, Ly6C, Cybb, 
TREM2, CD39), for T cell infiltration (CD3, CD8, TBX21) chemokine signaling (CCL2, 
CXCL10, CXCR4), pro-inflammatory cytokine signaling (IL1β, IL8, and TNFα), anti-
G
F
A
P
C
D
6
8
Ib
a
1
L
y 6
C
C
Y
B
B
T
R
E
M
2
C
D
3
9
C
D
3
C
D
8
C
C
L
2
C
X
C
R
4
C
X
C
L
1
0
T
N
F  IL
8
IL
1  IL
6
G
D
N
F
IG
F
1
IG
F
B
P
2
0
2
4
6
8
R
Q
N o n T ra n s g e n ic
S a lin e
S c ra m b le d
a n ti-m iR -1 5 5
E n d  S ta g e  S p in a l C o r d
C
D
6
8
L
y 6
C
C
Y
B
B
C
D
3
9
C
D
3
C
D
8
C
C
L
2
C
X
C
R
4
C
X
C
L
1
0
T
N
F  IL
8
IL
1  IL
6
IL
1
0
IG
F
1
T
B
X
2
1
0
2
4
6
8
R
Q
N o n T ra n s g e n ic
S a lin e
S c ra m b le d
a n ti-m iR -1 5 5
E n d  S ta g e  S p le e n
173 
inflammatory cytokine signaling (IL4, IL10), and various growth factors (GDNF, IGF1, and 
IGFBP2). Most of these markers were assayed in a pooled analysis by treatment group. Any 
marker that appeared changed in anti-miR-155 treated mice over both saline and scrambled mice 
was then analyzed individually in order to determine significance. This was completed for both 
end-stage spinal cords (A) and spleens (B); however, no significant change was observed 
following treatment for any marker here quantified. 
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Figure 5.10: FVB SOD1G93A ALS-model mice treated with anti-miR-155 and sacrificed at a 
specific mid-disease time point have a robust increase in a distinct set of 
neuroinflammatory markers. SOD1G93A FVB mice were treated with osmotic pumps and IP 
injections containing either saline, scrambled oligo, or anti-miR-155 (20ug/day pump; 25mg/kg 
IP) beginning at 80 days of age (n=7/group). All mice were sacrificed at a mid-disease stage, 117 
days, and mRNA from their whole spinal cords were quantified by qPCR. (A) A panel of 18 
G
F
A
P
C
D
6
8
Ib
a
1
L
y 6
C
C
Y
B
B
C
D
3
9
*C
D
3
*C
D
8
*T
B
X
2
1
*C
C
L
2
*C
X
C
L
1
0
C
X
C
R
4
T
N
F  IL
8
IL
1 
* I
L
6
IG
F
1
IG
F
B
P
1
0
2
4
6
8
R
Q
S a lin e
S c ra m b le d
a n ti-m iR -1 5 5
*  sa l vs  sc r:                  n .s .
s a l v s  a n ti-m iR -1 5 5 :  p < 0 .0 1
 s c r  v s  a n ti-m iR -1 5 5 :  p < 0 .0 1
*
*
*
*
**
A 
Ib a 1
R
Q
S
a
li
n
e
S
c
ra
m
b
le
d
a
n
t i
-m
iR
-1
5
5
0
1
2
C D 3
S
a
li
n
e
S
c
ra
m
b
le
d
a
n
t i
-m
iR
-1
5
5
0
5
1 0
1 5 C D 8
S
a
li
n
e
S
c
ra
m
b
le
d
a
n
t i
-m
iR
-1
5
5
0
5
1 0
1 5 T B X 2 1
S
a
li
n
e
S
c
ra
m
b
le
d
a
n
t i
-m
iR
-1
5
5
0
5
1 0
IL 6
S
a
li
n
e
S
c
ra
m
b
le
d
a
n
t i
-m
iR
-1
5
5
0
2
4
6
8 C C L 2
S
a
li
n
e
S
c
ra
m
b
le
d
a
n
t i
-m
iR
-1
5
5
0
5
1 0
1 5 C X C L 1 0
S
a
li
n
e
S
c
ra
m
b
le
d
a
n
t i
-m
iR
-1
5
5
0
2
4
6
8
H
DCB E
F G
175 
cellular and molecular markers for pro- and anti-inflammatory pathways was quantified. 
Interesting targets were those in which anti-miR-155 treated mice had a significant difference in 
a transcript over both saline and scrambled treated mice. 6 out of the 18 markers tested were 
significantly increased in anti-miR-155 treated mice at a p-value less than 0.01 by ANOVA with 
a Tukey’s post-hoc multiple comparison correction. Showing the individual data points for each 
mouse, anti-miR-155 treated ALS-model mice had significantly increased pro-inflammatory cell 
type markers including a pan T cell marker (C), a cytotoxic T cell marker (C), and a pro-
inflammatory Th1 cell marker (E). Also, the cytokine IL6 was robustly increased (F), as were 2 
chemokines (G,H), previously identified as increased in ALS. A microglia specific marker, Iba1, 
showed a non-significant trend towards also being increased following anti-miR-155 treatment 
(B). 
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Table 5.1: anti-miR-155 treated mice have extended survival and disease duration over 
both saline and scrambled treated mice. Median onset values are denoted for saline (n=20), 
scrambled (n=21), and anti-miR-155 (n=22) treated mice as determined by both age when the 
mouse reached weight peak and by a neurological score of 1. There was no significant change 
between either onset condition by both Mantel-Cox log-rank and Gehan-Breslow-Wilcoxon 
tests. However, survival and disease duration were significantly extended in only the anti-miR-
155 treated mice over both saline and scrambled mice as determined by both log-rank and 
Wilcoxon tests.  P-values are given for the indicated paired comparison (ex: Sal – Scr). 
 
Onset (days) Weight Peak       p-value:  Log-Rank   Wilcoxon  
Saline 91.5 Sal - Scr 0.10 0.26 
Scrambled 90 Sal - 155 0.13 0.12 
 anti-miR-155  87 Scr - 155 0.82 0.49 
 Neuroscore 
Saline 112.5 Sal - Scr 0.60 0.29 
Scrambled 115 Sal - 155 0.21 0.19 
anti-miR-155 115 Scr - 155 0.54 0.81 
Survival (days)    Survival              p-value:  Log-Rank   Wilcoxon  
Saline 129.5 Sal - Scr 0.51 0.24 
Scrambled 133 Sal - 155 0.007** 0.007** 
anti-miR-155 139 Scr - 155 0.018* 0.035* 
 Disease Duration 
Saline 38.5 Sal - Scr 0.081 0.15 
Scrambled 42 Sal - 155 <0.001*** 0.003** 
anti-miR-155 53 Scr - 155 0.038* 0.047* 
177 
 
Androulidaki, A., Iliopoulos, D., Arranz, A., Doxaki, C., Schworer, S., Zacharioudaki, V.,  
Margioris, A.N., Tsichlis, P.N., Tsatsanis, C., 2009. The kinase Akt1 controls 
macrophage response to lipopolysaccharide by regulating miRNAs. Immunity. 31, 220-
31. 
Beers, D.R., Henkel, J.S., Xiao, Q., Zhao, W., Wang, J., Yen, A.A., Siklos, L., McKercher, S.R., 
Appel, S.H., 2006. Wild-type microglia extend survival in PU.1 knockout mice with 
familial amyotrophic lateral sclerosis. Proc Natl Acad Sci U S A. 103, 16021-6. 
Beers, D.R., Henkel, J.S., Zhao, W., Wang, J., Appel, S.H., 2008. CD4+ T cells support glial 
neuroprotection, slow disease progression, and modify glial morphology in an animal 
model of inherited ALS. Proc Natl Acad Sci U S A. 105, 15558-63. 
Beers, D.R., Henkel, J.S., Zhao, W., Wang, J., Huang, A., Wen, S., Liao, B., Appel, S.H., 2011. 
Endogenous regulatory T lymphocytes ameliorate amyotrophic lateral sclerosis in mice 
and correlate with disease progression in patients with amyotrophic lateral sclerosis. 
Brain. 134, 1293-314. 
Benatar, M., 2007. Lost in translation: treatment trials in the SOD1 mouse and in human ALS. 
Neurobiol Dis. 26, 1-13. 
Benitez, B.A., Cooper, B., Pastor, P., Jin, S.C., Lorenzo, E., Cervantes, S., Cruchaga, C., 2013. 
TREM2 is associated with the risk of Alzheimer's disease in Spanish population. 
Neurobiol Aging. 34, 1711 e15-7. 
Bhattacharyya, S., Balakathiresan, N.S., Dalgard, C., Gutti, U., Armistead, D., Jozwik, C., 
Srivastava, M., Pollard, H.B., Biswas, R., 2011. Elevated miR-155 promotes 
inflammation in cystic fibrosis by driving hyperexpression of interleukin-8. J Biol Chem. 
286, 11604-15. 
Bhaumik, D., Scott, G.K., Schokrpur, S., Patil, C.K., Orjalo, A.V., Rodier, F., Lithgow, G.J., 
Campisi, J., 2009. MiRNAs miR-146a/b negatively modulate the senescence-associated 
inflammatory mediators IL-6 and IL-8. Aging (Albany NY). 1, 402-11. 
Bluml, S., Bonelli, M., Niederreiter, B., Puchner, A., Mayr, G., Hayer, S., Koenders, M.I., van 
den Berg, W.B., Smolen, J., Redlich, K., 2011. Essential role of miRNA-155 in the 
pathogenesis of autoimmune arthritis in mice. Arthritis Rheum. 63, 1281-8. 
Boillee, S., Yamanaka, K., Lobsiger, C.S., Copeland, N.G., Jenkins, N.A., Kassiotis, G., Kollias, 
G., Cleveland, D.W., 2006. Onset and progression in inherited ALS determined by motor 
neurons and microglia. Science. 312, 1389-92. 
Brettschneider, J., Toledo, J.B., Van Deerlin, V.M., Elman, L., McCluskey, L., Lee, V.M., 
Trojanowski, J.Q., 2012. Microglial activation correlates with disease progression and 
upper motor neuron clinical symptoms in amyotrophic lateral sclerosis. PLoS ONE. 7, 
e39216. 
Butovsky, O., Siddiqui, S., Gabriely, G., Lanser, A.J., Dake, B., Murugaiyan, G., Doykan, C.E., 
Wu, P.M., Gali, R.R., Iyer, L.K., Lawson, R., Berry, J., Krichevsky, A.M., Cudkowicz, 
M.E., Weiner, H.L., 2012. Modulating inflammatory monocytes with a unique miRNA 
gene signature ameliorates murine ALS. J Clin Invest. 122, 3063-87. 
178 
Cady, J., Koval, E.D., Benitez, B.A., Zaidman, C., Jockel-Balsarotti, J., Allred, P., Baloh, R.H., 
Ravits, J., Simpson, E., Appel, S.H., Pestronk, A., Goate, A.M., Miller, T.M., Cruchaga, 
C., Harms, M.B., 2014. TREM2 variant p.R47H as a risk factor for sporadic amyotrophic 
lateral sclerosis. JAMA Neurol. 71, 449-53. 
Chiu, I.M., Morimoto, E.T., Goodarzi, H., Liao, J.T., O'Keeffe, S., Phatnani, H.P., Muratet, M., 
Carroll, M.C., Levy, S., Tavazoie, S., Myers, R.M., Maniatis, T., 2013. A 
neurodegeneration-specific gene-expression signature of acutely isolated microglia from 
an amyotrophic lateral sclerosis mouse model. Cell Rep. 4, 385-401. 
Classen, A., Lloberas, J., Celada, A., 2009. Macrophage activation: classical versus alternative. 
Methods Mol Biol. 531, 29-43. 
Cleveland, D.W., Rothstein, J.D., 2001. From Charcot to Lou Gehrig: deciphering selective 
motor neuron death in ALS. Nat Rev Neurosci. 2, 806-19. 
D'Urso, P.I., D'Urso, O.F., Storelli, C., Mallardo, M., Gianfreda, C.D., Montinaro, A., Cimmino, 
A., Pietro, C., Marsigliante, S., 2012. miR-155 is up-regulated in primary and secondary 
glioblastoma and promotes tumour growth by inhibiting GABA receptors. Int J Oncol. 
41, 228-34. 
Eikelenboom, P., Veerhuis, R., Scheper, W., Rozemuller, A.J., van Gool, W.A., Hoozemans, J.J., 
2006. The significance of neuroinflammation in understanding Alzheimer's disease. J 
Neural Transm. 113, 1685-95. 
Eis, P.S., Tam, W., Sun, L., Chadburn, A., Li, Z., Gomez, M.F., Lund, E., Dahlberg, J.E., 2005. 
Accumulation of miR-155 and BIC RNA in human B cell lymphomas. Proc Natl Acad 
Sci U S A. 102, 3627-32. 
Faraoni, I., Antonetti, F.R., Cardone, J., Bonmassar, E., 2009. miR-155 gene: A typical 
multifunctional miRNA. Biochimica Et Biophysica Acta-Molecular Basis of Disease. 
1792, 497-505. 
Gonzalez Murcia, J.D., Schmutz, C., Munger, C., Perkes, A., Gustin, A., Peterson, M., Ebbert, 
M.T., Norton, M.C., Tschanz, J.T., Munger, R.G., Corcoran, C.D., Kauwe, J.S., 2013. 
Assessment of TREM2 rs75932628 association with Alzheimer's disease in a population-
based sample: the Cache County Study. Neurobiol Aging. 
Guerreiro, R., Wojtas, A., Bras, J., Carrasquillo, M., Rogaeva, E., Majounie, E., Cruchaga, C., 
Sassi, C., Kauwe, J.S., Younkin, S., Hazrati, L., Collinge, J., Pocock, J., Lashley, T., 
Williams, J., Lambert, J.C., Amouyel, P., Goate, A., Rademakers, R., Morgan, K., 
Powell, J., St George-Hyslop, P., Singleton, A., Hardy, J., 2013. TREM2 variants in 
Alzheimer's disease. N Engl J Med. 368, 117-27. 
Gurney, M.E., Pu, H., Chiu, A.Y., Dal Canto, M.C., Polchow, C.Y., Alexander, D.D., Caliendo, 
J., Hentati, A., Kwon, Y.W., Deng, H.X., et al., 1994. Motor neuron degeneration in mice 
that express a human Cu,Zn superoxide dismutase mutation. Science. 264, 1772-5. 
Hall, E.D., Oostveen, J.A., Gurney, M.E., 1998. Relationship of microglial and astrocytic 
activation to disease onset and progression in a transgenic model of familial ALS. Glia. 
23, 249-56. 
179 
Hirsch, E.C., Hunot, S., 2009. Neuroinflammation in Parkinson's disease: a target for 
neuroprotection? Lancet Neurol. 8, 382-97. 
Iorio, M.V., Ferracin, M., Liu, C.G., Veronese, A., Spizzo, R., Sabbioni, S., Magri, E., Pedriali, 
M., Fabbri, M., Campiglio, M., Menard, S., Palazzo, J.P., Rosenberg, A., Musiani, P., 
Volinia, S., Nenci, I., Calin, G.A., Querzoli, P., Negrini, M., Croce, C.M., 2005. MiRNA 
gene expression deregulation in human breast cancer. Cancer Res. 65, 7065-70. 
Janssen, H.L., Reesink, H.W., Lawitz, E.J., Zeuzem, S., Rodriguez-Torres, M., Patel, K., van der 
Meer, A.J., Patick, A.K., Chen, A., Zhou, Y., Persson, R., King, B.D., Kauppinen, S., 
Levin, A.A., Hodges, M.R., 2013. Treatment of HCV infection by targeting miRNA. N 
Engl J Med. 368, 1685-94. 
Jonsson, T., Stefansson, H., Steinberg, S., Jonsdottir, I., Jonsson, P.V., Snaedal, J., Bjornsson, S., 
Huttenlocher, J., Levey, A.I., Lah, J.J., Rujescu, D., Hampel, H., Giegling, I., 
Andreassen, O.A., Engedal, K., Ulstein, I., Djurovic, S., Ibrahim-Verbaas, C., Hofman, 
A., Ikram, M.A., van Duijn, C.M., Thorsteinsdottir, U., Kong, A., Stefansson, K., 2013. 
Variant of TREM2 associated with the risk of Alzheimer's disease. N Engl J Med. 368, 
107-16. 
Junker, A., Krumbholz, M., Eisele, S., Mohan, H., Augstein, F., Bittner, R., Lassmann, H., 
Wekerle, H., Hohlfeld, R., Meinl, E., 2009. MiRNA profiling of multiple sclerosis lesions 
identifies modulators of the regulatory protein CD47. Brain. 132, 3342-52. 
Kierdorf, K., Prinz, M., 2013. Factors regulating microglia activation. Front Cell Neurosci. 7, 44. 
Kobayashi, K., Imagama, S., Ohgomori, T., Hirano, K., Uchimura, K., Sakamoto, K., Hirakawa, 
A., Takeuchi, H., Suzumura, A., Ishiguro, N., Kadomatsu, K., 2013. Minocycline 
selectively inhibits M1 polarization of microglia. Cell Death Dis. 4, e525. 
Kurowska-Stolarska, M., Alivernini, S., Ballantine, L.E., Asquith, D.L., Millar, N.L., Gilchrist, 
D.S., Reilly, J., Ierna, M., Fraser, A.R., Stolarski, B., McSharry, C., Hueber, A.J., Baxter, 
D., Hunter, J., Gay, S., Liew, F.Y., McInnes, I.B., 2011. MiRNA-155 as a 
proinflammatory regulator in clinical and experimental arthritis. Proc Natl Acad Sci U S 
A. 108, 11193-8. 
Landgraf, P., Rusu, M., Sheridan, R., Sewer, A., Iovino, N., Aravin, A., Pfeffer, S., Rice, A., 
Kamphorst, A.O., Landthaler, M., Lin, C., Socci, N.D., Hermida, L., Fulci, V., Chiaretti, 
S., Foa, R., Schliwka, J., Fuchs, U., Novosel, A., Muller, R.U., Schermer, B., Bissels, U., 
Inman, J., Phan, Q., Chien, M., Weir, D.B., Choksi, R., De Vita, G., Frezzetti, D., 
Trompeter, H.I., Hornung, V., Teng, G., Hartmann, G., Palkovits, M., Di Lauro, R., 
Wernet, P., Macino, G., Rogler, C.E., Nagle, J.W., Ju, J., Papavasiliou, F.N., Benzing, T., 
Lichter, P., Tam, W., Brownstein, M.J., Bosio, A., Borkhardt, A., Russo, J.J., Sander, C., 
Zavolan, M., Tuschl, T., 2007. A mammalian miRNA expression atlas based on small 
RNA library sequencing. Cell. 129, 1401-14. 
Lu, L.F., Boldin, M.P., Chaudhry, A., Lin, L.L., Taganov, K.D., Hanada, T., Yoshimura, A., 
Baltimore, D., Rudensky, A.Y., 2010. Function of miR-146a in controlling Treg cell-
mediated regulation of Th1 responses. Cell. 142, 914-29. 
Makeyev, E.V., Maniatis, T., 2008. Multilevel regulation of gene expression by miRNAs. 
Science. 319, 1789-90. 
180 
Mantovani, A., Sozzani, S., Locati, M., Allavena, P., Sica, A., 2002. Macrophage polarization: 
tumor-associated macrophages as a paradigm for polarized M2 mononuclear phagocytes. 
Trends Immunol. 23, 549-55. 
Melanie Leitner, S.M., Cathleen Lutz 2009. Working with ALS Mice; Guidelines for preclinical 
testing and colony management. Vol., ed.^eds. Prize4Life, Inc. 
Miller, S.L.D.a.T.M., 2013. Direct Intraventricular Delivery of Drugs to the Rodent Central 
Nervous System. The Journal of Visualized Experiments. 75, e50326. 
Miller, T.M., Pestronk, A., David, W., Rothstein, J., Simpson, E., Appel, S.H., Andres, P.L., 
Mahoney, K., Allred, P., Alexander, K., Ostrow, L.W., Schoenfeld, D., Macklin, E.A., 
Norris, D.A., Manousakis, G., Crisp, M., Smith, R., Bennett, C.F., Bishop, K.M., 
Cudkowicz, M.E., 2013. An antisense oligonucleotide against SOD1 delivered 
intrathecally for patients with SOD1 familial amyotrophic lateral sclerosis: a phase 1, 
randomised, first-in-man study. Lancet Neurol. 12, 435-42. 
Numasawa, Y., Yamaura, C., Ishihara, S., Shintani, S., Yamazaki, M., Tabunoki, H., Satoh, J.I., 
2011. Nasu-Hakola disease with a splicing mutation of TREM2 in a Japanese family. Eur 
J Neurol. 18, 1179-83. 
O'Connell, R.M., Chaudhuri, A.A., Rao, D.S., Baltimore, D., 2009. Inositol phosphatase SHIP1 
is a primary target of miR-155. Proc Natl Acad Sci U S A. 106, 7113-8. 
O'Connell, R.M., Kahn, D., Gibson, W.S., Round, J.L., Scholz, R.L., Chaudhuri, A.A., Kahn, 
M.E., Rao, D.S., Baltimore, D., 2010. MiRNA-155 promotes autoimmune inflammation 
by enhancing inflammatory T cell development. Immunity. 33, 607-19. 
Paloneva, J., Kestila, M., Wu, J., Salminen, A., Bohling, T., Ruotsalainen, V., Hakola, P., 
Bakker, A.B., Phillips, J.H., Pekkarinen, P., Lanier, L.L., Timonen, T., Peltonen, L., 
2000. Loss-of-function mutations in TYROBP (DAP12) result in a presenile dementia 
with bone cysts. Nat Genet. 25, 357-61. 
Paloneva, J., Manninen, T., Christman, G., Hovanes, K., Mandelin, J., Adolfsson, R., Bianchin, 
M., Bird, T., Miranda, R., Salmaggi, A., Tranebjaerg, L., Konttinen, Y., Peltonen, L., 
2002. Mutations in two genes encoding different subunits of a receptor signaling complex 
result in an identical disease phenotype. Am J Hum Genet. 71, 656-62. 
Pedersen, I., David, M., 2008. MiRNAs in the immune response. Cytokine. 43, 391-4. 
Perrin, S., 2014. Preclinical research: Make mouse studies work. Nature. 507, 423-5. 
Ponomarev, E.D., Veremeyko, T., Barteneva, N., Krichevsky, A.M., Weiner, H.L., 2011. 
MiRNA-124 promotes microglia quiescence and suppresses EAE by deactivating 
macrophages via the C/EBP-alpha-PU.1 pathway. Nat Med. 17, 64-70. 
Pottier, C., Wallon, D., Rousseau, S., Rovelet-Lecrux, A., Richard, A.C., Rollin-Sillaire, A., 
Frebourg, T., Campion, D., Hannequin, D., 2013. TREM2 R47H variant as a risk factor 
for early-onset Alzheimer's disease. J Alzheimers Dis. 35, 45-9. 
 
 
181 
Rayaprolu, S., Mullen, B., Baker, M., Lynch, T., Finger, E., Seeley, W.W., Hatanpaa, K.J., 
Lomen-Hoerth, C., Kertesz, A., Bigio, E.H., Lippa, C., Josephs, K.A., Knopman, D.S., 
White, C.L., 3rd, Caselli, R., Mackenzie, I.R., Miller, B.L., Boczarska-Jedynak, M., 
Opala, G., Krygowska-Wajs, A., Barcikowska, M., Younkin, S.G., Petersen, R.C., 
Ertekin-Taner, N., Uitti, R.J., Meschia, J.F., Boylan, K.B., Boeve, B.F., Graff-Radford, 
N.R., Wszolek, Z.K., Dickson, D.W., Rademakers, R., Ross, O.A., 2013. TREM2 in 
neurodegeneration: evidence for association of the p.R47H variant with frontotemporal 
dementia and Parkinson's disease. Mol Neurodegener. 8, 19. 
Rogers, J., Strohmeyer, R., Kovelowski, C.J., Li, R., 2002. Microglia and inflammatory 
mechanisms in the clearance of amyloid beta peptide. Glia. 40, 260-9. 
Smith, R.A., Miller, T.M., Yamanaka, K., Monia, B.P., Condon, T.P., Hung, G., Lobsiger, C.S., 
Ward, C.M., McAlonis-Downes, M., Wei, H., Wancewicz, E.V., Bennett, C.F., 
Cleveland, D.W., 2006. Antisense oligonucleotide therapy for neurodegenerative disease. 
J Clin Invest. 116, 2290-6. 
Sonkoly, E., Stahle, M., Pivarcsi, A., 2008. MiRNAs and immunity: novel players in the 
regulation of normal immune function and inflammation. Semin Cancer Biol. 18, 131-40. 
Stanczyk, J., Pedrioli, D.M., Brentano, F., Sanchez-Pernaute, O., Kolling, C., Gay, R.E., Detmar, 
M., Gay, S., Kyburz, D., 2008. Altered expression of MiRNA in synovial fibroblasts and 
synovial tissue in rheumatoid arthritis. Arthritis Rheum. 58, 1001-9. 
Takahashi, K., Rochford, C.D., Neumann, H., 2005. Clearance of apoptotic neurons without 
inflammation by microglial triggering receptor expressed on myeloid cells-2. J Exp Med. 
201, 647-57. 
Volinia, S., Calin, G.A., Liu, C.G., Ambs, S., Cimmino, A., Petrocca, F., Visone, R., Iorio, M., 
Roldo, C., Ferracin, M., Prueitt, R.L., Yanaihara, N., Lanza, G., Scarpa, A., Vecchione, 
A., Negrini, M., Harris, C.C., Croce, C.M., 2006. A miRNA expression signature of 
human solid tumors defines cancer gene targets. Proc Natl Acad Sci U S A. 103, 2257-
61. 
Wang, X., Zhao, Q., Matta, R., Meng, X., Liu, X., Liu, C.G., Nelin, L.D., Liu, Y., 2009. 
Inducible nitric-oxide synthase expression is regulated by mitogen-activated protein 
kinase phosphatase-1. J Biol Chem. 284, 27123-34. 
Yanaihara, N., Caplen, N., Bowman, E., Seike, M., Kumamoto, K., Yi, M., Stephens, R.M., 
Okamoto, A., Yokota, J., Tanaka, T., Calin, G.A., Liu, C.G., Croce, C.M., Harris, C.C., 
2006. Unique miRNA molecular profiles in lung cancer diagnosis and prognosis. Cancer 
Cell. 9, 189-98. 
Zhu, S., Stavrovskaya, I.G., Drozda, M., Kim, B.Y., Ona, V., Li, M., Sarang, S., Liu, A.S., 
Hartley, D.M., Wu, D.C., Gullans, S., Ferrante, R.J., Przedborski, S., Kristal, B.S., 
Friedlander, R.M., 2002. Minocycline inhibits cytochrome c release and delays 
progression of amyotrophic lateral sclerosis in mice. Nature. 417, 74-8. 
 
 
 
182 
 
 
 
 
 
 
 
 
 
 
CHAPTER 6 
 
 
Conclusions, implications, and future directions 
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Summary 
MicroRNAs (miRNAs) are a newly discovered class of translational repressors with the 
power to modulate large numbers of genes upon incorporation into the Ago2 containing RNA 
induced silencing complex (RISC) via partial complementarity to target mRNAs (Bartel, 2009; 
Selbach et al., 2008). In studying the role of miRNAs in ALS, a microarray of miRNAs in ALS 
model SOD1G93A rodent spinal cord tissues identified 12 miRNAs as significantly upregulated. 
Six of these miRNAs tested in human ALS tissues were confirmed increased. Specifically, miR-
155 was increased 5-fold in mice and 2-fold in human spinal cords. miR-142-3p, miR-146a, and 
miR-155 showed an almost perfect correlation in dynamic expression patterns throughout 
disease in the ALS mouse model. Despite optimizing methods for miRNA isolation from low-
abundance samples, these miRNA targets do not appear to be ALS serum biomarkers.  
Following conflicting data on the cell-specific expression of miR-155 using conventional 
methods, we developed mice that permit high-throughput identification of cellular expression of 
microRNAs in neurons, motor neurons, astrocytes, and microglia. This was achieved by creating 
mice that express a GFP-myc tagged microRNA binding protein, Ago2, driven by Syn, ChAT, 
GFAP, or Lyz2 promoters, respectively. Using whole brainstem or whole spinal cord tissue 
input, immunoprecipitation with anti-myc conjugated magnetic beads allowed the pull-down of 
GFP-myc-Ago2 and its associated miRNAs from only the specific cell type of interest. 
Following validation of these mice though molecular and histological analysis, we performed 
miRNA microarrays on 3 mice from each line with brainstem and spinal cord whole tissue 
inputs. From this, we have generated a dataset of several hundred miRNAs and their cellular 
expression patterns in neural tissues. Specifically, we found miR-155 to be expressed at over 300 
fold greater level in spinal cord microglia over neurons.  
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To test miRNA inhibition in the central nervous system as a potential novel therapeutic, 
we developed oligonucleotide-based miRNA inhibitors (anti-miRs) that could inhibit miRNAs 
throughout the central nervous system and in the periphery. Anti-miR-155 caused global 
derepression of targets in peritoneal macrophages and, following intraventricular delivery, 
demonstrated widespread functional distribution in the brain and spinal cord. After treating 
SOD1G93A mice with anti-miR-155, we significantly extended survival by 10 days and disease 
duration by 15 days (38%) while a scrambled control anti-miR did not significantly improve 
survival or disease duration.  
Given the enrichment of miR-155 in glial cells in the brainstem and spinal cord, we tested 
if anti-miR-155 treatment affected the expression levels of neuroinflammatory transcripts for the 
prevalence and activation of astrocytes, myeloid cells, and lymphocytes. While no significant 
changes were observed in tissues from treated end-stage ALS-model mice, a separate cohort of 
SOD1G93A treated mice sacrificed at a defined mid-disease stage showed that anti-miR-155 
treatment correlated with significant increases in 6 specific markers of inflammation. Increased 
were transcripts for cytotoxic T cells, CD8 and TBX21, the pro-inflammatory cytokine Il6, and 
the chemokine ligands CCL2 and CXCL10. While not necessarily the mechanism through which 
anti-miR-155 confers a survival benefit, these studies better inform the complex nature of 
neuroinflammation in ALS. Overall, we have found that microRNAs are dysregulated in ALS, 
developed a high-throughput method of determining cell-specific expression of microRNAs, 
developed antisense oligonucleotides that can be used to successfully inhibit miRNAs 
throughout the brain and spinal cord, and discovered that miR-155 is a promising new 
therapeutic target for ALS.  
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Implications of the dissertation  
 Lists of dysregulated miRNAs have been generated for a myriad of neurodegenerative 
diseases including Alzheimer’s disease (Delay and Hebert, 2011), Parkinson’s disease 
(Mouradian, 2012), Huntington’s disease (Lee et al., 2011), and ALS (Campos-Melo et al., 
2013). However, fewer studies examine the role of the dysregulated miRNAs, if these 
microRNAs are important to disease progression, or if they are beneficial or detrimental 
contributors to disease pathology. Limitations in understanding the function of miRNAs in 
neurological disease is likely due in part to an inability to effectively modulate miRNA 
expression in vivo. Given our lab’s experience using antisense oligonucleotide (ASO) technology 
to inhibit mRNAs (Miller et al., 2013; Smith et al., 2006), we were well suited to translate these 
methods to inhibit miRNAs – both in terms of optimal delivery methods to target the central 
nervous system and with optimal ASO modifications that serve to increase potency and decrease 
drug toxicity. 
 To test the function of particular miRNAs of interest in the brain and spinal cord, we 
needed to develop a method to safely and effectively modulate miRNA expression and/or 
function in the CNS. After screening multiple anti-miR modifications in vitro and in vivo, we 
found superior target engagement and minimal toxicity with alternating blocks of 2’-MOE and 
2’fluoro sugar-modified nucleosides. Because ASOs are highly charged molecules that do not 
readily cross the blood-brain barrier, we tested the ability to broadly inhibit miRNAs of interest 
throughout the brain and spinal cord with implanted Alzet osmotic pumps that continuously 
infused anti-miRs directly into the cerebral lateral ventricle. We found that mice that received 
anti-miR treatment with this method had a broad distribution of the anti-miR in brain and spinal 
cord tissue and that the oligo was taken up by multiple cell types including neurons, microglia, 
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and astrocytes. Also, the miRNA of interest was successfully inhibited following anti-miR 
treatment, as determined by observing a derepression of target mRNA transcripts. Developing a 
method to effectively inhibit miRNA function in the CNS in vivo was essential to test the 
function of our miRNAs of interest in ALS and will likely prove useful to other studies of 
upregulated miRNAs in various neurological disorders.  
 While we directly infused anti-miRs to the rodent cerebral lateral ventricle, success in 
clinic has been achieved using a similar direct-infusion method. Recently, in a Phase I safety 
trial, ALS patients treated with an ASO against SOD1 via intrathecal spinal cord injections 
showed no adverse events related to the drug or the dose showing that a direct infusion method 
for ASO therapy is not only valid for preclinical rodent-based experiments but also has 
translational promise. More so, anti-miRs have been used safely and effectively in the periphery 
in recent human clinical trials (NCT00688012 and NCT00979927) (Janssen et al., 2013). The 
inability to target miRNA inhibitors broadly to the central nervous system was previously a 
limitation in miRNA research. Our novel treatment method to inhibit miRNAs in the brain and 
spinal cord using ASOs delivered directly to the CSF can now be used to study the importance of 
dysregulated miRNAs in various neurological disease rodent models in a manner that has true 
translational relevancy.  
 The most common model used for ALS translational research is the SOD1G93A mouse 
model; however, growing controversy exists on the usefulness of SOD1 ALS rodent models as 
more clinical trials fail to translate rodent targets to patients (Benatar, 2007; Perrin, 2014). 
Therefore, in studying the role of miRNA in ALS, we have taken steps to increase the 
translational potential of our use of this preclinical model. The considerations detailed here serve 
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to both increase confidence in the relevancy of our rodent-based data and also serve as a 
potential guide to other therapeutic studies using the ALS mouse model.  
One limitation of the popular SOD1G93A rodent model is that it only represents ALS 
caused by a single genetic mutation, which 98% of ALS patients do not harbor. Furthermore, in 
order to accelerate in vivo experiments, the ALS-rodent model was created to be highly 
aggressive, with the genomic insertion of approximately 15 copies of the ALS-causing gene. 
Due to these concerns over the ability of the SOD1G93A rodent line to accurately model ALS 
disease broadly, we used multiple rodent models and patient tissue samples to determine 
miRNAs of interest. Dysregulated miRNAs were only considered if they were identified in both 
the mouse and rat SOD1G93A models over nontransgenic rodents. More so, for rats, these 
miRNA targets had to be similarly altered over the SOD1WT rat line, which expresses 
approximately 15 copies of the wild-type human SOD1 gene. Furthermore, the more-
controversial TDP-43A315T ALS-FTD mouse line was used as a secondary validator of our top 
targets. Finally, we only considered important those miRNAs increased in both the rodent ALS 
model and in patient ALS tissue from both familial and sporadic ALS patients. The stringency 
used in identifying dysregulated miRNAs in ALS potentially caused some interesting miRNAs 
to be overlooked but served to increase confidence and reduce the number of false positive 
targets, which is an important consideration given the climate of failed clinical trials based on 
rodent research.  
This dissertation work has strong therapeutic implications in ALS research given the 
numerous considerations taken in the design, execution, and analysis of these experiments in 
order to increase translational relevancy.  Most therapeutic experiments in ALS-model mice 
that report a positive effect serve to delay onset (on average by 12 days) but do not robustly 
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extend disease duration (on average 3 days) (Benatar, 2007). As ALS patients typically enter 
the clinic after symptom onset, the most relevant therapeutic targets will likely be those that 
slow disease progression. Therefore, we carefully tracked both onset and survival measures in 
our treated ALS-model mice through both weight and neurological score assessments in order 
to accurately determine if our anti-miR treatment served to delay onset or extend disease 
duration. Also, we performed sample size calculations to determine the required number of 
mice required to observe a 10-day effect at 80% power, a necessary step in planning therapeutic 
experiments that is often overlooked in ALS research resulting in many underpowered 
experiments (Perrin, 2014). More so, while important studies, several published experiments in 
the ALS-model use methods that are not translatable to patients including genetic ablation 
(Beers et al., 2008) or target genes not expressed in humans (Butovsky et al., 2012). With the 
goal to determine potential miRNA therapeutic targets, we only considered miRNAs that were 
also human targets and only modified them in a manner relevant to potential clinical trials. Of 
published studies that have reported an extension in disease duration in the ALS-mouse model, 
the weighted mean difference in a meta-analysis was 10%, while we report a 38% extension in 
disease duration following anti-miR-155 treatment (Benatar, 2007). For further context, a 
previous study using antisense oligonucleotides against SOD1 in rats did not significantly alter 
onset, but extended survival by 10 days and extended disease duration by 37% (Smith et al., 
2006). Our data clearly identify miR-155 as a promising therapeutic target for ALS and may 
potentially apply more broadly to neurological disorders where miR-155 is increased including 
multiple sclerosis (Junker et al., 2009) and in glioblastoma (D'Urso et al., 2012). Importantly, 
inhibition of miR-155 extended survival using an ASO and a method with application to 
patients showing real therapeutic potential. 
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One possible limitation of our research is that we began treatment in the ALS-mouse 
model at 60 days of age – approximately 30 days prior to the most common definition of the 
onset of disease - weight peak. However, the definition of symptom onset remains controversial 
in the ALS field. For example, subtle changes in the gait SOD1G93A mice can be observed at 8 
weeks of age, well before weight loss is observed (Mancuso et al., 2011). Given the importance 
of conducting rodent preclinical studies in a manner best applicable to patients, we will test the 
effects of anti-miR-155 on survival in SOD1G93A mice with later treatment commencements. 
Because miR-155 expression begins to be upregulated at a mid-disease stage, we hypothesize 
that starting treatment at a later age will be similarly efficacious.  
  Next, arguably the most difficult aspect of miRNA research is understanding the 
function of the miRNA of interest. Because several miRNA experiments use animal and patient 
samples comprised of multiple cell types, the first step to understanding the role of a particular 
miRNA is to understand its cellular expression. The most popular methods for determining 
miRNA expression patterns in distinct cell types are fluorescence activated cell sorting (FACS), 
laser capture microdissection (LCM), cell culture models, and in situ staining; however, each of 
these methods has significant limitations. First, both FACS and LCM are low yield and require 
cellular dissociation and manipulations ex vivo that can introduce cellular stress and alter gene 
expression (Avvisato et al., 2007). Cell culture models often do not accurately describe the 
nature of in vivo cells, and miRNA in situs are technically difficult, expensive, and low 
throughput, only testing a single miRNA per experiment. In response to these limitations, we 
have adapted the recently published miRNA tagging and affinity purification (miRAP) method 
(He et al., 2012) to generate high-throughput and physiologically relevant lists of miRNA 
expression levels in neurons, motor neurons, microglia, and astrocytes in the mouse brain and 
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spinal cord. By creating mice that express a tagged miRNA binding protein behind cell type 
specific drivers, we were able to isolate miRNAs from specific cell types through 
immunoprecipitation of whole tissue input. miRAP has several advantages over traditional 
methods to quantify miRNAs from specific cell populations. One major benefit of a miRAP 
approach is that once the tissue of interest is isolated from the mouse, the first experimental step 
is to lyse the cells. This allows the isolated RNA to closely mimic its native state. This is 
especially important for neuroinflammatory regulators that quickly change expression patterns 
based on their environment. Second, this method allows for miRNAs throughout the cell to be 
isolated, including in dendrites and synapses that were previously hard to isolate with 
conventional methods. Third, unlike in situ’s that test one miRNA at a time, miRAP is a high-
throughput method allowing for quantification of hundreds of miRNAs. Finally, by isolating 
miRNAs bound to Ago2, only “active” miRNAs that have been incorporated into the RNA 
induced silencing complex (RISC) are being isolated. Overall, our high-throughput and 
physiologically relevant lists of miRNA expression patterns in neuronal and glial cell 
populations can potentially aid miRNA research broadly. Several lists of dysregulated miRNAs 
in disease have been generated using whole brain and spinal cord tissue, and in order to 
understand the physiological and pathological role of miRNAs, it is first necessary to know their 
cellular expression patterns for which these miRAP lists may be a reference.  
  The miRAP expression data sets may serve as a first-step to use descriptive lists of 
dysregulated miRNAs using whole tissues to design mechanistic experiments that aim to 
determine miRNA function. Our ALS-based research serves as one example of this potential. By 
quantifying miRNAs in end-stage ALS-model mouse spinal cord tissue as compared to littermate 
controls, we identified 6 miRNAs that were also upregulated in ALS patient autopsy spinal cord 
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tissue. Using the miRAP data sets that compare neuron, motor neuron, microglia, and astrocyte 
miRNA expression levels, we identified that one particular miRNA of interest, miR-155, was 
most enriched in microglia in the brain and spinal cord over the other cell types measured. With 
this expression data and the understanding that microglia play critical roles in neuroinflammation 
in ALS, we were therefore interested in studying alterations in neuroinflammatory pathways 
following anti-miR-155 treatment in ALS-model mice as a potential mechanism of action for 
miR-155. This serves as one example of the ability of the miRAP data sets to bridge descriptive 
and mechanistic miRNA experiments in the central nervous system. Finally, with the use of 
additional established Cre-drivers, the method for generating, validating, and using the miRAP 
mice detailed in Chapter 3 can be adapted for studying miRNA expression patterns in other cell 
types of interest.  
  Neuroinflammation has been well characterized in ALS, both in patients and in the 
mouse model. Increased numbers of microglia can be observed in affected tissues including the 
ventral horns of the spinal cord, corticospinal tracts, brainstem motor nuclei, and the motor 
cortex (Weydt and Moller, 2005). A number of recent experiments using the ALS-mouse model 
suggest that while overall blunting of the immune system is potentially detrimental, selectively 
modulating and even increasing components of the neuroimmune response in ALS may be 
beneficial. However, one of the largest remaining questions in studying neuroinflammation in 
ALS is whether microglia and lymphocytes are neuroprotective, neurotoxic, or both and whether 
modulating their activation states could be a valid therapy.  
  Given the putative role of miR-155 in being an immunomodulator (O’Connell et al., 
2007), its heightened expression in microglia, and the well characterized role of microglia in 
neuroinflammation in ALS, we quantified several transcripts of cellular and molecular markers 
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of neuroinflammation in ALS mice treated with anti-miR-155. While SOD1G93A mice treated 
with anti-miR-155 showed no significant change in the expression of any of the 19 
neuroinflammatory transcripts measured in spinal cord tissue at the end-stage of disease, mid-
disease stage treated mice had a significant increase in transcripts for a pan T-cell marker (CD3) 
a cytotoxic T-cell marker (CD8), a pro-inflammatory T-helper cell marker (TBX21), a pro-
inflammatory cytokine (IL6), and 2 chemokine ligands, CCL2 and CXCL10. These alterations 
are not thought to be caused by oligo toxicity as other pro-inflammatory transcripts were 
unchanged (including TNFα, IL-1β) and because treatment with a scrambled oligo that contains 
the same backbone modifications did not alter these transcript levels. 
These data are interesting as they suggest that relatively recent definitions in ALS of 
‘good’ M2 microglia correlated with anti-inflammatory transcripts and ‘bad’ M1 microglia 
correlated with pro-toxic cytokines is either too simplistic or incorrect. In 2013, by performing 
deep RNA sequencing, microglia from ALS-model mice were shown to have the potential to be 
concurrently both cytotoxic and protective by expressing a mixture of “M2” and “M1” genes 
throughout disease including IGF-1, Progranulin, DAP12 and MMP-12, Optineurin, and Nox2 
respectively (Chiu et al., 2013). Furthermore, research in Alzheimer’s disease suggests a 
beneficial role for microglia that express proinflammatory cytokines. By treating (APPSwe)/PS1 
AD model mice with the cytokine colony-stimulating factor (M-CSF), mice had a lower β-
amyloid plaque burden along with improved performances in learning and memory tasks 
(Boissonneault et al., 2009). These data support a beneficial role of microglia likely through 
increased phagocytosis and clearance of toxic proteins and cells. Overall, it remains unclear the 
best way to therapeutically target the immune response in ALS. However, in light of these recent 
studies, our observation of an increase in pro-toxic cytokines and T-cells transcripts following 
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anti-miR-155 treatment can be potentially better understood. One possible model in which anti-
miR-155 treatment results in a survival benefit in ALS-model mice is through alterations in 
neuroinflammatory properties, resulting in the increased clearance of detrimental proteins and/or 
cells potentially through augmenting microglia number or their activation profiles. Future 
experiments that target components of the inflammatory response will be required to test the 
validity and refine this hypothesis. 
While our data may be considered supportive for a beneficial role in furthering microglia 
and lymphocyte activation and recruitment in the ALS-mouse model, it is unclear if this is the 
mechanism of action for our anti-miR treatment. In data presented in Chapter 3, we saw a 
reduced but real signal of miR-155 in neurons, and in Chapter 4, we showed that anti-miR-155 is 
taken up by neurons, microglia, and astrocytes. We do not know if there is one cell type that is 
critical to the ameliorating effect of anti-miR-155 in the ALS-mouse model or which cell type 
this may be but have proposed experiments to discern this that are detailed later in this chapter. 
Overall, we have demonstrated a therapeutically relevant method to inhibit microRNAs 
broadly in the brain and spinal cord for the first time. We have also supplied the first published 
list of altered microRNAs in ALS spinal cord tissue. To aid in understanding the role of miRNAs 
in the CNS, physiologically relevant, high-throughput data sets were generated that detail 
relative expression levels of approximately 400 miRNAs in neuronal and glial cell types. The 
microglial enriched miRNA, miR-155, was identified as an exciting therapeutic target whose 
inhibition led to a robust survival increase in the ALS-mouse model along with a correlated 
increase in specific neuroinflammatory transcripts. MicroRNA inhibition, and miR-155 
specifically, remain exciting avenues for ALS research as potential therapeutic targets.  
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Future directions 
Further applications of miRAP mice  
 We have generated datasets of miRNA expression levels in neurons, motor neurons, 
astrocytes, and microglia in the brain and spinal cord which have allowed for the identification of 
cell type enriched and cell type specific microRNAs. While these lists are potentially useful as a 
resource for informing cell type specific expression for researchers using mixed cell type 
systems, several more sophisticated and intriguing applications of these datasets remain. These 
include ongoing experiments that will strive to identify miRNA drivers of cell type 
differentiation, provide insight into miRNA biogenesis and regulation, and identify miRNA 
dysregulation in neurodegenerative disease in a more precise manner. 
Recently, Andrew Yoo and others have discovered a method to reprogram patient 
fibroblasts to neurons in culture using a cocktail of microRNA mimics (Yoo et al., 2011), 
enabling mechanistic and translational research on affected cell types of disease that are 
otherwise difficult and/or impossible to isolate from patients. However, one limitation in this 
research is an inability to fine-tune these cellular programming pathways to more specific 
relevant cell types including motor neurons, and more so specifically to affected spinal motor 
neurons in ALS. By identifying miRNAs distinct between similar cell types (for example, spinal 
motor neurons versus brainstem motor neurons), additional miRNA drivers of cell-determination 
pathways may be identified that can allow for more precise reprogramming of cellular 
differentiation. To better identify miRNAs that have potential regulatory control over mRNAs 
known to be important to cellular differentiation, we will compare the miRAP miRNA 
microarray data to existing datasets on mRNAs from astrocytes, neurons and motor neurons 
already generated by others (Cahoy et al., 2008; Doyle et al., 2008). This integrated analysis of 
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microRNA and mRNAs will be conducted with multiple algorithms. These may include MMIA 
(microRNA mRNA Integrated Analysis), MAGIA (miRNA and genes integrated analysis), and 
others (Naifang et al., 2013). Therefore, we will be able to not only identify miRNAs uniquely 
expressed in distinct cell types, but also identify which of those miRNAs are potential drivers of 
mRNAs known to be important in cellular differentiation and identity. While ambitious, the 
importance of developing tissue culture models of difficult to isolate cells in neurological 
diseases warrants the effort necessary to test the utility of this approach to identify novel miRNA 
drivers of cellular differentiation. 
Furthermore, integrated miRNA-mRNA analysis may better inform direct binding 
partners. Identification of putative mRNA targets for a given miRNA typically begins with target 
prediction algorithms based on nucleotide sequences (for example, TargetScan); however, many 
false positives are generated with this method alone (Lewis et al., 2005). Therefore, experimental 
validation is then necessary which can be difficult and time consuming – often employing the 
use of miRNA mimics, antagomirs, or genetic ablation (van Rooij et al., 2012). However, a more 
refined list of putative mRNA targets can be generated prior to experimental validation by only 
considering mRNAs that exhibit inverse expression patterns as compared to the miRNA of 
interest by using a combinatorial analysis of miRAP datasets with mRNA expression lists. Thus, 
this extra, simple computational step could easily be used to generate putative target lists with a 
higher degree of confidence than by using target prediction algorithms alone, potentially 
allowing for fewer false positives to be screened through more ambitious experimental validation 
experiments. 
Next, by using both BAC-TRAP and miRAP mice, we can explore the regulation of 
microRNA biogenesis. Joe Dougherty has recently discovered that the GFP-L10a BAC-TRAP 
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mice have GFP+ nuclei. This has allowed us to sort GFP+ nuclei from specific cell populations 
from whole tissue. MicroRNAs are first transcribed from protein coding and non-coding genes 
by RNA polymerase II where a primary-miRNA (pri-miRNA) transcript is generated. The pri-
miRNA is then cleaved by the RNAse II enzymes Drosha and Dicer to generate a 70 nucleotide 
fragment known as the precursor-miRNA (pre-miRNA) (Krol et al., 2010). The pre-miRNA is 
then exported to the cytoplasm by Exportin-5 before being further cleaved by Dicer to form 
mature miRNA. This is referred to as the ‘linear’ or conical pathway (Winter et al., 2009). 
However, there have been reports of regulatory events in this processing that can suppress the 
maturation of let-7, as one example (Viswanathan et al., 2008). In collaboration with Joe 
Dougherty, we will compare and contrast primary miRNA transcripts, precursor miRNA 
transcripts, and mature miRNA transcripts for a given cell type. These data will have the 
potential to greatly inform the biogenesis of miRNAs. For example, we discovered miR-196 to 
be selectively expressed in neurons in the spinal cord and not the brainstem. By comparing pri-, 
pre-, and mature miRNA levels in these mice using ChAT-L10a-GFP mice and ChAT-Ago2-
GFP mice, we will be able to attribute the selective expression of miR-196 to be either a 
difference in transcription or a difference in processing regulation. Overall, we are well suited to 
perform these experiments that will strive to inform the importance of regulation of miRNA 
biogenesis 
Next, by isolating specific motor pools, we may be able to elucidate pathways that 
differentially confer resistance and susceptibility within a cell type across different tissues. In 
ALS, while most motor neurons succumb to disease, those that innervate the eyes, pelvic 
sphincters, and slow limb muscles are selectively spared. By comparing mRNA expression 
between resistant and vulnerable motor neurons in ALS model mice, Kaplan et al. were able to 
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identify a gene selectively expressed in vulnerable motor neurons, MMP9, that could be 
inhibited to reduce apoptosis (Kaplan et al., 2014). In experiments underway, we are using the 
ChAT-Cre line and the lox-stop-lox Ago2 as described in chapter 3 to isolate miRNAs from 
motor neurons from distinct affected or unaffected motor nuclei. We will test if a similar 
resistance or vulnerability mediating miRNA can be identified as was recently completed for 
mRNA. 
 Finally, we have begun crossing our neuronal and glial specific miRAP mice into disease 
models which will allow for the identification of miRNAs dysregulated in neurodegenerative 
disease in a more precise manner. We are also currently generating triple transgenic mice that 
express the cell type specific GFP-myc-Ago2 protein in the SOD1G93A mouse model. We have 
currently produced over 10 triple transgenic positive mice for the ChAT line and are actively 
generating mice for the other three cell specific lines as well. These triple transgenic mice will 
allow not only comprehensive identification of dysregulated miRNAs but an assignment of 
which cell types have altered miRNA expression levels in disease. This will increase insight into 
potential mechanisms of miRNA dysregulation in specific cell types while also identifying those 
miRNAs altered in disease. More so, these experiments might allow additional dysregulated 
microRNAs to be unearthed that were previously diluted by other cell types in disease. 
Furthermore, these data may aid in the design of therapeutics as it will inform which cell types 
have to be targeted.  
While we have determined the relative expression levels of miR-155 in specific cell types 
in the brain and spinal cord (Chapter 3), we have not determined if miR-155 increases in ALS 
due to an increased number of cells that express miR-155 or due to an increase of miR-155 
within cells. We do not know either which cell types are responsible for the robust increase in 
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expression levels for our miRNAs of interest. The triple transgenic mice being generated in the 
ALS line will allow us to determine the responsible cells that cause miR-155 levels to be 
increased in whole spinal cord tissue in ALS. This information will allow us to predict which 
pathological pathways miR-155 operates on during ALS and will suggest the necessary cells to 
target therapeutically. However, it requires noting that anti-miR-155 treatment may be beneficial 
in ALS model mice independent of miR-155 dynamics in various cell types. To definitively 
determine the important cells that confer a survival benefit following anti-miR-155 treatment, 
further large scale therapeutic intervention experiments are required and are detailed below. 
 
Further miR-155 studies: role on neuroinflammation and preclinical experiments 
 By inhibiting a dysregulated miRNA in ALS, miR-155, using antisense oligonucleotides 
we were able to afford a significant survival extension by increasing disease duration in ALS-
model mice. For this, we treated mice with anti-miR-155 both through osmotic pumps directed to 
the lateral ventricles and with intraperitoneal injections. Given miR-155 expression in both cells 
resident to the brain and spinal cord (microglia, astrocytes) and cell that circulate in the blood (T 
cells, monocytes), we first tested miR-155 as a potential therapeutic with a total approach (Fig 
6.1A). We will next test how CNS inhibition alone or peripheral cell inhibition alone affects 
survival in SOD1G93A ALS-mouse model (Fig 6.1B). This information will provide mechanistic 
information on the role of miR-155 in ALS. If peripheral inhibition alone is sufficient to 
recapitulate the survival extension, the best theory of how anti-miR-155 confers protection is by 
modulating activation and proliferation of circulating monocytes and lymphocytes. If a central 
treatment alone is sufficient, we will not know if infiltrated immune cells are the critical 
mediating cell type or if endogenous cells including neurons, astrocytes, and microglia are 
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instead. However, a follow-up novel treatment experiment can then be performed to discern the 
mediating cell type in the central nervous system using cell type specific delivery of miRNA 
sponges to ALS model mice using adeno-associated viruses. miRNA sponges are mRNAs that 
contain multiple miRNA binding sites (often 4-10), acting as dominant negative inhibitors (Ebert 
and Sharp, 2010). To test cell specific treatment of miR-155 knockdown in ALS model mice, 
miRNA sponges can be expressed behind cell type specific promoters and packaged into AAV9 
capsids using methods similar to published experiments that selectively target neurons (Gray et 
al., 2011) and astrocytes (Lawlor et al., 2009; von Jonquieres et al., 2013). These experiments 
using miRNA sponges are being proposed secondary to antimir experiments using oligos 
because while miRNA sponges are showing promise in their potency and adaptability since 
being developed in 2007 (Ebert et al., 2007), they can be limited in their ability to sufficiently 
inhibit abundant microRNAs and are not as prepared for safe delivery in patients as ASO 
technology (Ebert and Sharp, 2010). These are ambitious experiments being proposed to 
definitively determine the important cell(s) to target with miR-155 knockdown drugs, but beyond 
being mechanistically informative, these experiments may inform future preclinical trials. 
Peripheral dosing is much easier than intrathecal delivery; however, both are possible in patients 
(Miller et al., 2013). Furthermore, as additional backbone modifications are being developed for 
antisense oligonucleotides, there may be an opportunity to select for those oligos that show 
greatest potency in the cell type of interest.  
 Before carrying out these treatment experiments, we are first testing novel anti-miR-155 
oligos. Our collaborators at Regulus Therapeutics have generated five new anti-miR-155 oligos 
with alternative backbone and sugar modifications. Following an in vitro luciferase target 
engagement assay, three of these novel anti-miR-155 oligos outperformed the anti-miR-155 used 
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in our previous ALS-mouse model experiments. We are now in the process of screening these 
new oligos in vivo for toxicity and target engagement. We will pursue the central vs peripheral 
treatment experiment with the top oligo from this screen. 
 Finally, the timing of administration will also have to be tested. While SJL SOD1G93A 
mice do not have an overt phenotype until 90-100 days of age, cellular pathology including ER 
stress are observed earlier (Matus et al., 2013). Therefore, in our first therapeutic experiment, we 
began treatment at 60 days of age. Given that miR-155 levels are not increased until later in 
disease (Fig 2.4), a later start date for treatment might be equally beneficial and more 
therapeutically relevant and will require testing. 
Our descriptive experiments using ALS model mice and patient autopsy tissue data 
defined 6 dysregulated miRNAs in ALS. Another miRNA identified here may have a more 
potent effect either alone or in concert other miRNA targets. For example, miR-142-3p, miR-
146a, and miR-155 all had a near perfect correlation in their time course of upregulation in the 
ALS mouse model (Fig 2.5). A combinatorial strategy may afford the greatest survival benefit; 
however, as miRNAs have several downstream targets, the risk of toxicity and detrimental 
effects are likely to increase as the number of miRNAs targeted also increases. Nonetheless, 
given the highly correlative nature of these target miRNAs, a combinatory treatment strategy 
warrants testing for an even greater survival benefit. Overall, several therapeutic experiments 
remain in order to optimize microRNA inhibition therapies in ALS. First, the most potent anti-
miR-155 oligo will be identified, and then the best mode of delivery will be determined (central 
vs peripheral administration). Next, the effect of delaying the start of treatment can be tested as 
well as the effect of combinatorial strategies to inhibit miRNAs dysregulated in ALS. Beyond 
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identifying the method that allows for the greatest survival benefit, these experiments will also 
help elucidate the mechanism through which blunting miR-155 function in ALS is beneficial.  
 
Concluding remarks: 
In this dissertation work, we have generated exciting microRNA data, including a list of 
dysregulated miRNAs in ALS, a dataset of cell type specific miRNA expression patterns, and the 
identification of novel therapeutic targets. More so, we have also identified many promising 
research avenues to carry forward. The novel glial/neuronal specific miRAP mice have the 
potential to inform basic miRNA biology in terms of the regulation of miRNA biogenesis, the 
identification of drivers of cell type differentiation, and discovery of miRNA-mRNA targets. We 
are also applying these miRAP mice to models of neurodegeneration in order to create a list of 
miRNAs actively dysregulated in specific cell populations. Also, we have identified miR-155 as 
an exciting potential immunomodulator that may also be a therapeutic target in ALS. We are 
now pursuing more potent anti-miRs before testing central versus peripheral intervention 
experiments in the mouse model of ALS. These experiments may elucidate the necessary and 
sufficient cell types to target with anti-miR-155 to recapitulate a survival benefit in ALS-model 
mice while also informing the role of neuroinflammation in ALS. With a blend of mechanistic 
and translational work, the data presented here serves to inform the role of microRNAs in ALS 
while also developing methods to assist in future miRNA experiments. 
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Figure 6.1: Experimental plan for comparing anti-miR-155 treatment administered in 
the periphery vs in the central nervous system. (A) In the original anti-miR-155 experiment 
in ALS model SOD1G93A mice, we targeted both cells in the brain and spinal cord with osmotic 
pumps directed to the cerebral lateral ventricles and targeted peripheral cells with weekly IP 
injections.  (B) In our next large-scale anti-miR intervention experiment in the SOD1G93A 
mouse model, we will compare administration of a novel anti-miR-155 only to the central 
nervous system using Alzet osmotic pumps directed to the lateral ventricles, only to the 
periphery by IP injections, to a combination of the two (as completed previously).  
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